
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" encoding="utf-8"?-->


     <title></title>
<meta http-equiv="Content-Type" content="text/html">

<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_cryo_americancryostem.com_20210930 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20201001_20210930 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001468679 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wOS0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->

<div style="display: none">
<ix:header>
 <ix:hidden>
  <span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityCentralIndexKey" inside-table="false" id="fact-identifier-0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0001468679</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:booleanfalse" name="dei:AmendmentFlag" inside-table="false" id="fact-identifier-1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">false</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:CurrentFiscalYearEndDate" inside-table="false" id="fact-identifier-2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">--09-30</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:DocumentFiscalYearFocus" inside-table="false" id="fact-identifier-3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:DocumentFiscalPeriodFocus" inside-table="false" id="fact-identifier-4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span>
  <ix:nonfraction id="xdx2ixbrl0054" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0080" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0110" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0114" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0122" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0129" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0132" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0138" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0198" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0247" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0251" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0256" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0259" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0262" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0265" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0268" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0280" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0302" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0304" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0307" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0310" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0319" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0322" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0329" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0337" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0347" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0371" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0373" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0391" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0418" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0419" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0430" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0437" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0444" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0451" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0458" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0465" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0472" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0479" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0484" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0486" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0489" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0490" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0503" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0510" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0517" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0524" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0529" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0531" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0534" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0536" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0539" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0540" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0610" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0614" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0616" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0618" unitref="USD" xs:nil="true"></ix:nonfraction>
  <span><ix:nonnumeric contextref="From2019-10-012020-09-30" name="cryo:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" inside-table="false" id="fact-identifier-5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="false" iscustomonly="true">P1Y10M6D</ix:nonnumeric></span>
  <ix:nonfraction id="xdx2ixbrl0803" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="cryo:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" inside-table="false" id="fact-identifier-6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="false" iscustomonly="true">P2Y3M29D</ix:nonnumeric></span>
  <ix:nonfraction id="xdx2ixbrl0813" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0816" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="false" id="fact-identifier-7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">P3Y8M23D</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" inside-table="false" id="fact-identifier-8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">P3Y2M26D</ix:nonnumeric></span>
  </ix:hidden>
 <ix:references>
  <link:schemaref xlink:href="cryo-20210930.xsd" xlink:type="simple">
  </link:schemaref></ix:references>
 <ix:resources>
    <xbrli:context id="From2020-10-01to2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_HealthCareOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_HealthCareOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_RoyaltyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_RoyaltyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_LabEquipmentAndFurnitureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cryo:LabEquipmentAndFurnitureMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_RoyaltyMember_custom_BaoxinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">cryo:BaoxinMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_RoyaltyMember_custom_BaoxinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">cryo:BaoxinMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_RoyaltyMember_custom_CellSourceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">cryo:CellSourceMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_RoyaltyMember_custom_CellSourceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">cryo:CellSourceMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_ProductMember_custom_BaoxinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">cryo:BaoxinMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_ProductMember_custom_BaoxinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">cryo:BaoxinMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_ProductMember_custom_CryoVivaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">cryo:CryoVivaMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_ProductMember_custom_CryoVivaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">cryo:CryoVivaMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_ProductMember_custom_ScienceDiagnosticMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">cryo:ScienceDiagnosticMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_ProductMember_custom_ScienceDiagnosticMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">cryo:ScienceDiagnosticMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cryo:LaboratoryEquipmentMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cryo:LaboratoryEquipmentMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_LaboratoryLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cryo:LaboratoryLeaseholdImprovementsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_LaboratoryLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cryo:LaboratoryLeaseholdImprovementsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_LaboratoryFurnitureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cryo:LaboratoryFurnitureMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_LaboratoryFurnitureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cryo:LaboratoryFurnitureMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_OfficeLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cryo:OfficeLeaseholdImprovementsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_OfficeLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cryo:OfficeLeaseholdImprovementsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_OfficeFurnitureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cryo:OfficeFurnitureMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_OfficeFurnitureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cryo:OfficeFurnitureMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_BridgeNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:BridgeNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_BridgeNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:BridgeNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:ConvertibleNotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:ConvertibleNotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_ConvertibleNotes2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:ConvertibleNotes2Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_ConvertibleNotes2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:ConvertibleNotes2Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_ConvertibleNotes3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:ConvertibleNotes3Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_ConvertibleNotes3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:ConvertibleNotes3Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_ConvertibleNotes4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:ConvertibleNotes4Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_ConvertibleNotes4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:ConvertibleNotes4Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_ConvertibleNotes5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:ConvertibleNotes5Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_ConvertibleNotes5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:ConvertibleNotes5Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_ConvertibleNotes6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:ConvertibleNotes6Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_ConvertibleNotes6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:ConvertibleNotes6Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_ConvertibleNotes7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:ConvertibleNotes7Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_ConvertibleNotes7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:ConvertibleNotes7Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_PPPLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:PPPLoanMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_PPPLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:PPPLoanMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_FinanceLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:FinanceLeaseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_FinanceLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">cryo:FinanceLeaseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_OfficerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">cryo:OfficerOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_OfficerTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">cryo:OfficerTwoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_SalesRevenueNetMember_custom_ClientMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">cryo:ClientMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_SalesRevenueNetMember_custom_ClientMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">cryo:ClientMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_BaoxinLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">cryo:BaoxinLtdMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_BaoxinLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">cryo:BaoxinLtdMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_AccountsReceivableMember_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_AccountsReceivableMember_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001468679</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitnumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitnumerator>
        <xbrli:unitdenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitdenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 0pt; margin-bottom: 5pt; margin-right: 0"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid; width: 100%; margin-right: 0">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font-size: 14pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font-size: 14pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font-size: 14pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font-size: 18pt"><b>FORM
<span id="xdx_900_edei--DocumentType_c20201001__20210930_zu35RLyaiaL8"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:DocumentType" inside-table="false" id="fact-identifier-9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">(Mark One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><span style="font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_901_edei--DocumentAnnualReport_c20201001__20210930_z3r93mWEKiV1"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:booleantrue" name="dei:DocumentAnnualReport" inside-table="false" id="fact-identifier-10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">x</ix:nonnumeric></span></span></span><b>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font: 10pt Times New Roman, Times, Serif">For the
    fiscal year ended:</span></td>
    <td style="border-bottom: windowtext 1pt solid; width: 75%; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--DocumentPeriodEndDate_c20201001__20210930_zOnFadM0jZl2"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" inside-table="true" id="fact-identifier-11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">September
    30, 2021</ix:nonnumeric></span></span></b></span></td></tr>
</tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><span style="font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_907_edei--DocumentTransitionReport_c20201001__20210930_z9dbNK7e1ZFf"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" inside-table="false" id="fact-identifier-12" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">o</ix:nonnumeric></span></span></span><b>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; padding-bottom: 1pt"><span style="font-size: 10pt">For the
    transition period from</span></td>
    <td style="border-bottom: Black 1pt solid; width: 32%; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">to</span></td>
    <td style="border-bottom: Black 1pt solid; width: 40%; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td></tr>
</tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&nbsp;</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font: 10pt Times New Roman, Times, Serif">Commission file number:</span></td>
    <td style="border-bottom: windowtext 1pt solid; width: 75%; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityFileNumber_c20201001__20210930_zeovRrxWVmu7"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityFileNumber" inside-table="true" id="fact-identifier-13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">000-54672</ix:nonnumeric></span></span></b></span></td></tr>
</tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 100%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-size: 24pt"><b><span id="xdx_906_edei--EntityRegistrantName_c20201001__20210930_zQSOI5XrSiG"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityRegistrantName" inside-table="true" id="fact-identifier-14" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">American CryoStem Corporation</ix:nonnumeric></span></span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Exact name of registrant as specified in its charter)</span></td></tr>
</tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 48%; font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20201001__20210930_zAQ1XDni8jP8"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" inside-table="true" id="fact-identifier-15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Nevada</ix:nonnumeric></span></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 4%; padding-right: 3pt; padding-left: 3pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 48%; font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20201001__20210930_zRSCGn3PRfj4"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityTaxIdentificationNumber" inside-table="true" id="fact-identifier-16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26-4574088</ix:nonnumeric></span></span></b></span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or Other Jurisdiction of<br>Incorporation
    or Organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer<br>Identification No.)</span></td></tr>
</tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20201001__20210930_zylfHYWMzw0j"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityAddressAddressLine1" inside-table="true" id="fact-identifier-17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1 Meridian Road</ix:nonnumeric></span></span>, <span id="xdx_903_edei--EntityAddressCityOrTown_c20201001__20210930_zT4z9Lfv6Uu4"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityAddressCityOrTown" inside-table="true" id="fact-identifier-18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Eatontown</ix:nonnumeric></span></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20201001__20210930_zgu6NIvyiI42"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityAddressStateOrProvince" inside-table="true" id="fact-identifier-19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">NJ</ix:nonnumeric></span></span>  <span id="xdx_909_edei--EntityAddressPostalZipCode_c20201001__20210930_zuNuGEpPBNs2"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityAddressPostalZipCode" inside-table="true" id="fact-identifier-20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">07724</ix:nonnumeric></span></span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Address of Principal Executive Offices) (Zip Code)</span></td></tr>
</tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_901_edei--CityAreaCode_c20201001__20210930_zIRhMukJafK5"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:CityAreaCode" inside-table="true" id="fact-identifier-21" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">(732)</ix:nonnumeric></span></span> <span id="xdx_90F_edei--LocalPhoneNumber_c20201001__20210930_zdKd9x5FYcJa"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:LocalPhoneNumber" inside-table="true" id="fact-identifier-22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">747-1007</ix:nonnumeric></span></span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Registrant’s telephone number, including area code)</span></td></tr>
</tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0"><span style="font-size: 10pt">Securities registered pursuant
to Section 12(b) of the Act:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border: Black 1pt solid; width: 38%; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title
    of each class</b></span></td>
    <td style="border-top: Black 1pt solid; width: 24%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading
    symbol(s)</b></span></td>
    <td style="border-top: Black 1pt solid; width: 38%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
    of each exchange on which registered</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
</tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0"><span style="font-size: 10pt">Securities registered pursuant to Section 12(g) of the Act:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"><b>Common Stock, par value $0.001</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Title of Class)</span></td></tr>
</tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Wingdings">o</span><span style="font: 10pt Times New Roman, Times, Serif"> Yes </span><span style="font: 10pt Wingdings">x</span><span style="font: 10pt Times New Roman, Times, Serif">
<span id="xdx_909_edei--EntityWellKnownSeasonedIssuer_c20201001__20210930_zRSilmm5hTa3"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityWellKnownSeasonedIssuer" inside-table="false" id="fact-identifier-23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Wingdings">o</span><span style="font: 10pt Times New Roman, Times, Serif"> Yes </span><span style="font: 10pt Wingdings">x</span><span style="font: 10pt Times New Roman, Times, Serif">
<span id="xdx_90D_edei--EntityVoluntaryFilers_c20201001__20210930_zCNVFePz7MV7"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityVoluntaryFilers" inside-table="false" id="fact-identifier-24" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Wingdings">x</span><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_90F_edei--EntityCurrentReportingStatus_c20201001__20210930_zh1EIQD0iNr6"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityCurrentReportingStatus" inside-table="false" id="fact-identifier-25" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span> </span><span style="font: 10pt Wingdings">o</span><span style="font: 10pt Times New Roman, Times, Serif">
No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Wingdings">x</span><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_90E_edei--EntityInteractiveDataCurrent_c20201001__20210930_z2d5y1trpsw8"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityInteractiveDataCurrent" inside-table="false" id="fact-identifier-26" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span> </span><span style="font: 10pt Wingdings">o</span><span style="font: 10pt Times New Roman, Times, Serif">
No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth
company” in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Large accelerated filer&nbsp;<span style="font-family: Wingdings">o</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated filer&nbsp;<span style="font-family: Wingdings">o</span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--EntityFilerCategory_c20201001__20210930_zJ1nZHq3yiK9"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" inside-table="true" id="fact-identifier-27" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Non-accelerated Filer</ix:nonnumeric></span></span>&nbsp;&nbsp;&nbsp;<span style="font-family: Wingdings">x</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Smaller reporting company&nbsp;<span style="font-family: Wingdings"><span id="xdx_900_edei--EntitySmallBusiness_c20201001__20210930_z4N86L3P3Dz8"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness" inside-table="true" id="fact-identifier-28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">x</ix:nonnumeric></span></span></span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Emerging growth company&nbsp;<span style="font-family: Wingdings"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20201001__20210930_zvWX2rHuLktc"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" inside-table="true" id="fact-identifier-29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">o</ix:nonnumeric></span></span></span></span></td></tr>
</tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font: 10pt Wingdings">o</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font: 10pt Wingdings">x</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Wingdings">o</span><span style="font: 10pt Times New Roman, Times, Serif"> Yes </span><span style="font: 10pt Wingdings">x</span><span style="font: 10pt Times New Roman, Times, Serif">
<span id="xdx_909_edei--EntityShellCompany_c20201001__20210930_zIzdyQE1iVf9"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:booleanfalse" name="dei:EntityShellCompany" inside-table="false" id="fact-identifier-30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">State the
aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which
the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the
registrant’s most recently completed second fiscal quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">As of March 31, 2021 (the last business day of the
registrant’s most recently completed second fiscal quarter) was approximately $<span id="xdx_907_edei--EntityPublicFloat_iI_c20210331_zvOczr6C86Uk"><span><ix:nonfraction name="dei:EntityPublicFloat" contextref="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42,330,187</ix:nonfraction></span></span> (last sale $0.70).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">Indicate
the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">As of January 12, 2022, the registrant had <span id="xdx_906_edei--EntityCommonStockSharesOutstanding_iI_c20220112_z47AXc0dBr76"><span><ix:nonfraction name="dei:EntityCommonStockSharesOutstanding" contextref="AsOf2022-01-12" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">43,435,696</ix:nonfraction></span></span> shares of its common stock, par value $0.001, outstanding.</span></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 0pt"><div style="border-bottom: Black 4pt solid; font-size: 1pt; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1 -->

    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>TABLE OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</p>





<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 95%; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa001" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">PART I</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">1</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa002" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 1. Business.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">1</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa003" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 1A. Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">18</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa004" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 1B. Unresolved Staff Comments</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">40</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa005" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 2. Description of Property</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">40</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa006" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 3. Legal Proceedings</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">40</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa007" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 4. Mine Safety Disclosures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">40</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa008" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">PART II</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">41</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa009" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 5. Market for Common Equity and Related Stockholder Matters</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">41</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa010" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 6. Selected Financial Data</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">42</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa011" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">42</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa012" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 7A. Quantitative and Qualitative Disclosures about Market Risk</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">45</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa013" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 8. Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">46</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa014" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">46</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa015" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 9A. Controls and Procedures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">46</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa016" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 9B. Other Information.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">46</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa017" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">PART III</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">47</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa018" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 10. Directors, Executive Officers, and Corporate Governance</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">47</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa019" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 11. Executive Compensation</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">48</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa020" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 12. Security Ownership of Certain Beneficial Owners and Management</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">48</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa021" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 13. Certain Relationships and Related Transactions</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">51</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa022" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 14. Principal Accountant Fees and Services</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">51</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa023" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">PART IV</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">52</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa024" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Item 15. Exhibits</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">52</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa025" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">PART F/S</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">F-1</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa026" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">INDEX TO FINANCIAL STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">F-1</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2.5pt; padding-bottom: 2.5pt"><a href="#acryoa027" tabindex="18"><span style="font-size: 10pt">AUDITED FINANCIAL STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt"><span style="font-size: 10pt">F-1</span></td></tr>
</tbody></table>





<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>FORWARD LOOKING
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Included in
this Form 10-K are “forward-looking” statements, as well as historical information. Although we believe that
the expectations reflected in these forward-looking statements are reasonable, we cannot assure you that the expectations reflected
in these forward-looking statements will prove to be correct. Our actual results could differ materially from those anticipated
in forward-looking statements as a result of certain factors, including matters described in the section titled “Risk Factors.”
Forward-looking statements include those that use forward-looking terminology, such as the words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “project,” “plan,”
“will,” “shall,” “should,” and similar expressions, including when used in the negative. Although
we believe that the expectations reflected in these forward-looking statements are reasonable and achievable, these statements
involve risks and uncertainties, and we cannot assure you that actual results will be consistent with these forward-looking statements.
We undertake no obligation to update or revise these forward-looking statements, whether to reflect events or circumstances after
the date initially filed or published, or to reflect the occurrence of unanticipated events or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 10pt; margin-bottom: 0; text-align: center"><span id="acryoa001"></span><span style="font-size: 10pt">PART
I</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><span style="font-size: 10pt"><span id="acryoa002"></span>Item 1.
Business</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt"><b>Company
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>History</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We were
incorporated in the state of Nevada on March 13, 2009. On April 20, 2011, we acquired, through our wholly owned subsidiary
American CryoStem Acquisition Corporation, substantially all of the assets from, and assumed substantially all of the
liabilities of, ACS Global, Inc. (“ACS”) in exchange for our issuance of 21,000,000 shares of our common stock,
par value $0.001 per share, to ACS (the “Asset Purchase”). We filed a Current Report on Form 8-K with the
Securities and Exchange Commission (SEC) on April 27, 2011, disclosing the Asset Purchase and certain related matters
including, but not limited to, the appointment of our present officers and directors as well as the resignation by the former
chief executive officer and sole director. Our fiscal year ends September 30 of each calendar year. Upon the closing of the
Asset Purchase: (i) ACS Global became our majority shareholder, (ii) John Arnone was appointed as our chief executive officer
and president Anthony Dudzinski was appointed as our chief operating officer, treasurer and secretary, and (iii) John Arnone
and Anthony Dudzinski were appointed to our board of directors, with Mr. Arnone being appointed as Chairman of the Board. Mr.
Dudzinski is also a director, president and treasurer of ACS Global and Mr. Arnone is a director and secretary of ACS
Global.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>About American
CryoStem Corporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">American CryoStem
Corporation; (CRYO) founded in 2008, is a biotechnology pioneer, having developed standardized adipose tissue derived technologies
(Adult Stem Cells) for the fields of regenerative and personalized medicine. These standardized technologies which include granted
patents, are the basis for our chemistry, manufacturing, and controls (cGMP Manufacturing) of our ATCell™ autologous cellular
therapy product for use in clinical investigations for Biologic License Applications with the US Food and Drug Administration
(FDA). Our laboratory stem cell products are characterized adult human Mesenchymal Stem Cell (MSC’s) derived from adipose
tissue that work in conjunction with our patented (non-animal) medium lines and knowhow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
filed its first Investigational New Drug Application (IND) with the FDA for our ATCell™ cellular therapy product. The IND
filing is titled “ATCell™ Expanded Autologous Adipose Derived Mesenchymal Stem Cells deployed via Intravenous Infusion
for the Treatment of Post-Concussion Syndrome (PCS) in Retired Athletes and Military Personnel” File number 19089 was approved
by the FDA on September 17, 2020 to commence the Phase 1 Clinical Trial. Post-concussion syndrome is a chronic, incurable central
nervous system condition affecting a significant number of the United States military and athletes, especially those involved
in contact sports such as football, boxing, soccer, and other sports where participants have suffered one or more concussions
or mild traumatic brain injuries (mTBI). Published research has indicated that up to 30% of all military personal, active and
retired, may suffer from this condition. According to the Department of Defense evaluation of U.S. military casualty statistics,
From 2000-2019 Q3, 413,858 United States Military personnel worldwide experienced a; were considered mild, 9.8% moderate, and
2.3% penetrating or severe.</span></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
built and validated a new cGMP clean room processing and manufacturing area at our facility in Monmouth Junction NJ, implemented
and validated cGMP Standard Operating Procedures (SOPs) and installed a new Quality Management System to support its IND filings
and an increased focus on patent and product development and support additional clinical activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The
Company has built a domestic and international patent portfolio consisting of 32 patents. Our 4 primary operating patents
regarding the “collection – processing – cryopreservation and return to point-of-care” of adipose
derived stem cells, have been granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is expanding its efforts to attract and cultivate collaborative partners to accelerate its product development efforts, harnessing
its manufacturing platform and tissue processing platforms. The R&amp;D collaborations are to discover, develop, and commercialize
cellular therapies, laboratory products and combinations thereof with synergistic technologies to create regenerative medicine
applications and develop new intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Adipose
Tissue</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company’s manufacturing platform technologies, cell transportation products, cell culture mediums and cell therapies are
focused on the acquisition and processing of adipose tissue as the primary raw material. Many of our developed technologies have
been successfully applied to other raw materials such as bone marrow, umbilical and placenta tissue. Adipose tissue, also known
as fat tissue or fatty tissue, is a connective tissue that is mainly composed of fat cells called adipocytes. Adipocytes are energy
storing cells that contain large globules of fat known as lipid droplets surrounded by a structural network of fibers. tissue
and other stromal tissues. The Company is focused on adipose tissue because it contains higher densities of mesenchymal stems
cells (often 500 to 1000 times more) per gram of raw material when compared to other sources (bone marrow, umbilical cord tissue,
etc). The higher cellular density of adipose tissue supports the ability to create regenerative cellular products more efficiently
and with less expansion (lower passages and population doublings), which is preferred when producing cellular therapy products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Adipose tissue
is considered one of the top human stem cell sources considering its accessibility, abundance, and least painful collection procedure
when compared to other sources such as bone marrow. The adipose derived mesenchymal stem cells (ADSCs) that adipose tissue contains
can be maintained and expanded in culture for long periods of time without losing their differentiation capacity, leading to large
cell quantities being increasingly used in cell therapy purposes. Many published and peer reviewed reports show that ADSC-based
cell therapy products demonstrated optimal efficacy and efficiency in various clinical indications for both autologous and allogeneic
purposes, hence they are increasingly being considered as potential tools for replacing, repairing, and regenerating dead or damaged
cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Adipose tissue
is a specialized type of connective tissue that arises from the differentiation of mesenchymal stem cells into adipocytes during
fetal development. Mesenchymal stem cells are multipotent cells that can transform into various cell types, including fat cells,
bone cells, cartilage cells, and muscle cells among others. Adipose tissue can be found in a number of different places throughout
the body. Adipose tissue is the most abundant type of fat in humans. It is distributed within subcutaneous fat, visceral fat,
and bone marrow fat. Subcutaneous fat is found throughout the whole body, in the spaces between the skin and underlying muscles.
Visceral fat is predominantly found around the organs in the abdominal cavity, such as the liver, intestines and kidneys, as well
as in the peritoneum (a serous membrane that lines the outside of the abdominal organs). Adipose tissue is also present in bone
marrow (a sponge-like tissue present in the central cavity of bones). In addition, adipose tissue can be found in the pericardium
surrounding the heart, or cushioning other parts of the body, like the soles of the feet, eyeballs, and certain blood vessels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The main function
of adipocytes is to store excess energy in the form of fatty molecules, mainly triglycerides. Fat storage is regulated by several
hormones, including insulin, glucagon, catecholamines (adrenaline and noradrenaline), and cortisol. Depending on the body’s
immediate energy requirements, these hormones can either stimulate adipose tissue formation and storage (i.e. lipogenesis) or
initiate the release of fat from adipose tissue (i.e. lipolysis). Under the influence of insulin, for instance, adipocytes can
increase the uptake of blood glucose and transform it into fatty molecules, thereby increasing fat storage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition
to being an energy storing reservoir, adipose tissue performs important endocrine and metabolic roles by secreting several biologically-active
factors known as adipokines. These molecules contribute to a variety of different functions, including regulation of energy balance,
food intake and satiety, inflammatory response, and metabolism of steroid hormones. Finally, adipose tissue also helps cushion
and protect parts of the body, as well as insulate the body from extreme temperatures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition
to adipocytes, adipose tissue contains the stromal vascular fraction (SVF) comprised of cells including preadipocytes, fibroblasts,
vascular endothelial cells, and a variety of immune cells such as adipose tissue macrophages. Far from being hormonally inert,
adipose tissue has, in recent years, been recognized as a major endocrine organ, as it produces hormones such as leptin, estrogen,
resisting, and cytokines (especially TNFα). Adipose tissue contains some of the highest concentrations of adult stem cells,
progenitor cells and immune cells.</span></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Processing
Technology </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The FDA considers
processing and expanding cells as the manufacturing of a drug product. The Company’s completed proprietary, patented processing
and manufacturing platform is designed for the collection, preparation and cryo-preservation of pure adipose tissue and adipose
tissue derived cells. The processing platform has been validated to enable the Company to deliver cellular therapy samples with
repeatable and identifiable characteristics of safety, potency, viability, and purity which are the core FDA requirements for
the cGMP manufacturing of all drug products. Our manufacturing platform is approved by FDA for use
in our current clinical study of Post Concussion Syndrome for the manufacturing of the cellular therapy samples. The Company believes
that the platform is suitable to support the Company’s growing pipeline of product development and planned clinical studies,
and future biologic license applications for an array of target diseases and conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
believes the reproducibility of scientific studies is a substantial issue in cellular therapy research, from drug discovery and
development through clinical trials as researchers throughout the world continue to use different protocols for processes associated
with cell sample preparation, cryopreservation, and cold chain management. We believe our validated manufacturing processes for
our ATCell™ product solves this issue. The samples we produce with our patented platform and proprietary products have proven
purity, consistent viabilities above 80 percent, and cell identification panels across six biomarkers and proven sterility. Our
standardizing handling, storage, and transportation protocols substantially improve the quality and reproducibility of adipose
tissue derived stem cells and the adipose tissue collection, processing, storage and retrieval which is designed to permit us
to accelerate the time line of creating and processing cellular therapy products - from lab research to regulatory submission
and FDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Each
individual process has the potential to create multiple autologous products and to generate multiple revenue streams including
customer fees for storage of biomaterials. Our processing platform and methodology allow the opportunity for continuing revenue
streams from each tissue sample received and processed including, cellular therapy treatments, pure tissue storage for secondary
procedures, processing, and handling fees and CRYO storage and release fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We
are leveraging our patented platform and developing our product portfolio to create a global footprint of licensed laboratory
affiliates, physician’ networks, patients, research organizations, and licensees who purchase tissue collection, processing
and storage services or consumables from our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1468679/000101905622000053/acryo001.jpg" src="https://www.sec.gov/Archives/edgar/data/1468679/000101905622000053/acryo001.jpg"><span style="font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Products
and Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Therapy Product
Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">During the Company’s
initial stage of developing its manufacturing protocol and products chose adipose tissue as its source material following review
and experiments that included other biomaterials and cell sources such as bone marrow and peripheral blood samples. The selection
of adipose tissue is based upon a number of factors including high cell density and its wide array of other cell types including
precursor and immune cells that may be derived and developed as future products. Although the Company is currently focused on
the development of cellular therapy products utilizing adipose derived mesenchymal cells, the platform is designed to be easily
extendable to permit the acquisition and expansion of additional cellular derivatives from other biomaterials.</span></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">A significant
amount of research, case studies and anecdotal evidence has been published over the past several decades concerning the study
of cellular therapies for a wide range of diseases and maladies from ALS and Parkinson’s to wound healing and immunological
support. The Company, recognizing that each new application for therapy approval requires a standalone clinical study, has refined
its development strategy to initially encompass mild traumatic brain injury and immunosuppression as core targets for its development
strategy. We focus our efforts on expanding our product pipelines based upon our intellectual property portfolio, collaborative
development relationships, target market size, medical need, disease classification, and international licensing and partnering
opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The completion,
submission and approval of our validated manufacturing platform is the culmination of the Company’s development efforts.
Validation of the manufacturing platform for the study has provided the Company with the opportunity to expand its efforts and
resources on the further development of its downstream intellectual property. The objective is to provide deliverable commercial
cell therapy products to address patient populations with large unmet medical needs such as brain injuries and conditions that
include immunologic complications. The Company’s continuing efforts in the development of additional products includes an
increased focus on the recruitment of collaborative partners and the extension of our existing manufacturing capabilities to development
of other adipose tissue derivative and cellular/biomaterial combination products. Leveraging our repeatable processing platform
provides the Company with contributable technology and capabilities to rapidly develop clinical studies, accumulate complementary
scientific data and attract strong collaborative and developmental partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our activities
include supporting collaborations by providing our products and services (ACSelerate<sup>™</sup> and ATCELL<sup>™</sup>)
with the goal and expectation that our products and services become the basis for new cell based Regenerative Medicine and cellular
therapy applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Part of this
strategic approach to therapy product development is to design, develop and launch new products and services that rely on our
core processing technology and leverage existing products and services. Examples of this approach are the use of the CELLECT<sup>®
</sup>collection kit/ box and materials to collect fresh tissue for cellular therapy sample processing, use of our patented non-animal
growth medium for cell culture and use of our storage medium for cryo-storage. Management is currently pursing collaborative product
development agreements with healthcare institutions, universities, and other biotech companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>2022 Therapy
Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
has developed and refined its pipeline around its flagship cellular product, ATCell™, for clinical therapeutic use. The
initiation of this pipeline strategy occurred with the filing, approval and commencement of its Post Concussion Syndrome Phase
1 clinical study. During this review process, the US FDA fully reviewed the Company’s manufacturing platform contained in
the Chemistry, Manufacturing and Control section of the Investigational New Drug (IND) submission. The Company’s filing
included unpublished research of ATCell™ use in an animal model as well as a report covering its safety results from a pilot
study that included the treatment of more than 80 patients that received one or more treatments with the ATCell™ product
that resulted in no reported adverse events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The
                                         Company filed its first Investigational New Drug Application (IND) with the US Food and
                                         Drug Administration (FDA) for the ATCELL cellular therapy product. The IND filing is
                                         titled “<i>ATCell™ Expanded Autologous Adipose Derived Mesenchymal Stem Cells
                                         deployed via Intravenous Infusion for the Treatment of Post Concussion Syndrome (PCS)
                                         in Retired Athletes and Military Personnel</i>”, File number 19089, which was approved
                                         by the FDA on September 17, 2020. The Company intends to invite additional developers
                                         of cellular therapies to initiate additional arms of the clinical study focused on the
                                         use of ATCELL™ for use in systemic inflammatory response relief for patient suffering
                                         from systemic diseases. A number of these additional study targets have been identified
                                         and ongoing discussions support the Company’s belief that clinical investigations
                                         can be developed and rapidly added upon completion of the new treatment protocol and
                                         outcome assessment methodologies. </span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">DMD
                                         – The Company has completed the protocol for the treatment of Duchene Muscular
                                         Dystrophy and is in final discussions with its Collaborative partner, to select the principal
                                         investigator (PI) and clinical trial site selection.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">3.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Long
                                         COVID – The Company has completed the protocol for treatment of Long COVID and
                                         is currently finalizing its FDA filings. We have completed, along with a government partner
                                         the clinical protocol for a new Investigational New Drug (IND) application to be filed
                                         with FDA within the next 90 days for Long COVID. According to the Centers for Disease
                                         Control and Prevention, “post-COVID conditions can be considered a lack of return
                                         to a usual state of health following acute COVID-19 illness.” In the US, following
                                         COVID recovery, it is reported that up to 30% of those afflicted, diagnosed, or treated
                                         for COVID-19 have continuing symptoms and medical complications following recovery from
                                         the acute illness</span></td></tr></tbody></table>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">4.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Wound
                                         Healing – the creation of topical applications and ingredients used by physicians in
                                         the wound care and cosmetic industries as well as therapeutic cellular applications and
                                         bio-materials development. An initial pilot study involving a minimum of 10 participants
                                         for the assessment of its autologous tissue products for the wound healing market is
                                         underway. The Company is combining its tissue products, which <b>do not require</b> FDA
                                         approval, with current standard-of-care methods to accelerate and improve the healing
                                         of diabetic and non-diabetic wounds and ulcers.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">5.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">ATGRAFT™
                                         – products include adipose tissue and cell sample processing and storage as a form of
                                         personal “bio-insurance”, and adipose tissue (fat) storage for cosmetic fat
                                         engraftment procedures. High demand for pure and natural aesthetics in fast growing cosmetic
                                         industry with non-FDA required plastic, cosmetic, and reconstructive surgical “fat
                                         filler”. The global facial fat transfer market alone is expected to growth with
                                         a CAGR of 10.7% to $4.2b by 2027</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>About ATCELL™</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
has established and trademarked ATCELL™ as the brand name for its line of adipose derived stem cell products. ATCELL™
is a purified sample of adipose tissue derived from adipose tissue through our manufacturing processes that can be incubated and
grown (cultured) to large quantities in cGMP conditions.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>ATCELL<i><sup>™
</sup></i>Adipose Derived Mesenchymal Cells </b>Processed and characterized adipose derived cells created using the Company’s
proprietary, validated and patented Standard Operating Procedures (SOPs) of its manufacturing platform and the Company’s
ACSelerate<b><i><sup>™ </sup></i></b>patented cell culture media. Cell lines may also be custom created for patients desiring
to store their cells for their own future use in Regenerative Medicine procedures, shipped “On Demand”. Customer samples
are collected by the physician in an mini liposuction procedure and delivered to the Company’s facility utilizing the CELLECT<b><i><sup>®
</sup></i></b>collection system and ACSelerate<sup>™</sup> transport<b><i><sup> </sup></i></b>medium to conform to our validated
quality control standards. The Company charges its customers a fee to process newly collected client tissue samples into cellular
samples.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">ATCELL’s
repeatable sample manufacturing process is designed to comply with the requirements of FDA to produce highly consistent and validated
cellular products necessary to achieve regulatory approval. The validation of our manufacturing process and quality control results
are of great value in biomanufacturing and serve as the basis for approval and commercial product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company’s
ATCELL<b><i><sup>™</sup></i></b> cell lines are cultured in our patented ACSelerate<b><i><sup>™ </sup></i></b>cell
culture media. All processed samples: tissue, cells, and research materials are made available for clinical study therapies, tissue
transfer or sale to research institutions. All samples are tested for sterility, disease, lifespan, and population doubling rate
(PDL). Cell morphology is confirmed by (i) flow cytometry (6 markers) and (ii) tri-lineage differentiation analysis using ACSelerate<b><i><sup>™
</sup></i></b>differentiation media. Each ATCELL<b><i><sup>™</sup></i></b> line can be further processed and differentiated
allowing the Company to provide genetically matched cell types. We believe this research methodology may provide opportunities
for the Company’s ATCELL<b><i><sup>™</sup></i></b> and ACSelerate<b><i><sup>™</sup></i></b> products to become
the building blocks of additional commercial application development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
believes it can earn additional fees based upon storage and retrieval fees and for future product creation. Cell culturing and
differentiation may be performed upon receipt of the raw tissue sample or at any time on a previously processed and cryopreserved
tissue or master cell sample. ATCELL<b><i><sup>™ </sup></i></b>has shown that it is ideally suited for differentiation into
additional cell types (bone, cartilage, etc.) utilizing our patented ACSelerate<b><i><sup>™ </sup></i></b>line of differentiation
mediums.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The ATCELL<b><i><sup>™
</sup></i></b>processing, products and services are incorporated into multiple granted patents including the granted claim of:
“Systems and Methods for the Digestion of Adipose Tissue Samples Obtained from a Client for Cryopreservation” US 10,154,664
issued December 18, 2018, and “Business Method for Collection, Processing, Cryogenic Storage and Distribution of a Biologic
Sample Material” US Patent Number 10,014,079, issued July 3, 2018. The ACSelerate™ Medium products are incorporated
into our granted patents “Cell Culture Media, Kits and Methods of Use”; US Patent No. 7,989,205 issued August 2, 2011,
with additional claims granted in US Patent No. 9,487,755 granted November 8, 2016.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Tissue Processing
and Storage Services:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ATGRAFT</span><span style="font: 10pt SimSun"><sup>™</sup></span><span style="font: 10pt Times New Roman, Times, Serif"><b>–</b> An
adipose tissue (fat) collection, processing and storage solution used by cosmetic and plastic surgeons to provide their patients
with multiple tissue transfer and storage options. The ATGRAFT<i><sup>™ </sup></i>service, through one liposuction procedure,
allows individuals to prepare for multiple future cosmetic or regenerative procedures by using their own stored adipose tissue
as natural biocompatible filler, or for multiple cellular therapy applications over time without the trauma of further liposuctions.
Many physicians currently offering tissue transfer or “stem cell (SVF)” therapies are required to perform a concurrent
tissue harvest for each transfer or procedure which increases the opportunities for infection at the harvest site and the development
of long-term complications related to the formation of scar tissue (stroma) at the harvest site(s). </span></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">ATGRAFT<i><sup>™
</sup></i>supported procedures include; breast reconstruction, layered augmentations, buttocks enhancement, volume corrections
of the hands, feet, face and neck areas that experience significant adipose tissue (fat) volume reduction as we age. ATGRAFT<i><sup>™
</sup></i>is processed and stored utilizing our cGMP standards so that any stored fat tissue sample may in the future be further
processed to create, “ATCELL<i><sup>™</sup>”</i>, for use in Regenerative Medicine applications. The ATGRAFT<i><sup>™
</sup></i>service is included in our granted patent “Business Method for Collection, Processing, Cryogenic Storage and Distribution
of a Biologic Sample Material” US Patent Number 10,014,079, issued July 3, 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company’s
charges processing fees for ATGRAFT<sup>™</sup> tissue processing and minimum annual storage fees based on the volume of
tissue processed. These processing and storage fees may be paid by the collecting/treating physician or the consumer. The Company
earns additional fees upon sample retrieval, for the thawing, packaging and shipment of the stored samples to the physician or
clinical “point-of-care” for immediate use upon receipt. Additionally, physicians may request that any stored ATGRAFT<i><sup>™
</sup></i>tissue sample of 25ml or greater be reprocessed utilizing the Company’s ATCELL<i><sup>™</sup></i> and Autokine-CM<i><sup>™
</sup></i>processing to create topical therapy or cosmetic products, on-demand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Laboratory
Products; Culture Medium, and Manufacturing Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>CELLECT</b><sup>®
</sup><b>Collection, Transportation, and Storage System </b>– An unbreakable “chain of custody” solution to
collect and deliver tissue samples utilizing proprietary and patent pending methods and materials. The CELLECT<sup>®</sup>
service is the required platform for the collection and transportation of live adipose tissue samples to American CryoStem Corporation’s
processing facility. Tissue collected and transported in our CELLECT kits is monitored through the transportation process to assures
the highest viability upon laboratory receipt. The CELLECT<sup>®</sup> system incorporates our ACSelerate–TR<sup>™
</sup>transport medium to support the health of the tissue during transport. The ability to support the health of the collected
tissue using our proprietary material and services greatly enhances our highly consistent and repeatable manufacturing and processing
protocol. The CELLECT<sup>®</sup> service is included in our granted patent “Business Method for Collection, Processing,
Cryogenic Storage and Distribution of a Biologic Sample Material” US Patent Number 10,014,079, issued July 3, 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">American CryoStem
is the first tissue bank to globally incorporate through its CELLECT<i><sup>®</sup></i> service the International Blood Banking
identification, labeling and product identification coding system. This labeling system is an acceptable machine-readable labeling
standard, product description, and bar-coding system for FDA Center for Biologics Evaluation and Research under 21 CFR 606.12(c)13.
American CryoStem conforms to this standard in its laboratory facility and all cellular and tissue products produced at the facility
carry our W3750 ICCBBA facility identifier allowing any hospital, clinic, laboratory and regulator worldwide to identify the origin
and obtain additional information on any sample produced at an American CryoStem laboratory facility. The Company requires use
of this standard in all laboratories that license or utilize our technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>ACSelerate<sup>™ </sup>Cell
Culture Media Products </b>– Manufactured patented cell culture media products for growing human stromal
cells (including all cells found in human skin, fat and other connective tissue). Certain of the Company’s
ACSelerate<i><sup>™ </sup></i>cell culture media lines are available in animal serum free, which may be suitable for
human and therapeutic uses, or in a low serum version for application development and research purposes. The patented
ACSelerate<b><i><sup>™ </sup></i></b>cell culture media line(s) were specifically developed to address increasing
industry demand for fetal bovine serum-free cell culture products. The use of fetal bovine serum (FBS) and other animal
products in cellular therapy application development and manufacture raises concerns and generates debates within the
scientific and regulatory community relating to potential human/animal cross-contamination. These same concerns may lead to
additional expensive and expansive testing and documentation requirements with the FDA during the application and approval
process for new cellular therapies manufactured with or containing animal or animal derived products. FDA concerns are
evidenced in their Guidance’s and Guidelines regarding cellular therapy involving human cells, tissues and products
(HCT/Ps) published and maintained by the FDA. Management believes that eliminating or greatly reducing FBS in
cellular manufacturing, applications and products can eliminate or ease these scientific and regulatory concerns and may
prove to be a winning strategy for cellular therapy application developers seeking FDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
entered into a licensing and manufacturing agreement with PeproTech (April 4, 2016) a life sciences company formed in 1988. PeproTech
is the trusted source for the development and manufacturing of high quality cytokine products for the life-science and cell therapy
markets. PeproTech has grown into a global enterprise with state-of-the-art manufacturing facilities in the US, and offices
around the world. With over 2,000 products PeproTech has developed and refined innovative protocols to ensure quality, reliability
and consistency. The licensed medium is marketed under both PeproTech’s PeproGrow and the Company’s ACSelerate
MAX brands.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On August 2,
2011, the Company was issued US patent number 7,989,205 for “Cell Culture Media, Kits and Methods of Use.” The granted
claims include media variations for cellular differentiation of ADSCs into osteoblasts (bone), chondrocytes (cartilage), adipocytes
(fat), neural cells, and smooth muscles cells in both HSA medium grade and FBS (research) grade. This patent covers both non-GMP
research grades and cGMP grades suitable for cell culture of adipose-derived stem cells. Additionally, on November 8, 2016, the
Company was granted additional claims from the continuation U.S. Serial No. 13/194,900 issued as a new Patent Serial No. 9,487,755.
Prior to the issuance the Company filed a continuation in part (CIP) containing additional claims related to our ongoing media
development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
supports its marketing efforts by making ATCELL<b><i><sup>™ </sup></i></b>samples available for research purposes and for
internal product development through our collaborative and partnering programs. We believe these cell lines may be suitable for
use by private researchers and universities for use in pre-clinical trial studies and in-vitro research. We also believe that
the Company’s ability to provide these materials for these research and development collaborators, partners and other third
parties extends the Company’s ability to become a primary source of clinical grade materials and services necessary to support
approved applications and treatments.</span></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has created several versions of its <i>ACSelerate<b><sup>™ </sup></b></i>cell culture media including</span><span style="font-size: 10pt">:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>ACSelerate-MAX<sup>™
                                         </sup></i>-xeno serum free cell culture media,</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>ACSelerate-SFM<sup>™
                                         </sup></i>- animal serum free cell culture media,</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>ACSelerate-LSM<sup>™
                                         </sup></i>- low FBS (0.05%) cell culture media, </span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>ACSelerate-CY<sup>™</sup></i>-
                                         for differentiation of <i>ATCELL<sup>™</sup></i> into chondrocytes (<i>ATCELL-CY<sup>™</sup></i>),
                                         </span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>ACSelerate-OB<sup>™</sup></i>-
                                         for differentiation of <i>ATCELL<sup>™</sup></i> into osteoblasts (<i>ATCELL-OB<sup>™</sup></i>)
                                         </span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>ACSelerate-AD</i><sup>™
                                         </sup>- for differentiation of <i>ATCELL<sup>™</sup></i> into adipocytes (<i>ATCELL-AD<sup>™</sup></i>)
                                         </span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>ACSelerate-MY<sup>™</sup></i>-
                                         for differentiation of <i>ATCELL<sup>™ </sup></i>into myocytes (<i>ATCELL-MY<sup>™</sup></i>)
                                         </span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>ACSelerate-CP<sup>™</sup></i>-
                                         non-DMSO (Dimethyl Sulfoxide) cellular cryopreservation media </span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>ACSelerate-TR</i><sup>™</sup>-
                                         sterile transportation medium designed to maintain the viability of the tissue during
                                         the shipment of adipose tissue to our processing facility. </span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
continues to optimize additional versions of <i>ACSelerate</i><sup>™ </sup>media that may be necessary for use in future
applications. On December 31, 2014 the Company filed a patent application for an advanced medium formulation titled Human Albumin
Serum for Cell Culture Medium for Growth of Human Adipose Stromal Cells. (US Serial No. 62/098799) representing the initial results
of this ongoing optimization program. On December 31, 2015, the Company converted the provisional patent application to an international
PCT filing (PCT/US/68350) under the title Human Serum for Cell Culture for Growth of Human Adipose Stromal Cells. To date the
patent has also been filed in the following additional countries: China and Hong Kong, India, Mexico, Brazil, the European Union,
US, Japan, Thailand, Brazil, Russia, Australia, New Zealand, Canada, and Saudi Arabia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Contract
Manufacturing, Autokine-CM</b><sup>® </sup><b>Anti-Aging, Autologous Skin Care Product Line </b>– Under agreement
with Personal Cell Sciences Corp. (PCS), we manufacture the key ingredient Autokine-CM<i><sup>®</sup></i> (autologous
adipose derived stem cell conditioned medium) for PCS’ U-Autologous<i>™</i> anti-aging topical formulation. Every
product is genetically unique to the patient and custom blended, deriving its key ingredients from the individual
client’s own adipose derived stem cells. The Company provides its CELLECT<sup>® </sup>Tissue Collection service to
collect the required tissue to manufacture the U-Autologous<i><sup>™</sup></i> product and processes it under the same
Standard Operating Procedures (SOP’s) that it developed for the ATGRAFT<i><sup>™</sup></i> and
ATCELL<i><sup>™</sup></i> processing services utilizing ACSelerate<i><sup>™ </sup></i>cell culture media. The
Company receives collection, processing and storage fees and earns a royalty on all U-Autologous product sales. The
utilization of the Company’s core services in its contract manufacturing relationships provides opportunities for the
Company to promote ATGRAFT<i><sup>™</sup></i> and ATCELL<i><sup>™</sup></i> products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">CRYO’s
contract manufacturing services can be extended to develop custom and/or white label products and services for both local and
global cosmetic and regenerative medicine companies, physicians, wellness clinics and medical spas. The Company intends to expand
its relationships and contract manufacturing regionally through its physician networks and globally through its International
Licensing Program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>International
Licensing Program – </b>COVID RISK FACTOR</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0; text-align: justify"><span style="font-size: 10pt"><i>The
development of our products could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak
of an infectious disease like the recent outbreak of COVID-19. For example, as a result of measures imposed by the governments
in regions affected by COVID-19 businesses have been suspended due to quarantines or “stay at home” orders intended
to contain this outbreak. Furthermore, many patients had concerns about making hospital and physician office visits for fear of
contracting the virus. These factors may have direct adverse impact on our ability to enroll participants in our clinical trial
programs. In addition, travel restrictions, stay-in-place orders and other measures including information control. specifically
in Asian countries, such as China, imposed by governmental agencies and health organizations to prevent the spread of COVID-19
and protect the citizenry, have had an adverse impact on the flow of information, goods and services between nations. The supply
disruptions have resulted in shortages of goods and materials. This could also impact our ability to produce the products we need
to conduct our clinical trials. In addition, these measures have resulted in delays to the regulatory process, which may also
have an adverse impact on our business. We are still assessing our business plans and the impact COVID-19 may have on our ability
to advance the development of our drug candidates or to raise financing to support the development of our drug candidates, we
cannot assure you that we will be able to avoid part or all of any impact from the spread of COVID-19 or its consequences, including
downturns in business sentiment generally or in our sector in particular.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is aware many jurisdictions outside the US currently permit cellular therapies and regenerative medicine applications. The Company
has targeted these jurisdictions for licensing its technologies to local operators and facilities and receives numerous unsolicited
international inquiries concerning the sale or licensing of our SOPs, culture medium products and tissue banking services for
use in the Regenerative Medicine and Medical Tourism Markets. The Company believes that the inquiries to date are a result of
the global boom in Medical Tourism, Regenerative and Personalized Medicine and the slow pace of approval of cellular therapies
and regenerative medicine applications in the US. To address the Company’s sales, marketing and branding opportunities globally,
the Company has included in its international licensing program metrics to vet potential partners and collaborators and their
facilities. To date we have licensed our technologies in Hong Kong, China, and Thailand.</span></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company believes it can take advantage of the significant growth of the global cellular therapy market through its international
licensing and marketing efforts. A recently published study by Transparency Market Research predicts the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become
worth US$270.5 bn by 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(https://www.transparencymarketresearch.com/pressrelease/stem-cells-market.htm)
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>China</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">On July
12, 2018 the Company announced the national launch of its ATGRAFT<sup>TM</sup> tissue collection, processing and storage
technology by Baoxin Asia Pacific Biotechnology (Shenzhen) Co. Ltd. (“Baoxin”) in China. The Company’s management
team traveled throughout south east China with the management and marketing team of Baoxin to present the ATGRAFT<sup>TM</sup> platform
to leading plastic and cosmetic surgery hospitals in Shenzhen, Nanning, Guangzhou, Guangxi and Changsha. Additionally, Mr. Arnone
and Mr. Dudzinski attended the signing of investment documents between Baoxin and Chinese government and Banking officials in
Shenzhen, China as well as the official launch presentation and evening gala hosted by Baoxin in Shenzhen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The China
launch activities were in support of the Company’s licensing and supply agreement with Baoxin, under which Baoxin agreed to pay
the Company a minimum annual guarantee against a fixed fee per process and purchase certain necessary consumables from CRYO required
for the collection, processing and storage of the collected adipose tissue. Under the terms of the Agreements signed in Fiscal
2018, the Company invested in and currently holds five percent (5%) of Baoxin shares. Additionally, Mr. Arnone and Mr. Dudzinski
were elected to serve as Directors of Baoxin during their visit to Shenzhen, China. Mr. Arnone resigned as a board Member of Baoxin
in 2019. Mr. Dudzinski continues to serve the Company’s interests as a board member of Baoxin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
Fiscal 2020 and 2021, due to the continuing effects of the COVID pandemic and associated government policies and regulations Baoxin
suspended its processing activities. Baoxin is an emerging biotechnology company in China that has relied to date on investment
to fund operation and build their facilities, as is typical for these types of companies. During 2020 and 2021, Baoxin developed
a new state of the art facility with sizable clean rooms and biomaterial storage space. The facility was completed in February
2021 and officially opened in May of 2021. Unfortunately, due to the continued effects of COVID and the appearance of new variants
Baoxin has been unable to restart operations and its marketing programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Hong
Kong</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">On June
30, 2014 the Company granted Health Information Technology Company, LTD (“HIT”) exclusive rights to utilize the Company’s
Standard Operating Procedures (SOP’s) to market the Company’s ATGRAFT™ tissue storage service for Hong Kong.
The Agreement calls for upfront fees, royalties and the purchase by HIT of certain consumables manufactured by the Company. The
Company and HIT reached further agreement to extend their relationship on a non exclusive basis to include HIT’s cord blood
laboratory located in Shenzhen, Guangdong Province, one of China’s most successful Special Economic Zones. The HIT agreement
includes initial upfront fees and royalty payments for predetermined gross revenue volumes. HIT will also purchase CRYO ACSelerate™
storage media, CELLECT™ collection and transportation kits as well as other American CryoStem products necessary for clinical
adipose tissue processing and storage at the Shenzhen facility. The final master licensing agreement is for a period of 5 years
with renewal options and was executed between the parties on September 24, 2014. The HIT license has been extended per the terms
of Schedule B of the Term Sheet, dated June 30, 2014, for an additional 3-year period to June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In 2017
as part of the Company’s transaction with Baoxin, HIT and the Company agreed to transfer certain product and distribution
rights granted to HIT under its 2014 agreement to Baoxin. The Company was paid of fee of US$100,000 in the transaction and was
provided with an initial ownership position in a planned Regenerative Treatment Center to be established by HIT in Hong Kong.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The current
pandemic, changes in Chinese regulations and policies regarding Hong Kong, recent political unrest and the inability of Chinese
citizens to cross the border between Hong Kong and China have significantly curtailed the ability of HIT to implement its business
plans to utilize the Company’s technology and purchase the associated consumables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Thailand</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On April
5, 2018 the Company announced further expansion of its global laboratory and cellular technology footprint by entering into an
agreement to license its ATGRAFT™ and ATCELL™ adipose tissue (fat) processing and storage technologies with CRYOVIVA
(Thailand) Ltd., a Bangkok, Thailand based Cord Blood processing and storage facility. CRYOVIVA, Thailand, currently offers collection,
processing and storage of Cord Blood derived biologics to patients throughout Thailand and South East Asia.</span></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">American
CryoStem licensed to CRYOVIVA (Thailand) Ltd., established in 2007, the rights to utilize the Company’s Standard Operating
Procedures (SOP’s) to create and market the Company’s ATGRAFT™ tissue storage service and ATCELL™ adipose
derived stem cell processing and storage services in Thailand. The financial terms generally, call for the payment of certain
training fees and, a percentage of the gross revenue subject to annual minimum payments generated from our products. Additionally,
the Agreement calls for the purchase of CRYO consumable products required for ATGRAFT™ and ATCELL™ sample processing
including CRYO’s ACSelerate™ non-DMSO cryogenic tissue storage media, transportation media, Cellect™ tissue
collection kit, and ACSelerate – Max™ cell culture medium.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The current
COVID pandemic has delayed CRYOVIVA’s scheduled launch of its marketing campaign several times and unfortunately, CRYOVIVA
suspended their tissue banking operations in 2020 and 2021. We are currently in discussions with them concerning the restart of
their operations and initiation of their marketing program for calendar 2022 although there is no certainty that the effects of
the pandemic will ease sufficiently to do so in the near term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Japan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In June
2015, The Company entered into a licensing agreement with CellSource, LTD. (“CellSource”) located in Shibuya, Tokyo
Japan for the licensing of our AGRAFT<sup>™</sup> tissue processing and storage technology and the purchase of our CELLECT<sup>®
</sup>collection products which include our ACSelerate-TR<sup>™</sup> transport medium. The non-exclusive agreement expired
in June of 2020.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Collaborations
/ Partnering Opportunities / Acquisitions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
recognizes the benefits of collaborations with industry and university partners and has increased its efforts to attract and develop
these relationships. Strategically, the Company believes that with a current approved IND application with the US FDA and the
strength of its granted and pending patent portfolio, that it can attract new partners and collaborative arrangements These relationships
are generally covered by Confidential Non-Disclosure Agreements and include Material Transfer Agreements (MTA) under which the
Company may supply ATCELL<sup>™ </sup>and/or ACSelerate<sup>™</sup> medium products for evaluation, testing, and the
development of new cellular therapy applications. The Company has entered into Non-Disclosure and Material Transfer Agreements
with a number of potential collaborators. No assurance can be given that these efforts or relationships will ultimately result
in new technology for future commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
has developed a strategy to expand the opportunities to commercialize its products by increasing its ability to identify and pursue
collaborative and partnering opportunities by cultivating and engaging new relationships with biotechnology companies engaged
in similar or complimentary development activities. Included in this strategy is the increased recruitment of consultants and
other biotechnology experts to identify potential collaborators, partners and acquisition candidates. The Company’s goal
is to develop additional standardized cellular processing models to support FDA IND treatment protocol approvals. This may be
accomplished by further identifying, and validating certain mechanisms and characteristics of mesenchymal stem cells related to
regulating modulation of immune response(s) and promoting tissue regeneration and stability (homeostasis) for the treatment of
traumatic injuries, inflammation, auto-immune diseases, and brain and organ damage associated with viruses such as SARS-CoV-2
(COVID-19), including, the expanding group of patients dealing with the chronic and debilitating symptoms of what is commonly
termed “Long Haul COVID” or “Long COVID.” To date the Company has completed agreements with the following
entities for development of new products and cellular therapy targets although the successful commercialization of new products
and therapies resulting from these activities cannot be assured or predicted at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">WRNMMC</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">On
December 3, 2020, the Company entered into a Cooperative Research and Development Agreement (CRADA) with Walter Reed National
Military Medical Center (WRNMMC), the nation’s largest and most renowned joint military medical center serving the Army,
Navy, Air Force and Marines located in Bethesda, Maryland.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">A
Cooperative Research and Development Agreement (CRADA) is a written agreement between a government agency and a non-federal entity
that allows the federal government and its non-federal partners to optimize and maximize use of their resources, exchange technical
expertise in a protected fashion, share intellectual property resulting from collaborative effort, and speed commercialization
of federally developed technology. The Company has committed to provide materials including ATCell samples and Umbilical Cord
stem cells, ACSelerate Max Growth and differentiation mediums testing and other processing supplies, processing and testing methods.
The Company maintains the rights to commercialize all technology developed under this CRADA Agreement. The technology is centered
on creating in vitro (test tube) assays to standardize and commercialize new treatment protocols; optimizing quality control measures;
and developing standardized protocol potency assays for precise therapy dosing. Management believes that these new assays can
be commercialized to generate substantial sales and licensing revenues and create value for the Company’s stakeholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Through
the Collaboration entitled “Stem Cells for Regeneration and Medical Innovation, a multi-faceted and multi-staged research
project with WRNMMC Biomedical Laboratories, the Company plans to develop, validate and standardize baseline and assay metrics
to identify mesenchymal stem cell (MSC) characteristics and quantities across various cell biomarkers and exosome expressions
data sets for its ATCell™ product for biologics developers’ use worldwide. The focus of the Collaboration is to enable
the creation of predictive and prescriptive cellular models which will further enhance American CryoStem’s mission as a
premier biologics’ manufacturer and developer and be highly valuable to the medical community, biotech developers, and the
public at large.</span></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">WRNMMC
is part of The <b>Military Health System (MHS)</b> which is the enterprise within the United States Department of Defense
that provides health care to active duty, Reserve component and <span style="text-decoration: underline">retired</span> <span style="text-decoration: underline">U.S. Military</span> <span style="text-decoration: underline">personnel</span> and
their dependents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The
missions of the MHS are complex and interrelated: To ensure America’s 1.4 million active duty and 331,000 reserve-component
personnel are healthy so they can complete their national security missions.</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">·</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">To
ensure that all active and reserve medical personnel in uniform are trained and ready to provide medical care in support of operational
forces around the world.</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">·</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">To
provide a medical benefit commensurate with the service and sacrifice of more than 9.5 million active-duty personnel, military
retirees, and their families.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 10pt 0; text-align: justify"><span style="font-size: 10pt">The
MHS also provides health care, through the TRICARE health plan, to:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">·</span></td><td style="text-align: justify"><span style="font-size: 10pt">Active-duty service members
and their families,</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">·</span></td><td style="text-align: justify"><span style="font-size: 10pt">Retired service members and
their families,</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">·</span></td><td style="text-align: justify"><span style="font-size: 10pt">Reserve component members
and their families,</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">·</span></td><td style="text-align: justify"><span style="font-size: 10pt">Surviving family members,</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">·</span></td><td style="text-align: justify"><span style="font-size: 10pt">Medal of Honor recipients
and their families</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">·</span></td><td style="text-align: justify"><span style="font-size: 10pt">Some former spouses, and</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">·</span></td><td style="text-align: justify"><span style="font-size: 10pt">Others identified as eligible
in the Defense Enrollment Eligibility Reporting System</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; margin-left: 0; text-align: justify"><span style="font-size: 10pt">The
MHS has a $50+ billion budget and serves approximately 9.5 million beneficiaries. The MHS employs more than 144,217 in 51 hospitals,
424 clinics, 248 dental clinics and 251 veterinary facilities across the nation and around the world, as well as in contingency
and combat-theater operations worldwide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; margin-left: 0; text-align: justify"><span style="font-size: 10pt"><b>RACEMD</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; margin-left: 0; text-align: justify"><span style="font-size: 10pt">In March
2022, the Company entered into a collaborative agreement with RACEMD, a 501c(3) charitable organization focused on the improvement
of treatments and therapies for patient with Duchenne Muscular Dystrophy. Duchenne muscular dystrophy (DMD) is a severe type of
muscular dystrophy that primarily affects boys. Muscle weakness usually begins around the age of four and worsens quickly. Muscle
loss typically occurs first in the thighs and pelvis followed by the arms. Most affected individuals are unable to walk by the
age of 12. Some may have intellectual disability. DMD affects about one in 3,500 to 6,000 males at birth. It is the most common
type of muscular dystrophy. The life expectancy is 26; however, with excellent care, some may live into their 30s or 40s. The
disease is much rarer in girls, occurring approximately once in 50,000,000 live female births.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; margin-left: 0; text-align: justify"><span style="font-size: 10pt">The terms
of the Agreement call for the Company to work with RACEMD to develop clinical therapies and studies focused on mitigating the
effect of the disease, improve muscle strength and quality of life in the short term and to build upon successes to seek a more
curative cellular therapy solution to extend life expectancy over the long term. The Company is in the final stages of completing
its plans with RACEMD to submit an initial safety study for use of ATCell as the treatment protocol and expects to make its initial
filing to FDA in early 2022. RACEMD has committed to funding the initial studies and to assist the Company in creating non-dilutive
funding opportunities for larger advanced studies in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>PeproTech,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On April
4, 2016 the Company entered into an Agreement with PeproTech, Inc of Rocky Hill, NJ. Under the Agreement PeproTech manufactures,
markets and distributes the Company’s ACSelerate – Max cell growth medium. The Company and PeproTech completed the
optimization and scale up manufacturing studies and the licensed medium is marketed under both PeproTech’s, PeproGrow and
the Company’s ACSelerate MAX brands. PeproTech plans to leverage its current global sales relationships which reach a majority
of all research laboratories worldwide to maximize distribution of the optimized media while the Company will concentrate its
sales efforts on its collaborative and international licensing partners. Additionally, the Company and PeproTech are discussing
the licensing of additional American CryoStem patented media and products for production and distribution by PeproTech, any additional
media licensed to PeproTech will undergo similar optimization and scale up production testing prior to being released for sale.
The Company is in ongoing discussion with PeproTech related to increasing the visibility and sales of the medium and the optimization
of additional medium products focused on the differentiation of adult stem cells that are synergistic to the cell culture medium.</span></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Regulatory
Information </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On January 3,
2018, the Company received a warning letter from the U.S. FDA concerning its contract manufacturing services at its Monmouth Junction,
NJ facility. The FDA informed the Company that the Agency determined that its autologous adipose derived cell product, ATCELL™
is a drug under current FDA regulations and guidance. The Company voluntary ceased shipment of its ATCell product within the United
States in January of 2018. Since the Company’s initial response to the warning letter it spent considerable time and effort
to comply with the concerns and observations highlighted in the letter. Specifically, the Company designed and filed it first
Investigation New Drug Application with FDA which was approved on September 17, 2020. The Company implemented, qualified and validated
its completely redesigned manufacturing new clean manufacturing space, SOPs and Quality Management program in its facility in
Monmouth Junction, N.J. Our SOPs are the key to compliantly operating our tissue processing facility. In 2018 the Company hired
a cGMP consultant to assist with the update of all SOP’s, data collection forms, Quality Control Program and laboratory
operations to conform with cGMP in response to the observations made by FDA. To ensure delivery of the highest quality services,
we incorporated into these SOPs, certain accreditation requirements of the American Association of Blood Banks (AABB), the American
Association of Tissue Banks (AATB) and the Foundation for the Accreditation of Cellular Therapy (FACT-JACIE). The Company is planning
to seek accreditation by one or more of the associations in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
filed its final responses to FDA regarding the Warning Letter in early January of 2020. Based upon the Company’s IND approval
and FDA policy, the final dispensation of the Warning Letter is on hold by the FDA Office of Regulatory Affairs (ORA) pending
completion of the study and the filing by the Company of the formal Biologics License Application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In response
to the Warning Letter and in preparation of the IND filing, the Company expanded its existing facilities and undertook a complete
remediation of its laboratory operations in expectation of the (IND) filing with the FDA for the use of autologous adipose derived
cells for the relief of inflammation associated with certain conditions resulting from mild traumatic Brain Injury (mTBI) or concussive
trauma. The Company also leased additional space, certified and validated a new Clean Room designed specifically for cellular
expansion, medium filling and tissue processing. In addition, the Company retained consultants to assist its personnel in the
review and re-validation of its operating procedures, equipment and processing methods as well as designing new procedures for
upgraded and newly acquired laboratory operating and testing equipment. These new validated manufacturing methods and upgraded
laboratory facility were reviewed by the FDA during the IND application process. Due to the construct of our core technologies,
the FDA regulatory pathway enables the Company to “cross-reference” the Chemistry Manufacturing and Control (CMC)
modules of the current study for use in subsequent new INF treatment applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company’s
New Jersey laboratory facility is registered with the FDA (FEI 3008307548) as a processing and storage facility for Human Cells,
Tissues and Cellular and Tissue Based Products (HCT/Ps) since 2010. We have discussed our operations with the State of New Jersey
Health Department and Department of Environmental Protection (DEP) to ascertain any special regulations to which we may be subject.
Based upon these discussions, and our use of a registered medical waste disposal company, we do not at this time have any special
registrations or regulations for compliance with the State of New Jersey.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have consistently
endeavored to ensure that our processes, methodologies and procedures remain among the highest standards in the global tissue
collection, processing and storage market. To this end, we have equipped ourselves with state-of-the-art quality processing and
testing equipment, which we believe helps to ensure that every sample collected and processed is sterile (free from adventitious
agents), viable and capable of significant cellular growth and expansion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Quality Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company’s
quality management program attempts to ensure that during processing and testing of each adipose tissue, or cellular sample, the
appropriate quality management tests and processing methodologies are performed, and the data is collected, recorded and reviewed
by the laboratory management team. In 2018 the Company hired a Quality Control consultant to assist the Company in updating its
Quality Control Program, laboratory processes, Sops, data collection, and laboratory, product and materials validation programs.
The new system was completed, qualified and validated in 2019 and has been implemented in the new clean processing facility the
Company qualified in 2019 to support our intended clinical studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Quality Management
is a significant focus of clinical studies and is subject to both FDA regulation and guidance, as well as The International Council
for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH guidelines are applied by a growing number
of global regulatory authorities. ICH’s mission is to achieve greater harmonization worldwide to ensure that safe, effective and
high-quality medicines are developed, and registered and maintained in the most resource efficient manner whilst meeting high
standards. Since October 2015, ICH has grown as an organization and now includes 19 International Members and 35 Observers. The
FDA requires incorporation of the quality standard into clinical study and cGMP manufacturing and the Company has incorporated
the relative requirements of these guidelines into both its approved IND and its cGMP manufacturing standard operating procedures
as required. The Company employs this strategy in its efforts to accelerate regulatory approvals in the US.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Chain
of Custody Control</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Central to the
individual sample testing is an unbroken chain of custody and tracking. Sample tracking begins with the creation of each CELLECT
collection box. All samples, processing, quality management, batch, and storage documents and records, are coded with this unique
number. All records and testing samples are cross referenced and verified as required by the standard operating procedures.</span></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Testing
Design and Standard Operating Procedures (SOPs)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Testing methods
are standardized and operate under a complete set of SOPs and Quality Management (QM) processes. All SOPs are designed to be in
compliance with the US Food and Drug Administration’s regulations and guidance for aseptic processing. Strict QM is enforced
to avoid and/or record any process deviations. In 2018 in response to the FDA letter the Company undertook a major reorganization
and upgrade of all of its methods, SOPs, processes and facility to upgrade its facility from a registered tissue bank to a Biologic
Drug Manufacturer. This update was completed concurrently with the validation and qualification of the Company’s new quality
management system that was completed, validated and qualified in 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">From the Company’s
formation, our strategy has been to invest time and capital in intellectual property protection. This strategy is intended to
strengthen our Company’s foundation in any defensive or offensive legal challenge. In addition, we are developing our IP
portfolio to ensure and enhance our business flexibility and allow us to gain favorable terms in potential future collaborative
partnerships with third parties. Our intellectual property portfolio currently includes four issued U.S. patents (No. 7,989,205,
and Serial No. 9,487,755, <i>Cell Culture Media Kits and Methods of Use, “Systems and Methods for the Digestion of Adipose
Tissue Samples Obtained from a Client for Cryopreservation” US 10,154,664 issued December 18, 2018, and “Business
Method for Collection, Processing, Cryogenic Storage and Distribution of a Biologic Sample Material” US Patent Number 10,014,079,
issued July 3, 2018</i>); and has additional pending patent applications which are detailed in the following chart:</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border: Black 1pt solid; width: 39%; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="border-top: Black 1pt solid; width: 31%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Technology</b></span></td>
    <td style="border-top: Black 1pt solid; width: 30%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Patent
    / Application Number</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><span style="font-size: 10pt">Cell
    culture media, Kits, and Methods of Use</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">ACS cell culture media line</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Covers 12 types of Medium</span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">US Patent No. 7,989,205</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Issued August 2, 2011</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><span style="font-size: 10pt">Cell
    culture media, Kits, and Methods of Use</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">ACS cell culture media line</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Additional claim Granted
        for all 12 medium types</span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">US Patent No. 9,487,755</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Issued November 8, 2016</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Continuation of US Patent
        No. 7,989,205</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><span style="font-size: 10pt">Cell
    culture media, Kits, and Methods of Use</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">ACS cell culture media line</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Continuation of Granted Patent
        covering additional improvements</span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">US Patent Application No.
        15/344,805</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Continuation of US Patent
        No. 7,989,205</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><span style="font-size: 10pt">Human
    serum for cell culture medium for growth of human adipose stromal cells</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">A cell culture medium for
        growth of human adipose stromal cells for human and therapeutic applications</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&nbsp;</span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">PCT/US15/68350</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">30 month National Phase entry
        date of June 31, 2017, additional International Filings for China, India, the European Union, Saudi Arabia, Israel, Brazil,
        Mexico, Australia and New Zealand.</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><span style="font-size: 10pt">A
    Business Method for Collection, Cryogenic Storage and Distribution of a Biological Sample Material </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Company Core Tissue Collection
        Processing and Storage Methodology</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Covers CELLECT Kit, Transport
        and Cryopreservation Medium for ATGRAFT and ATCELL Products</span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">US Serial No 13/194,900</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Filed June 6, 2010</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Patent Application Published</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">December 5, 2013 Claims Granted
        US Patent No. 10,014,079. Continuation filed upon issuance.</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><span style="font-size: 10pt">A
    Business Method for Collection, Cryogenic Storage and Distribution of a Biological Sample Material </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Company Core Tissue Collection
        Processing and Storage Methodology</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Continuation covering Improvements</span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><span style="font-size: 10pt">Developed
    Improvement established; Divisional, Continuation-In-Part claiming priority to US Serial No. 13/194,900 imminent (PCT
    Application filing planned)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><span style="font-size: 10pt">Systems
    and Methods for the Digestion of Adipose Tissue Samples Obtained From a Client For Cryopreservation </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Adipose Tissue Digestion
        Laboratory Processing Methods</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&nbsp;</span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><span style="font-size: 10pt">U.S.
    Serial No.
    13/646,647 filed
    October 6, 2011, Claims Granted US Patent No.10,154,664. Continuation filed upon issuance. </span></td></tr>
</tbody></table>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<table cellspacing="0" cellpadding="0" style="border-top: Black 0.5pt solid; width: 100%; background-color: white; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Technology</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Patent
    / Application Number</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt; width: 39%"><span style="font-size: 10pt">Systems
    and Methods for the Digestion of Adipose Tissue Samples Obtained From a Client For Cryopreservation </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt; width: 31%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Adipose
                                         Tissue Digestion Laboratory Processing Methods</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&nbsp;</span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt; width: 30%"><span style="font-size: 10pt">Developed
    Improvement established; Divisional, Continuation-In-Part claiming priority to US Serial No. 13/646,900 imminent (PCT
    Application filing planned)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><span style="font-size: 10pt">Compositions
    and Methods for collecting, Washing, Cryoprocessing, Recovering and Return of Lipoaspirate to Physicians for Autologous Adipose
    Transfer Procedures”</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><span style="font-size: 10pt">Company
    Adipose Tissue Storage Platform for Cosmetic Procedures Covers the core processing adipose tissue for ATGRAFT adipose tissue
    dermal filler product</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">U.S.
                                         Serial No. 14/406,203 National Phase entry date of December 5, 2014 based on PCT/US2013/044621</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&nbsp;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">European Union Application
        No. EPI3800847.9</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">China Application No. 2013800391988</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><span style="font-size: 10pt">Compositions
    and Methods for “Collecting, Washing, Cryoprocessing, Recovering and Return of Lipoaspirate to Physicians for Autologous
    Adipose Transfer Procedures”</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Company Adipose Tissue Storage
                                                                                                                                          Platform for Cosmetic Procedures Covers additional claims related to ATGRAFT process not included in
                                                                                                                                          original application</span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><span style="font-size: 10pt">Developed
    Improvement established; Divisional, Continuation-In-Part claiming priority to US Serial No. 14/406,203 imminent (PCT
    Application filing planned)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><span style="font-size: 10pt">Systems
    and methods to isolate and expand stem cells from urine</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Isolation
                                         of stem cells from urine of patients for use in research and therapeutics</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 4pt"><span style="font-size: 10pt">US
    Serial Nos. 62/335,426 and 62/439,106</span></td></tr>
</tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Additionally,
the Company has in-licensed the following IP:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border: Black 1pt solid; width: 39%; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Patent
    Title </b></span></td>
    <td style="border-top: Black 1pt solid; width: 31%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Use
    of Patent</b></span><b><span style="font-size: 10pt; color: white"> </span></b></td>
    <td style="border-top: Black 1pt solid; width: 30%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Application
    # </b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"><span style="font-size: 10pt">Cosmetic compositions
        including tropoelastin isomorphs</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"><span style="font-size: 10pt">(wound healing)</span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 4pt"><span style="font-size: 10pt">Protein
    Genomics and American CryoStem (Autogenesis) collaboration </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 4pt"><span style="font-size: 10pt">USPTO
    #5,726,040 </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"><span style="font-size: 10pt">Cosmetic compositions</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"><span style="font-size: 10pt">(wound healing)</span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 4pt"><span style="font-size: 10pt">Protein
    Genomics and American CryoStem (Autogenesis) collaboration </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 4pt"><span style="font-size: 10pt">USPTO
    #6,451,326 </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"><span style="font-size: 10pt">Recombinant hair
        treatment compositions</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"><span style="font-size: 10pt">(wound healing)</span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 4pt"><span style="font-size: 10pt">Protein
    Genomics and American CryoStem (Autogenesis) collaboration </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 4pt"><span style="font-size: 10pt">USPTO
    #6,572,845 </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"><span style="font-size: 10pt">Wound healing compositions
        and methods using tropoelastin and lysyl oxidase</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"><span style="font-size: 10pt">(wound healing)</span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 4pt"><span style="font-size: 10pt">Protein
    Genomics and American CryoStem (Autogenesis) collaboration </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 4pt"><span style="font-size: 10pt">USPTO:
    #6,808,707 </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"><span style="font-size: 10pt">Business methods,
        processes and systems for collection, cryogenic storage and distribution of cosmetic formulations from an obtained stem
        cell based a biological</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0"><span style="font-size: 10pt"></span></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 4pt"><span style="font-size: 10pt">Personal
    Cell Sciences and American CryoStem collaboration </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 4pt"><span style="font-size: 10pt">USPTO
    application #61/588,841 </span></td></tr>
</tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><i>Trademarks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition
to patents, the Company has registered the following trademarks with the U.S. Patent and Trademark Office: <i>American CryoStem<sup>®</sup>,
CELLECT<sup>®</sup></i> and <i>ATGRAFT</i><sup>™</sup>. We plan to obtain additional registered trademarks for our future
products, slogans and themes to be used in our marketing initiatives, including, for example,<i> ACSelerate-SFM<sup>™</sup></i>,
<i>ACSelerate- LSM<sup>™</sup></i> and <i>ATCELL<sup>™</sup>. </i>The Company has also secured a number of online
domain names relevant to its business, including www.americancryostem.com and www.acslaboratories.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Market
Size and Opportunities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">By leveraging
our proprietary Adipose Tissue Processing Platform, the Company is working to address multiple high growth, multi-billion dollar
market opportunities prevailing within the Regenerative Medicine, Cosmeceuticals, Medical Tourism and Cell Therapy markets. The
Company regularly reviews independent market research to gauge the market size of its intended domestic and international markets
and to identify additional areas within these markets where the Company’s laboratory products, cell culture medium, and
tissue and cellular processing services can be marketed, sold and/or licensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Global
Stem Cells Market</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">A
report from Transparency Market Research (TMR) forecasts that the global stem cells market is expected to register a
healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025. Depending upon geography, the key
segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa.
At present, North America dominates the market because of the substantial investments in the field, impressive economic growth,
rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will
likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 4pt 0 2pt; text-align: justify"><span style="font-size: 10pt; font-weight: normal">A
report published by Markets and Markets Research in 2017 titled “ Cell
Expansion Market by Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative
Medicine &amp; Stem Cell Research, Cancer), End user (Research Institute, Cell Bank) - Global Forecasts to 2021”. The report
states: “ The global cell expansion market is expected to reach USD $18.76 Billion
by 2021 from USD $8.34 Billion in 2016 at a CAGR of 17.6%. Geographically, the cell expansion market is dominated by North America,
followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American segment is primarily driven by increasing
incidence of chronic diseases in the North American countries. According to the American Medical Association and the American
Medical Group Association, more than 50% of Americans suffered from one or more chronic diseases in 2012; the number of Americans
suffering from chronic diseases was around 133 million in 2005 and this figure is expected to reach around 157 million by 2020.
With this significant growth in the number of patients suffering from chronic diseases, the market for cell expansion is expected
to grow in this region in the coming years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Regenerative
Medicine Market</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Global
Translational Regenerative Medicine market is expected to grow significantly over the forecast period. The Global Translational
Regenerative Medicine market was valued at $5.8bn in 2016. Vision gain forecasts this market to increase to $14.5bn in
2021. The market is estimated to grow at a CAGR of 19.9% in the first half of the forecast period and 17.7% from 2016 to 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Cell Culture
Market </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Cell Culture
Market Global Forecast to 2023</b>, according to “marketsandmarkets” the cell culture market is expected to reach USD $26.28 Billion by 2023 from USD
$15.32 Billion in 2018, at a CAGR of 11.4%. Growth in this market is driven by the growing number of regulatory approvals for
cell culture-based vaccines, increasing demand for monoclonal antibodies (mAbs), funding for cell-based research, growing preference
for single-use technologies, and the launch of advanced cell culture products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Marketing
and Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The key objective
of our marketing strategy is to position American CryoStem in the market as the “Gold Standard” for adipose tissue
collection, cell processing and cryogenic storage, research/commercial uses and therapeutic applications of adipose tissue within
the current regulatory framework. The combination of a traditional sales approach supported by continuous internal and external
marketing program(s) is closely coordinated with the expansion of our laboratory processing capabilities. Our initial marketing
efforts intend to disseminate current and future uses of adipose tissue and adult stem cells which support our business model,
products and services. We intend to continue to employ both print advertising and social media sales campaigns. In addition, we
plan to continue to utilize key leaders, and early adopters in the medical community as a marketing resource to enhance awareness
of our proprietary, patented products and services and to increase the number of surgeons who join our network, university and
private collaboration and consumers who use our products and services.</span></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We plan to continue
direct marketing programs focused on reaching regenerative medicine physicians and plastic and cosmetic surgeons to join our network
of providers that offer our services to their patients. This marketing initiative has been implemented using a traditional sales
approach common to the pharmaceutical and biotechnology industries. This fundamental sales approach at the core of our marketing
activities is being strategically and tactically expanded using a combination of in-house sales personnel and outside independent
channels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our plan, capital
permitting, provides for a comprehensive integrated marketing approach using various traditional and new media, such as the Internet,
social media/blogging, video, print, TV, radio and trade shows to reach targeted potential consumers and promote awareness of
our Company and our branded products and services. The essence of this targeted strategy is to reach the end-users as quickly
as possible and to accelerate the adoption curve of our products and services. We also plan to utilize outside marketing resources
and trade groups to increase the number of surgeons willing to offer our products and services to their patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b>Development of Regional
U.S. Markets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Physician
Network - </i></b>The Company continues to develop regional relationships to leverage its new products and services through existing
cosmetic surgery and regenerative medicine practices. The Company continues to develop and expand its network of physicians seeking
to adopt its products and services, initially focusing on surgeons performing liposuction, tissue transfer and regenerative procedures
involving the use of adipose tissue. The Company intends to continue expanding its efforts to medical professionals interested
in tissue storage and Regenerative Medicine applications utilizing ASDCs and establish itself as a primary source of collection,
processing, and preparation of cellular therapies as they are developed and approved for patient use by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Development
of International Markets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>International
Licensing Program</i> – </b>Globally, many jurisdictions outside the US permit the use of adipose tissue based cellular
therapies and regenerative medicine applications. The Company has received numerous inquiries concerning the sale or licensing
of our products and services in these jurisdictions. The Company believes that the inquiries to date are a result of the global
boom in Medical Tourism and the slow pace of approval of cellular therapies and regenerative medicine applications in the US.
To address these inquiries and to expand the Company’s sales, marketing and branding opportunities the Company has designed
and is offering an International Licensing Program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The program
is designed to permit the licensing of the Company’s products and services to organizations that meet the Company’s
financial and technical criteria. The licensing program allows for a variety of business relationship including franchising, partnering
and joint venturing. Marketing efforts to date have been to clinics, physician and hospitals in foreign jurisdictions capable
of rapidly building or committing the appropriate facilities and personnel to create the required laboratory facilities to operate
the CELLECT<sup>®,</sup> ATGRAFT™ and ATCELL™ services in their local market. Strategically, the Company’s
international licensees will maintain the branding of the Company’s services along the lines of the “Intel Inside”
branding program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Qualified
Licensees can quickly take advantage of the rapidly expanding opportunity to collect, process, store and culture individual regenerative
cell samples for their clients with the comfort and confidence that they are providing services that have been developed to conform
to US FDA standards. Core to the relationship is the developed proprietary and patent pending processing and laboratory operational
methodologies contained in our Standard Operating Procedures, Training, and Continuous Quality Management, Testing Program, and
Laboratory Operations manuals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Licensing
programs may be initiated through a letter of intent (LOI) agreement between the Company and the prospective licensee. This LOI
agreement is designed for due diligence and facility qualifications purposes. The Company receives an initial fee under the agreement
which may or may not be credited toward future royalty payments. Following evaluation of the prospective licensee the Company
will enter into a final Agreement which outlines all upfront fees, minimum royalties and consumable purchase obligations of the
Licensee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Significant
to our international development activities is the global expansion of the American CryoStem branded services and patented products,
as well as the expansion of the Company’s services, technology and products as the core platform to implement cellular therapies
and regenerative medicine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Baoxin
Asia Pacific Biotechnology (Shenzhen) Co. Ltd. </b>On July 12, 2018 The Company announced
the national launch of CRYO’s ATGRAFT<sup>TM</sup> tissue collection, processing and storage technology by Baoxin Asia Pacific
Biotechnology (Shenzhen) Co. Ltd. (“Baoxin”) in China. The management team traveled throughout southeast China with
the management and marketing team of Baoxin to present the ATGRAFT<sup>TM</sup> platform to leading plastic and cosmetic
surgery hospitals in Shenzhen, Nanning, Guangzhou, Guangxi and Changsha. The China launch activities are in support of the Company’s
previously announced licensing and supply agreement with Baoxin, under which Baoxin will pay the Company a minimum annual guarantee
against a fixed fee per process and purchase certain necessary consumables from CRYO required for the collection, processing and
storage of the collected adipose tissue. Under the terms of the Agreements signed in Fiscal 2018, the Company invested in and
currently holds five percent (5%) of Baoxin shares. Additionally, Mr. Arnone and Mr. Dudzinski were elected to serve as Directors
of Baoxin during their visit to Shenzhen, China. During 2019 Mr. Arnone resigned from the board of Baoxin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">During Fiscal
2020 and 2021, due to the continuing effects of the COVID pandemic and associated government policies and regulations Baoxin suspended
its processing activities. Baoxin is an emerging biotechnology company in China that has relied to date on investment to fund
operation and build their facilities, as is typical for these types of companies. During 2020 and 2021, Baoxin developed a new
state of the art facility with sizable clean rooms and biomaterial storage space. The facility was completed in February 2021
and officially opened in May of 2021. Unfortunately, due to the continued effects of COVID and the appearance of new variants
Baoxin has been unable to restart operations and its marketing programs. See Note 3, Note 13 and Note 14 for additional information.</span></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Health
Information Technology Company, LTD (Hong Kong)</b> - On June 30, 2014 the Company granted Health Information Technology Company,
LTD (“HIT”) exclusive rights to utilize the Company’s Standard Operating Procedures (SOP’s) to market
the Company’s ATGRAFT™ tissue storage service for Hong Kong. The Agreement calls for upfront fees, royalties and the
purchase by HIT of certain consumables manufactured by the Company. The Company and HIT have reached further agreement to extend
their relationship on a non-exclusive basis to include HIT’s cord blood laboratory located in Shenzhen, Guangdong Province,
one of China’s most successful Special Economic Zones. The HIT agreement includes, initial upfront fees and royalty payments
for predetermined gross revenue volumes. HIT will also purchase CRYO ACSelerate™ storage media, CELLECT™ collection
and transportation kits as well as other American CryoStem products necessary for clinical adipose tissue processing and storage
at the Shenzhen facility. The final master licensing agreement is for a period of 5 years with renewal options and was executed
between the parties on September 24, 2014. The HIT license has been extended per the terms of Schedule B of the Term Sheet, dated
June 30, 2014, for an additional 3 year period to June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In 2017
as part of the Company’s transaction with Baoxin, HIT and the Company agreed to transfer certain product and distribution
rights granted to HIT under its 2014 agreement to Baoxin. The Company was paid a fee in the transaction and was provided with
an initial ownership position in a planned Regenerative Treatment Center to be established by HIT in Hong Kong.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The
current pandemic, changes in Chinese regulations and policies regarding Hong Kong, recent political unrest and the inability of
Chinese citizens to cross the border between Hong Kong and China have significantly curtailed the ability of HIT to implement
its business plans to utilize the Company’s technology and purchase the associated consumables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>CRYOVIVA
(Thailand), Ltd.</b> - On April 5, 2018 the Company announced further expansion of its global laboratory and cellular technology
footprint by entering into an agreement to license its ATGRAFT™ and ATCELL adipose tissue (fat) processing and storage technologies
with Cryoviva (Thailand) Ltd., a Bangkok, Thailand based Cord Blood processing and storage facility. Cryoviva, Thailand, currently
offers collection, processing and storage of Cord Blood derived biologics to patients throughout Thailand and South East Asia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">American
CryoStem has licensed to Cryoviva (Thailand) Ltd., established in 2007, the rights to utilize the Company’s Standard Operating
Procedures (SOP’s) to create and market the Company’s ATGRAFT™ tissue storage service and ATCELL™ adipose
derived stem cell processing and storage services in Thailand. The financial terms generally, call for the payment of certain
training fees and, a percentage of the gross revenue subject to annual minimum payments generated from our products. Additionally,
the Agreement calls for the purchase of CRYO consumable products required for ATGRAFT and ATCELL sample processing including CRYO’s
ACSelerate™ non-DMSO cryogenic tissue storage media, transportation media, Cellect™ tissue collection kit, and ACSelerate
– Max™ cell culture medium.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The
current COVID pandemic has delayed CRYOVIVA’s scheduled launch of its marketing campaign several times and
unfortunately, CRYOVIVA suspended their tissue banking operations in 2020 and 2021. We are currently in discussions with them
concerning the restart of their operations and initiation of their marketing program for calendar 2022 although there is no certainty
that the effects of the pandemic will ease sufficiently to do so in the near term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>CellSource
Tokyo, Japan</b> - In the second quarter of 2015 the Company entered into negotiations with CellSource, LLC in Tokyo, Japan for
the licensing of its ATGRAFT<sup>™</sup> products and services and on June 2, 2015 the Company and Cell Source entered into
an initial term sheet licensing the ATGRAFT<sup>™</sup> technology to CellSource for Japan. The non- exclusive agreement
expired in June of 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Scientific
and Medical Advisory Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We continue
to actively recruit and enlist the services of highly qualified peer leaders through our Scientific and Medical Advisory Board
to assist us in our industry speaking engagements and education platform. This education platform is designed to focus on physicians,
and industry needs and demands as they relate to current and future treatments utilizing our adipose tissue platform and adult
stem cell technologies. Additionally, certain members of our advisory board provide assistance and input to management on the
oversight of our research relationships, laboratory development and quality management systems. As of September 30, 2020, the
following are currently members of our Scientific and Medical Advisory Board:</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Dayong Gao,
Ph.D.</b> - Dr. Gao is a world-renowned Professor of Mechanical Engineering and Biomedical Engineering at the University of Washington
in Seattle. He has been actively engaged in cryopreservation research for more than 20 years, with specific emphasis on fundamental
and applied cryobiology, which is the investigation of mechanisms in cryo-injury and cryo-protection with respect to living biological
systems at low temperatures; with the development of optimal methods and technologies for the cryopreservation; and with the banking
of living cells and tissues for biomedical applications. Dr. Gao has published 175 research papers in prestigious scientific/biomedical
journals, with over 250 papers/abstracts in conference proceedings. He has obtained 16 patents and authored two scientific books
and numerous chapters in 17 scientific books. He currently serves on the Editorial Board, as Editor-in-Chief, of six scientific
journals, and is the Editor of the Cryopreservation Engineering section of <i>Biopreservation and Biobanking</i>. His research
in cryobiology and cryopreservation has been funded by the National Institutes of Health, the American Cancer Society, the Bill
and Melinda Gates Foundation, the American Heart Association, the Whitaker Foundation, the Washington Research Foundation and
the Kentucky Science Foundation, among others. Dr. Gao graduated with B.Sc. degree from the University of Science and Technology
in China and received a Ph.D. in Mechanical Engineering from Concordia University, Montreal, Canada.</span></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Fredric A.
Stern, MD. F.A.C.S.</b> - Dr. Stern is the founder and Medical Director of the Stern Center for Aesthetic Surgery in Bellevue,
Washington. Following his education at Columbia University Medical School, Dr. Stern earned his Board Certification in Ophthalmology
at the University of Washington, and underwent extensive additional training in oculofacial plastic and laser surgery. In 1987,
he joined Virginia Mason Medical Center in Seattle, serving as Director of the Oculoplastic Surgery Division for ten years. While
at Virginia Mason, Dr. Stern performed an extensive number of cosmetic laser procedures. He is honored to have been chosen as
one of a select group of instructors of the <i>Botox Cosmetic</i><sup>® </sup>National Education Faculty, as well as the <i>Radiesse<sup>™
</sup></i>Medical Education Faculty. Dr. Stern is also an instructor for the <i>Sciton</i><sup>™</sup><i>Laser</i>. In 2011,
he was voted the Best Plastic Surgeon in Western Washington by <i>KING 5</i> (NBC affiliate) TV’s viewing audience. Dr.
Stern is a Fellow of the American College of Surgeons, the American Academy of Facial Plastic and Reconstructive Surgeons, the
American Academy of Cosmetic Surgery, and the American Society of Liposuction Surgery, as well as a member of the International
Society of Hair Restoration Surgery. In addition, over the past several years, he has appeared on <i>Northwest Afternoon</i>,
<i>Evening Magazine</i>, as well as <i>KOMO</i>, <i>KIRO</i> and <i>Q13</i> news, discussing and demonstrating the latest techniques
in facial and eyelid laser cosmetic surgery, <i>Botox</i><sup>®</sup> and laser-assisted liposuction. He is also an accomplished
winemaker &amp; published novelist. Dr. Stern’s latest novel is a medical thriller titled, <i>The Sigma Project</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Vincent
Giampapa, MD F.A.C.S</i></b> - Dr. Giampapa is the founder /di<span style="text-decoration: underline">r</span>ector of the Regenerative Medicine Institute located in
Costa Rica, the Plastic Surgery Center International and The Giampapa Institute for Anti-Aging Medical Therapy located in Montclair,
NJ. Dr. Giampapa’s research focuses on stem cell technologies and their applications to improve the cellular aging process
in order to enhance health span and quality of life. As a result of his research, Dr. Giampapa has been awarded medical and intellectual
property patents with the United States Patent and Trademark Office for developments involving unique cell culture delivery techniques,
new drug delivery systems, stem cell reprogramming, DNA repair, and telomerase maintenance. He is a co-founder of The Academy
of Anti-Aging Medicine (A4M), comprised of over 26,000 members representing over 110 nations, the first president of the Board
of Anti-Aging Medicine and the founder of healthycell®, an advanced cell health nutritional supplement and StemBank™,
a blood derived stem cell extraction and storage company. Dr. Giampapa will have an active role assisting the Company with the
development of its “From laboratory to clinic/physician’s office” services and applications platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Rand McClain,
DO</i></b> - Dr. McClain earned his medical degree at Western University and completed his internship at the University of Southern
California’s Keck School of Medicine Residency Program (U.S.C. California Hospital). Dr. McClain has
dedicated over 35 years of his personal and professional life studying nutrition, exercise, herbs and supplements and is also
a Master of Acupuncture and Traditional Chinese Medicine. Dr. McClain has participated in professional and elite amateur sport
as an individual participant and as well as a member of two U.S. teams and continues to participate competitively. His work is
published in peer-reviewed and popular journals and he enjoys sharing and participating in the beneficial changes he helps create
in people’s lives. Dr. McClain has worked with some of the best and original innovators in Sports, Regenerative Medicine
(“Anti-Aging”), Cosmetic and Family Medicine. He also practices as part of the Regenerative Medicine Institute
an organization dedicated to advancing cellular treatments, procedures and research in the use of all available avenues to slow
or reverse physiological and cosmetic effects of aging. Dr. McClain currently serves as Chief Medical Officer of Live Cell Research,
a company dedicated to the discovery and development of products designed to enhance health and quality of life through epigenomic
manipulation. Dr. McClain is also a Medical Advisory Board member of American Cryostem Corporation a publicly traded company operating
laboratories dedicated to the collection, processing, bio-banking, culturing and differentiation of autologous adipose tissue
(fat) and adipose derived stem cells (ADSCs). Dr. McClain is a Board Member of Z.E.N. Foods, a gourmet food delivery and nutrition
service company that provides individually designed meal programs in conjunction with health providers and its own registered
dietician. Dr. McClain is also proud to be a member of the National Veteran Foundation’s Advisory Board. Dr. McClain has
also joined the investigative team of the Company’s recently approved clinical study to assist the team with the review
of prospective candidates and for the review of study data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>John
“Jay” Schwartz, PhD </i></b>- Dr. Schwartz, holds a PhD in biochemistry and molecular biology and, served as an academic
researcher at Harvard and MIT for over 10 years. He is an accomplished life sciences entrepreneur, business mentor, consultant,
and investor with a demonstrated track record of identifying and driving commercially-viable early-stage companies from initial
bench conceptualization and funding to clinical development and exist. Dr. Schwartz 30+ years of entrepreneurship spans technical
development and commercialization of drugs, medical devices, combination products, and diagnostics; regulatory approval, Orphan
Drug/accelerated approval, clinical reimbursement, as well as intellectual property strategies. Most recently, he led AcuityBio
Corp to a successful acquisition by Cook Biotech. Over his career, he had led and advised multiple companies to successful exits
via acquisition in transactions ranging from $35 to $500 million</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our principal
executive offices are located at 1 Meridian Road, Eatontown, New Jersey 07724 and our telephone number is (732) 747-1007. Our
website is <b><i>www.americancryostem.com</i></b>. We also lease and operate a tissue processing laboratory at Princeton Corporate
Plaza in Monmouth Junction NJ. Our laboratory website address is <b><i>www.acslaboratories.com</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Employees</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Currently,
we have six (6) employees and continue to use consultants on an as needed basis. As we grow, we will need to attract an unknown
number of additional qualified employees, however we could be unsuccessful in attracting and retaining the persons needed.</span></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Available
information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We file electronically
with the U.S. Securities and Exchange Commission (SEC) our annual reports on Form 10-K, quarterly reports on Form 10-Q, current
reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange
Act of 1934. The public can obtain materials that we file with the SEC through the SEC’s website at http://www.sec.gov or
at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549. Information on the operation of
the Public Reference Room is available by calling the SEC at 800-SEC-0330.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt"><span id="acryoa003"></span>Item
1A. Risk Factors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><i>An
investment in our Common Stock involves a high degree of risk. Before making an investment decision, you should give careful consideration
to the following risk factors, in addition to the other information included in this prospectus, including our financial statements
and related notes, before deciding whether to invest in shares of our Common Stock. The occurrence of any of the adverse developments
described in the following risk factors could materially and adversely harm our business, financial condition, results of operations
or prospects. In that case, the trading price of our Common Stock could decline, and you may lose all or part of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left; text-indent: 0"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Risks
Related to our Financial Position</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
have generated minimal product related revenues to date and do not expect to generate significant revenues in the near future
if at all. To obtain revenues from sales of our product candidates, we must succeed, either alone or with third parties, in developing,
obtaining regulatory approval for, manufacturing and marketing products with commercial potential. We may never succeed in these
activities, and we may not generate sufficient revenues to continue our business operations or achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 2pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">We
have a history of net losses. We expect to continue to incur increasing net losses for the foreseeable future, and we may never
achieve or maintain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
incurred significant net losses in each year since our inception in 2009. We had an accumulated deficit as of September 30, 2021,
and 2020 of $19,277,765 and $16,398,179, respectively. Our net losses have resulted principally from costs incurred in our development
activities. We anticipate that our net losses will substantially increase over the next several years as we plan to expand our
research and development activities, including the clinical development of ATCell and ATGraft products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Because
of the numerous risks and uncertainties associated with drug product development and commercialization, we are unable to accurately
predict the timing or amount of future expenses or when, or if, we will be able to achieve or maintain profitability. We have
financed our operations primarily through the sale of equity securities, the issuance of convertible debt securities and upfront
and milestone payments pursuant to our collaboration and license agreements. The size of our future net losses will depend, in
part, on the rate of growth or contraction of our expenses and the level and rate of growth, if any, of our revenues. Our ability
to achieve profitability depends on our ability, alone or with others, to complete the development of our products successfully,
obtain the required regulatory approvals, manufacture, and market our proposed products successfully or have such products manufactured
and marketed by others and gain market acceptance for such products. These are formidable, time consuming and costly challenges
and we may never achieve commercialization or profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b>We
have significant payment obligations under certain Notes due through 2021. Any non-payment of the Notes when due in the absence
of an extension of the maturity date would constitute event of default under the Notes, and our financial condition may be adversely
affected.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">As
of September 30, 2021, the Company had issued and outstanding: $226,500 aggregate principal amount of Bridge Notes, which matured,
between January through July 2015 and bear interest at the rate of 8% per annum; $83,500 aggregate principal amount of Convertible
Notes which matured in September 2014, convertible into shares of Common Stock and the rate of one (1) share of Common Stock for
each $0.35 of principal amount and/or interest so converted; $45,000 of 8% convertible notes which matured in September of 2016,
convertible into shares of Common Stock and the rate of one (1) share of Common Stock for each $0.30 of principal amount and/or
interest so converted; $150,000 of 5% convertible notes which mature in Fiscal 2021, convertible into shares of Common Stock at
the rate of one (1) share of Common Stock for each $0.33 of principal amount and/or interest so converted; $155,000 of 8% convertible
notes which matured on January 31, 2018, convertible into shares of Common Stock at the rate of one (1) share of Common Stock
for each $0.20 of principal amount and/or interest so converted; $40,000 of 8% convertible notes which matured in January 31,
2018 convertible into shares of Common Stock and the rate of one (1) share of Common Stock for each $0.15 of principal amount
and/or interest so converted; and $100,000 aggregate principal amount of Convertible Notes which matured in Fiscal 2020, convertible
into shares of Common Stock and the rate of one (1) share of Common Stock for each $0.40 of principal amount and/or interest so
converted; $150,000 of 8% convertible notes which matures in December 31, 2022 convertible into shares of Common Stock and the
rate of one (1) share of Common Stock for each $0.75 of principal amount and/or interest so converted. No assurances can be given
that the Company will have sufficient funds to repay the principal and/or interest on such Bridge Notes when due or on the Convertible
Notes; such Convertible Notes are converted into Common Stock prior to maturity. In such event, we might be subject to, among
other things, non-payment claims of the Note holders, and our financial condition may be adversely affected.</span></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">We
will require substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce
or cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt"><b>Development
of our ATCell</b> and other product candidates we may acquire in the future will require substantial additional funds to conduct
research, development and clinical trials necessary to bring each of these product candidates to market and to establish or contract
for manufacturing, marketing and distribution capabilities. Our future capital requirements will depend on many factors, including,
the following:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">the
                                         scope, rate of progress, results and costs of our non-clinical studies, clinical trials,
                                         and other research and development activities;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">the
                                         scope, rate of progress and costs of our manufacturing development and commercial manufacturing
                                         activities;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 9.75pt"><span style="font-size: 10pt">the
                                         cost, timing and outcomes of regulatory proceedings, including NDAs and SPAs we file
                                         with the FDA and similar filings with the EMA and other foreign regulatory authorities;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">payments
                                         required with respect to development milestones we achieve under our in-licensing agreements;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">the
                                         costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">the
                                         costs associated with commercializing our product candidates, if they receive regulatory
                                         approval;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">the
                                         cost and timing of establishing sales and marketing capabilities;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">competing
                                         technological efforts and market developments;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">our
                                         ability to maintain and establish collaborative and distribution arrangements to the
                                         extent necessary;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">revenues
                                         received from any future products;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">the
                                         ability to achieve and receive milestone payments and co-development payments for our
                                         candidates licensed to collaborators; and,</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">payments
                                         received under any future strategic collaborations.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 9.8pt 0 11.7pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
anticipate that we will continue to generate significant net losses for at least the next several years as we continue to incur
increasing pipeline expenses to complete our clinical trial programs for ATCell, seek regulatory approvals, build commercial capabilities,
acquire and develop new drug candidate programs, and expand our corporate infrastructure. We believe that the net proceeds from
our financing efforts, together with our existing cash and cash equivalents will allow us to fund our operating plan through 2022.
However, our operating plan may change as a result of factors currently unknown to us. Changing circumstances may cause us to
consume capital faster or slower than we currently anticipate or to alter our operations. We have based our estimates of future
net losses on assumptions that may prove to be wrong, and we could utilize our available financial resources sooner than we currently
expect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Our
revenue and expense forecasts may prove to be inaccurate, and any change in the foregoing assumptions could require us to obtain
additional financing earlier than anticipated. There is a risk of delay or failure at any stage of developing a product candidate,
and the time required, and costs involved in successfully accomplishing our objectives cannot be accurately predicted. Actual
drug research and development costs could substantially exceed budgeted amounts, which could force us to delay, reduce the scope
of or eliminate one or more of our development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
may never be able to generate sufficient product revenue, if at all, to cover our expenses. Until we do, we expect to seek additional
funding through public or private equity or debt financings, collaborative relationships, capital lease transactions or other
available financing transactions. However, additional financing may not be available on acceptable terms, if at all, and such
financings could be dilutive to existing security holders. Moreover, if additional funds are obtained through arrangements with
collaborators, such arrangements may require us to relinquish rights to certain of our technologies, product candidates or products
that we would otherwise seek to develop or commercialize ourselves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">If
adequate funds are not available, we may be required to delay, reduce the scope of or eliminate one or more of our development
programs. Our failure to obtain adequate financing when needed and on acceptable terms would have a material adverse effect on
our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 2pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>The
report of our independent registered public accounting firm included a “going concern” explanatory paragraph.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">The
accompanying financial statements have been prepared on a going-concern basis which contemplates the continuation of operations,
realization of assets and liquidation of liabilities in the ordinary course of business. However, primarily as a result of our
recurring losses and limited cash balances, the report of our independent registered public accounting firm on our financial statements
as of and for the years ended September 30, 2020 and 2021 included an explanatory paragraph indicating that there is substantial
doubt about our ability to continue as a going concern. If we are unable to raise sufficient capital in this offering or otherwise
as and when needed, our business, financial condition and results of operations will be materially and adversely affected, and
we will need to significantly modify our operational plans to continue as a going concern.</span></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b>The
Company may not have complied with various state securities laws in connection with prior issuances/sales of its securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">Since
April 2011, the date of the closing of the Asset Purchase, through September 30, 2021, the Company sold approximately $5,288,127
gross amount of its equity and debt securities. In connection with such sales, the Company may have violated various state securities
laws. If the Company was determined by a court, FINRA or regulatory body with the required jurisdiction to have violated such
laws, any such violation could result in the Company being required to offer rescission rights to each such prior purchase from
the Company to rescind such purchases and pay to the prior purchaser an amount of funds equal to the purchase price paid by such
prior investors plus interest from the date of any such purchase. No assurances can be given the Company will, if it is required
to offer such purchasers rescission right, have sufficient funds to pay the prior purchasers the amount required. In addition,
if the Company violated one or more securities laws of a state in connection with prior offers and/or sales of its securities,
each such state could bring an enforcement, regulatory and/or other legal action against the Company which, among other things,
could result in the Company having to pay substantial fines, not being able to sell securities in such states in the future and/or
having a determination made by any such states against the Company that the Company failed to comply with such states’ securities
laws, which could result in the Company, among other untoward effects including those set forth above, not being able to have
its Common Stock be eligible for continued quotation on the OTC pink sheets and/or other trading markets and/or mediums that the
Common Stock is then trading and/or eligible for quotation on and/or in the future seeks to be quoted or traded on.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 10pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Shares
eligible for future sale may adversely affect the market for our Common Stock. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 10pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">As of September 30, 2021, we had 11,536,500
of Common Stock issuable upon exercise of all outstanding stock options and warrants, and 2,334,784 shares issuable on the conversion
of outstanding Convertible Notes. When these securities are exercised or converted into shares of our Common Stock, the number
of our shares of Common Stock outstanding will increase. Such increase in our outstanding shares, and any sales of such shares
into the public market, could have a material adverse effect on the market for our Common Stock and the market price of our Common
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 10pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">In
addition, from time to time, certain of our shareholders may be eligible to sell all or some of their shares of Common Stock by
means of ordinary brokerage transactions in the open market pursuant to Rule 144, promulgated under the Securities Act, subject
to certain limitations. In general, pursuant to Rule 144, after satisfying a six-month holding period: (i) affiliated shareholders
(or shareholders whose shares are aggregated) may, under certain circumstances, sell within any three month period a number of
securities which does not exceed the greater of 1% of the then outstanding shares of common stock and (ii) non-affiliated shareholders
may sell without such limitations, provided we are current in our public reporting obligations. Rule 144 also permits the sale
of securities by non-affiliates that have satisfied a one year holding period without any limitation or restriction. Any substantial
sale of our common stock pursuant to Rule 144 or pursuant to any resale prospectus may have a material adverse effect on the market
price of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Risks
Related to Our Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 2pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Cell
therapy is a developing field and a significant market for our services has yet to emerge in the US.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">Cell
therapy and regenerative medicine is a developing field, which we believe few cell therapy products or services approved for and/or
commercial use. We are wholly dependent on the acceptance of cell therapy (and specifically stem cells) to develop into a large
and profitable industry. We hope to develop services related to the collection, processing, storage of stem cells and application
development. We believe the market for stem cell and tissue-based therapies is in its infancy, substantially research oriented
and financially speculative and has yet to achieve substantial commercial success. Stem cell products and services may in general
be susceptible to various risks, including undesirable and unintended side effects, unintended immune system responses, inadequate
therapeutic efficacy, lack of acceptance by physicians, hospital and consumers, or other characteristics that may prevent or limit
their approval or commercial use. Management believes that the demand for tissue processing and stem cell processing and the number
of people who may use cell or tissue-based therapies is difficult, if not impossible, to forecast. Our success is dependent on,
among other items, the establishment of a market for our proposed services and our ability to capture a share of this market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Our
proposed services may not attain commercial acceptance absent endorsement by physicians.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">Our
proposed services will compete against individual adipose tissue and cellular samples derived from alternate sources, such as
bone marrow, umbilical cord blood and perhaps embryos. We believe that physicians and hospitals are historically slow to adopt
new technologies like ours, whatever the merits, when older technologies continue to be supported by established providers. Overcoming
such inertia often requires very significant marketing expenditures or definitive product performance and/or pricing superiority.
Management currently believes physicians’ and hospitals’ inertia and skepticism to be a significant barrier as we
attempt to gain market penetration with our proposed services. Failure to achieve market acceptance of our proposed services would
have a material adverse effect on our future prospects.</span></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Our
facilities may require compliance with PHS and FDA regulations and there is no assurance we are in and/or in the future will be
in compliance with these protocols or that the PHS or FDA may find deficiencies upon inspection of our facility.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The
Company believes that its processing methodologies, and its Monmouth Junction, New Jersey laboratory facilities to be in compliance
with all current applicable regulations and guidelines as defined by the United States Public Health Service Act (“<b><span style="text-decoration: underline">PHS</span></b>”
or the “<b><span style="text-decoration: underline">PHS Act</span></b>”) and the Food and Drug Administration (“<b><span style="text-decoration: underline">FDA</span></b>”) regulations
and guidance as they relate to the operation of a tissue processing and storage facility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">On
January 3, 2018 the Company received a warning letter from the US. FDA concerning its contract manufacturing services provided
to Cells on Ice. The FDA informed the Company through the letter that the FDA determined that its autologous adipose derived cell
product ATCELL is a drug under current FDA regulations and guidance. In response to the letter the Company ceased shipment of
its ATCELL product within the United States. Since receiving the Warning Letter from the FDA the Company undertook a complete
reorganization and remediation of its laboratory facility and operations and an expansion of its existing facility. The Company
believes that its effort, new clean room laboratory facility, SOP and Quality Management system upgrades, and filing the IND application
(No. 19089) on October 22, 2019 and approved by FDA on September 17, 2020, will satisfy the FDA’s concerns; no assurance
can be given that we are in fact in compliance and/or in the future will be in compliance with these regulations or that upon
inspection by PHS and/or FDA that we will not be required to amend our procedures or limit our operations based upon the finding
of the inspection. Based upon discussions with the FDA Office of Regulatory Affairs (ORA), the disposition of the warning letter
is deferred, per current FDA policy, until the completion of the clinical studies and the submission of a Biologics License Application
filing by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 4.9pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Clinical
trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be
predictive of future trial results.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Our
product candidates may not prove to be safe and efficacious in clinical trials and may not meet all the applicable regulatory
requirements needed to receive regulatory approval. To receive regulatory approval for the commercialization of our product candidates,
we must conduct, at our own expense, extensive preclinical testing and clinical trials to demonstrate safety and efficacy of these
product candidates for the intended indication of use. Clinical testing is expensive, can take many years to complete, if at all,
and its outcome is uncertain. Failure can occur at any time during the clinical trial process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">The
results of preclinical studies and early clinical trials of new drugs do not necessarily predict the results of later-stage clinical
trials. The design of our clinical trials is based on many assumptions about the expected effects of our product candidates, and
if those assumptions are incorrect the clinical trials may not produce statistically significant results. Preliminary results
may not be confirmed on full analysis of the detailed results of an early clinical trial. Product candidates in later stages of
clinical trials may fail to show safety and efficacy sufficient to support intended use claims despite having progressed through
initial clinical testing. The data collected from clinical trials of our product candidates may not be sufficient to support the
filing of an NDA or to obtain regulatory approval in the United States or elsewhere. Because of the uncertainties associated with
drug development and regulatory approval, we cannot determine if or when we will have an approved product for commercialization
or achieve sales or profits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>If
we experience delays or difficulties in enrolling patients in our ongoing or planned clinical trials, our receipt of necessary
regulatory approvals could be delayed or prevented.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">We
may not be able to initiate or continue our ongoing or planned clinical trials for our product candidates if we are unable to
identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or comparable
foreign regulatory authorities. If our strategies for patient identification and enrollment prove unsuccessful, we may have difficulty
enrolling or maintaining patients appropriate for our product candidates. The conditions for which we currently plan to evaluate
our product candidates include orphan or rare diseases, and diseases with high unmet medical needs with limited patient pools
from which to draw for clinical trials. Clinical investigators will need to decide whether to offer their patients enrollment
in clinical trials of our product candidates versus treating these patients with commercially available drugs that have established
safety and efficacy profiles. The eligibility criteria of our clinical trials, once established, will further limit the pool of
available trial participants. Some of our competitors may have ongoing or planned clinical trials for product candidates that
would treat the same patients as our clinical product candidates, and patients who would otherwise be eligible for our clinical
trials may instead enroll in clinical trials of our competitors’ product candidates. Patient enrollment is also affected
by other factors, including:</span></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">severity
                                         of the disease under investigation;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">our
                                         ability to recruit clinical trial investigators of appropriate competencies and experience;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">the
                                         incidence and prevalence of our target indications;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 9.7pt"><span style="font-size: 10pt">clinicians’
                                         and patients’ awareness of, and perceptions as to the potential advantages and
                                         risks of our product candidates in relation to other available therapies, including any
                                         new drugs that may be approved for the indications we are investigating;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">competing
                                         studies or trials with similar eligibility criteria;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">invasive
                                         procedures required to enroll patients and to obtain evidence of the product candidate’s
                                         performance during the clinical trial;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">availability
                                         and efficacy of approved medications for the disease under investigation;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">eligibility
                                         criteria defined in the protocol for the trial in question;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">the
                                         size and nature of the patient population required for analysis of the trial’s
                                         primary endpoints;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">efforts
                                         to facilitate timely enrollment in clinical trials;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">whether
                                         we are subject to a partial or full clinical hold on any of our clinical trials;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">reluctance
                                         of physicians or patient advocacy organizations to encourage patient participation in
                                         clinical trials;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">the
                                         ability to monitor patients adequately during and after treatment;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">our
                                         ability to obtain and maintain patient consents; and</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">proximity
                                         and availability of clinical trial sites for prospective patients.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 9.85pt 0 11.7pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">Our
inability to enroll and maintain a sufficient number of patients for our clinical trials would result in significant delays or
may require us to abandon one or more clinical trials altogether. There may be competing trials, as well as the limited bandwidth
of pediatric oncology institutions for running trials, which can lead to the prioritization of certain trials, leading to delays
in our clinical trials. Enrollment delays in our clinical trials, including delays due to the COVID-19 pandemic, may result in
increased development costs, which would cause our value to decline and limit our ability to obtain additional financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 4.9pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
may experience delays in clinical testing of our product candidates. We do not know whether planned clinical trials will begin
on time, will need to be redesigned or will be completed on schedule, if at all. In addition to delays in patient enrollment,
clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a clinical
trial, in securing clinical trial agreements with prospective sites with acceptable terms, in obtaining institutional review board
approval to conduct a clinical trial at a prospective site or in obtaining sufficient supplies of clinical trial materials. Any
delays in completing our clinical trials will increase our costs, slow down our product development and timeliness and approval
process and delay our ability to generate revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>We
may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude
approval of our product candidates.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Our
clinical trials may be suspended at any time for a number of reasons. For example, we may voluntarily suspend or terminate our
clinical trials if at any time we believe that they present an unacceptable risk to the clinical trial patients. In addition,
the FDA or other regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if
they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements or that they
present an unacceptable safety risk to the clinical trial patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Administering
any product candidate to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical
trials of our product candidates and could result in the FDA or other regulatory authorities denying further development or approval
of our product candidates for any or all targeted indications. Ultimately, some or all of our product candidates may prove to
be unsafe for human use. Moreover, we could be subject to significant liability if any volunteer or patient suffers, or appears
to suffer, adverse health effects as a result of participating in our clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Our
clinical trials may not result in drugs approved for commercialization.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">The
grant of regulatory approvals for the commercial sale of any of our proposed products will depend, in part, on us and/or any collaborators
successfully conducting extensive clinical testing to demonstrate safety and efficacy in humans. The results of preclinical and
clinical testing may prove to be negative or inconclusive. As results of particular clinical trials are received, we and/or our
collaborators, if any, may abandon projects that we might have otherwise believed to be promising. Our interpretation of clinical
trial results may not be accepted by governmental regulators. The products that are successfully developed, if any, will be subject
to requisite regulatory approval prior to their commercial sale, and the approval, even if obtainable, may take several years.
Generally, only a very small percentage of new pharmaceutical products initially developed are approved for sale. Even if a new
pharmaceutical product is approved for sale, it may not be commercially successful. We may encounter unanticipated problems relating
to development, manufacturing, distribution and marketing, some of which may be beyond our financial and technical capacity to
resolve. The failure to address such problems adequately could have a materially adverse effect on our business, financial condition
or results of operations. We may not succeed in the development and marketing of any new drug products, and any products we are
able to get approved for marketing may be rendered obsolete or uncompetitive by products of competitors.</span></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Many
factors may affect the outcome of prospective clinical trials. The design of prospective clinical trials is often based on limited
or incomplete data. The current Phase I clinical trial design of the ATCell PCS program is based in part on data collected from
a Pilot Treatment Program, and a retrospective analysis of that data. Retrospective analysis of clinical trial results may lead
to incorrect conclusions. In addition, standard of care will change over time. Patients enrolling in the current clinical trial
may have been exposed to and treated with therapeutics and other therapies different than patients enrolled in the prior Pilot
Study. Thus, the results of the prior Pilot Study may not be predictive of results in the current Phase I clinical trial. Our
current clinical Phase I trial of ATCell may not enroll a sufficient number of patients or it may not be ultimately concluded
according to the current design and protocol, for reasons including, but not limited to, the study drug administration regimen
and participation requirements, changes in standard of care, and acceptability by patients and investigators of the study control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>We
may not be able to fulfill the extensive, time consuming and costly regulatory requirements to enable us to develop and market
our drug candidates.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Our
drug development programs are subject to regulatory control by multiple federal, state, local, national, and multinational regulatory
agencies, including the FDA and the EMA. Before we can market and commercialize our drug candidates, we will need to apply for
and receive regulatory approval by multiple federal, state, local, national, and multinational regulatory agencies, including
the FDA and EMA. If the data, information, applications, files, and regulatory documentation from our drug development programs
are incomplete or inadequate, we could be subject to suspension or withdrawal of permission to conduct clinical trials from the
regulatory authorities, including the FDA and EMA. We can make no assurances as to the completeness or adequacy of the data, information,
applications, files, and regulatory documentation from our drug development programs and we may never receive approval for marketing
and commercialization from the regulatory authorities, including the FDA and EMA, or such approval could be delayed substantially,
requiring us to conduct costly additional clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Furthermore,
regulatory authorities’ assessment of the data and results required to demonstrate safety and efficacy can change over time
and can be affected by many factors, such as the emergence of new information, including on other products, changing policies
and agency funding, staffing and leadership. We cannot be sure whether future changes to the regulatory environment will be favorable
or unfavorable to our business prospects. For example, average review times at the FDA for marketing approval applications can
be affected by a variety of factors, including budget and funding levels and statutory, regulatory and policy changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>Guidelines
and recommendations published by various organizations can impact the use of our products candidates.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Government
agencies promulgate regulations and guidelines directly applicable to us and to our product candidates. In addition, professional
societies, practice management groups, private health and science foundations and organizations involved in various diseases from
time to time may also publish guidelines or recommendations to the health care and patient communities. Recommendations of government
agencies or these other groups or organizations may relate to such matters as usage, dosage, route of administration and use of
concomitant therapies. Recommendations or guidelines suggesting the reduced use of our product candidates or the use of competitive
or alternative products that are followed by patients and health care providers could result in decreased use of our proposed
product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 2pt; margin-bottom: 0"><span style="font-size: 10pt"><b>Results
of earlier clinical trials may not be predictive of the results of later-stage clinical trials.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">The
results of preclinical studies and early clinical trials of product candidates may not be predictive of the results of later-stage
clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy results
despite having progressed through preclinical studies and initial clinical trials. Many companies in the biopharmaceutical industry
have suffered significant setbacks in advanced clinical trials due to adverse safety profiles or lack of efficacy, notwithstanding
promising results in earlier studies. Similarly, our future clinical trial results may not be successful for these or other reasons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">This
product candidate development risk is heightened by any changes in the planned clinical trials compared to the completed clinical
trials. As product candidates are developed through preclinical to early to late-stage clinical trials towards approval and commercialization,
it is customary that various aspects of the development program, such as manufacturing and methods of administration, are altered
along the way in an effort to optimize processes and results. While these types of changes are common and are intended to optimize
the product candidates for late-stage clinical trials, approval and commercialization, such changes carry the risk that they will
not achieve these intended objectives.</span></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Any
of these changes could make the results of our planned clinical trials or other future clinical trials we may initiate less predictable
and could cause our product candidates to perform differently, including causing toxicities, which could delay completion of our
clinical trials, delay approval of our product candidates, and/or jeopardize our ability to commence product sales and generate
revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>Reimbursement
may not be available for our product candidates, which would impede sales.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Market
acceptance and sales of our product candidates may depend on coverage and reimbursement policies of third-party insurers as well
as health care reform measures. Decisions about formulary coverage as well as levels at which government authorities and third-party
payers, such as private health insurers and health maintenance organizations, reimburse patients for the price they pay for our
products as well as levels at which these payors pay directly for our products, where applicable, could affect whether we are
able to commercialize these products as well as market acceptance of our products. We cannot assure that reimbursement will be
available for any of our products or that coverage or reimbursement policies will not reduce the demand for, or the price of,
our products. We have not commenced efforts to have our product candidates reimbursed by government or third-party payors. If
coverage and reimbursement are not available or are available only at limited levels, we may not be able to commercialize our
products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">In
recent years, officials have made numerous proposals to change the health care system in the United States. These proposals include
measures that would limit or prohibit payments for certain medical treatments or subject the pricing of drugs to government control.
In addition, in many foreign countries, particularly the countries of the European Union, the pricing of prescription drugs is
subject to government control. If our products are or become subject to government regulation that limits or prohibits payment
for our products, or that subjects the price of our products to governmental control, we may not be able to generate revenue,
attain profitability or commercialize our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">As
a result of legislative proposals and the trend towards managed health care in the United States, third-party payors are increasingly
attempting to contain health care costs by limiting both coverage and the level of reimbursement of new drugs. They may also impose
strict prior authorization requirements and/or refuse to provide any coverage of uses of approved products for medical indications
other than those for which the FDA has granted market approvals. As a result, significant uncertainty exists as to whether and
how much third-party payors will reimburse patients for their use of newly approved drugs, which in turn will put pressure on
the pricing of drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>If
we lose key personnel, our development programs could be delayed, and our business could be harmed.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Our
future success will depend, in part, on the leadership and efforts of our senior executive officers, directors, members of our
Scientific Advisory Board and consultants. In particular, we rely and will continue to rely on the leadership and expertise provided
by our founder and Chief Executive Officer, John S Arnone and Chief Operating Officer, Anthony Dudzinski. We do not maintain “key
man” insurance for Mr. Arnone or Mr. Dudzinski However, we do have an employment agreement with them but that does not guarantee
that they will always remain with the company. If Mr. Arnone or Mr. Dudzinski were to terminate their relationship with us for
any reason, or if they were to become disabled or die, it would have a material adverse impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">In
addition to Mr. Arnone and Dudzinski, we have other key personnel that are critical to our business. Most of these persons are
currently “contract employees”, which means they perform services for us on a contractual basis. Nevertheless, if
their relationship with us were to terminate, it could have a material adverse impact on our business and operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">In
addition, to execute our growth strategy we also must attract, train, retain and motivate additional highly skilled employees
and knowledgeable advisors required for the expansion of our activities. Our failure to do so could have a materially adverse
effect on our business, including delays in our drug development programs. Given the current state of the U.S. job market in general,
that the pool of qualified personnel with experience in the pharmaceutical and biotechnology industry is limited overall, and
that we will be competing with other companies that have far greater resources than we have and that can offer prospective employees
greater opportunities than we can, we expect to experience difficulty in hiring and retaining highly skilled personnel with appropriate
qualifications. In sum, we cannot assure you that we will be able to retain the services of our existing personnel or attract
additional qualified employees and such failure would likely have a materially adverse effect on us.</span></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 2pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>We
will need to increase the size of our organization, and we may experience difficulties in managing growth.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
are a small company with four (4) full-time employees and two (2) contract employees who provide services to us under contractual
arrangement but who are not treated as statutory employees. We anticipate that most, if not all, these contract employees will
become statutory employees upon consummation an additional planned funding. To continue our clinical trials and commercialize
our product candidates, we need to expand our employee base for managerial, operational, financial and other resources. Future
growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain
and integrate additional employees. We plan to add additional employees to assist us with our clinical and commercial programs.
Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend,
in part, on our ability to manage any future growth effectively. To that end, we must be able to:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">manage
                                         development efforts effectively;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">manage
                                         our clinical trials effectively;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">integrate
                                         additional management, administrative, manufacturing and sales and marketing personnel;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">maintain
                                         sufficient administrative, accounting and management information systems and controls;
                                         and</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">hire
                                         and train additional qualified personnel.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">We
may not be able to accomplish these tasks, and our failure to accomplish any of them could harm our financial results and impact
our ability to achieve development milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 2pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>We
currently have no sales and marketing organization. If we are unable to establish a direct sales force or build appropriate relationships
in the United States to promote our products, the commercial opportunity for our products may be diminished.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.4pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
currently have no sales and marketing organization. If any of our product candidates are approved by the FDA, we will need to
create a sales and marketing team from the ground up or hire a third-party to provide those services. Our current intention is
to create our own, in-house sales and marketing team to market our products domestically. Whether we pursue that strategy or opt
to outsource that function, we will incur significant additional expenses. In addition, if we decide to build our own sales and
marketing team, the effort will require us to commit a significant additional management resources. We will also have to compete
with other pharmaceutical and biotechnology companies, many of whom have greater financial resources than we have, to recruit,
hire and train sales and marketing personnel. We cannot assure you that our efforts will be successful no matter how much time,
effort and capital we commit. In addition, we cannot assure you that we will be able to a retain a third party to perform those
services on acceptable terms, if at all, should that be necessary. If we elect to rely on third parties to sell our product candidates
in the United States, we may receive less revenue than if we sold our products directly. In addition, although we would intend
to use due diligence in monitoring their activities, we may have little or no control over the sales efforts of those third parties.
In the event we are unable to develop our own sales force or collaborate with a third party to sell our product candidates, we
may not be able to commercialize our product candidates which would negatively impact our ability to generate revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Security
breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and
reputation to suffer.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">In
the ordinary course of our business, we collect and store sensitive data, including intellectual property, our proprietary business
information and that of our suppliers and business partners, as well as personally identifiable information of storage customers,
clinical trial participants and employees. Similarly, our business partners and third-party providers possess certain of our sensitive
data. The secure maintenance of this information is critical to our operations and business strategy. Despite our security measures,
our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance
or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed, publicly
disclosed, lost or stolen. Any such access, disclosure or other loss of information, including our data being breached at our
business partners or third-party providers, could result in legal claims or proceedings, liability under laws that protect the
privacy of personal information, disrupt our operations, and damage our reputation which could adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Risks
Relating to Manufacturing Activities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>We
have limited manufacturing capabilities and may not be able to obtain and maintain adequate manufacturing from contractors. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We
have limited manufacturing capability of our own. We may not be able to establish or maintain arrangements with contractors that
can manufacture products at a cost or in quantities, of sufficient quality and timeliness, necessary to meet the supply requirements
of our clinical study programs. In addition, we anticipate that we will need to rely on third parties to manufacture certain products
even if they have been approved for use. We will need to establish and rely upon third party contractors to develop methods to
scale-up manufacturing of commercial quantities of any of our products that receives regulatory approval. In addition, we may
experience significant growth upon approval of our products and be required to build large scale manufacturing facilities and
laboratories to meet demand and may not be able to complete the facilities on time or at all.</span></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>We
may not be able to manufacture our product candidates in commercial quantities, which would prevent us from commercializing our
product candidates.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">To
date, our product candidates have been manufactured in small quantities for preclinical studies and clinical trials. If any of
our product candidates is approved by the FDA or comparable regulatory authorities in other countries for commercial sale, we
will need to manufacture such product candidate in larger quantities. We may not be able to successfully increase the manufacturing
capacity for any of our product candidates in a timely or economic manner, or at all. Significant scale-up of manufacturing may
require additional validation studies, which the FDA must review and approve. If we are unable to successfully increase the manufacturing
capacity for a product candidate, the clinical trials as well as the regulatory approval or commercial launch of that product
candidate may be delayed or there may be a shortage in supply. Our product candidates require precise, high-quality manufacturing.
Our failure to achieve and maintain these high-quality manufacturing standards in collaboration with our third-party manufacturers,
including the incidence of manufacturing errors, could result in patient injury or death, product recalls or withdrawals, delays
or failures in product testing or delivery, cost overruns or other problems that could harm our business, financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Materials
necessary to manufacture our product candidates may not be available on commercially reasonable terms, or at all, which may delay
the development and commercialization of our product candidates.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">If
we rely on the third-party manufacturers of our product candidates to purchase from third-party suppliers the materials necessary
to produce the product candidates for our clinical trials, and we will rely on such manufacturers to purchase such materials to
produce finished products for any commercial distribution of our products if we obtain marketing approval. Suppliers may not sell
these materials to our manufacturers at the time they need them to meet our required delivery schedule or on commercially reasonable
terms, if at all. We do not have any control over the process or timing of the acquisition of these materials by our manufacturers.
If our manufacturers are unable to obtain these materials for our clinical trials, testing of the affected product candidate would
be delayed, which may significantly impact our ability to develop the product candidate. If we, or our manufacturers, are unable
to purchase these materials after regulatory approval has been obtained for one of our products, the commercial launch of such
product would be delayed or there would be a shortage in supply of such product, which would harm our ability to generate revenues
from such product and achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Risks
Relating to Regulation of Our Industry</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>The
biopharmaceutical industry is subject to significant regulation and oversight in the United States; in addition to approval
of products for sale and marketing, our failure to comply could be costly and hurt our business.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.4pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">In
addition to FDA restrictions on marketing of biopharmaceutical products, several other types of state and federal laws have been
applied to restrict certain marketing practices in the biopharmaceutical industry in recent years. These laws include anti-kickback
statutes and false claims statutes. If we or our representatives are found to have engaged in practices that involve remuneration
intended to induce prescribing, purchases or recommendations, we may be subject to anti-kickback liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 4.9pt; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">If
we or our representatives are found, for example, to have marketed a product for unapproved, and thus non-reimbursable, uses,
or to have provided free product to customers with the expectation that the customers would bill government programs for the product,
we could be subject to liability under federal or state false claims laws. Sanctions under these federal and state laws may include
civil monetary penalties, exclusion of a manufacturer’s products from reimbursement under government programs, criminal
fines and imprisonment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Because
of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could
be subject to challenge under one or more of these laws, which could have a material adverse effect on our reputation and results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 2pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">We
may be subject to federal and state healthcare fraud and abuse laws and health information privacy and security laws. If we do
not fully comply with such laws, we could face substantial penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">If
we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations
may be directly, or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without
limitation, the federal anti-kickback statute. These laws may impact, among other things, our proposed sales, marketing and education
programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which
we conduct our business. The laws that may affect our ability to operate include but are not limited to:</span></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">HIPAA,
                                         which created new federal criminal statutes that prohibit executing a scheme to defraud
                                         any healthcare benefit program and making false statements relating to healthcare matters;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">HIPAA,
                                         as amended by the Health Information Technology and Clinical Health Act and its implementing
                                         regulations, which impose certain requirements relating to the privacy, security and
                                         transmission of individually identifiable health information;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                         federal physician sunshine requirements under the Affordable Care Act requires manufacturers
                                         of drugs, devices, biologics and medical supplies to report annually to HHS information
                                         related to payments and other transfers of value to physicians, other healthcare providers,
                                         and teaching hospitals, and ownership and investment interests held by physicians;
                                         and</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">state
                                         law equivalents of each of the above federal laws, such as anti-kickback and false claims
                                         laws which may apply to items or services reimbursed by any third-party payor, including
                                         commercial insurers, and state laws governing the privacy and security of health information
                                         in certain circumstances, many of which differ from each other in significant ways and
                                         may not have the same effect, thus complicating compliance efforts.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">If
our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply
to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring
of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements,
which could subject us to sanctions, damage our reputation, and otherwise hurt our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply
with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we have established, comply
with federal and state health-care fraud and abuse laws and regulations, report financial information or data accurately or disclose
unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject
to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and
regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer
incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained
during clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible
to identify and deter employee misconduct, and the precautions we take to detect and prevent misconduct may not be effective in
controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits
stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us, and we are not
successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including
the imposition of significant fines or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>If
we decide to pursue a Fast Track Designation by the FDA, it may not lead to a faster development or regulatory review or approval
process.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
may seek Fast Track Designation for one or more of our product candidates. If a drug is intended for the treatment of a serious
or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the product
sponsor may apply for FDA Fast Track Designation. The FDA has broad discretion whether to grant this designation, so even if we
believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant
it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared
to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported
by data from our clinical development program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>We
may seek Orphan Drug Designation from the FDA and/or EMA for additional product candidates that we acquire or develop in the future.
However, we may be unsuccessful in obtaining or may be unable to maintain the benefits associated with Orphan Drug Designation,
including the potential for market exclusivity.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
may seek Orphan Drug Designation for product candidates we obtain in the future from the FDA and/or the EMA; however, we
may be unsuccessful. There can be no assurance that the FDA or EMA will grant orphan designation for any indication for which
we apply, or that we will be able to maintain such designation for our current or any future candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">In
the United States, Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding towards
clinical trial costs, tax advantages and user-fee waivers. If a product candidate with an Orphan Drug Designation subsequently
receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period
of orphan drug exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same drug
or biologic for that time period, except in limited circumstances, such as a showing of clinical superiority to the product with
orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. The applicable exclusivity
period is ten years in Europe, but such exclusivity period can be reduced to six years if a product no longer meets the criteria
for orphan designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Moreover,
orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation
was materially defective or if the manufacturer is unable to assure sufficient quantities of the drug to meet the needs of patients
with the rare disease or condition.</span></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Even
if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition
because different products can be approved for the same condition. Even after an orphan drug is approved, the FDA or comparable
foreign regulatory authority can subsequently approve the same drug for the same condition if such regulatory authority concludes
that the later drug is clinically superior if it is shown to be safer, more effective or makes a major contribution to patient
care. Orphan drug exclusivity may also be lost if the FDA later determines that the initial request for designation was materially
defective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">In
addition, orphan drug exclusivity does not prevent the FDA from approving competing drugs for the same or similar indication containing
a different active ingredient. In addition, if a subsequent drug is approved for marketing for the same or a similar indication
as any of our product candidates that receive marketing approval, we may face increased competition and lose market share regardless
of orphan drug exclusivity. Orphan drug designation neither shortens the development time or regulatory review time of a drug
nor gives the drug any advantage in the regulatory review or approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Health
care reform measures could adversely affect our business.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">In
the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare
system that could hurt our future results of operations. In particular, there have been, and continue to be, a number of initiatives
at the federal and state levels that seek to reduce healthcare costs. Legally mandated price controls on payment amounts by third-party
payors or other restrictions could harm our ability to generate revenues. Bidding procedures to determine what pharmaceutical
products and which suppliers will be included in prescription drug and other healthcare programs could reduce ultimate demand
for our products or put pressure on our product pricing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 4.9pt; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Increases
in importation or re-importation of pharmaceutical products from foreign countries into the United States could put competitive
pressure on our ability to profitably price our products, which, in turn, could adversely affect our results of operations. We
might elect not to seek approval for or market our products in foreign jurisdictions to minimize the risk of re-importation, which
could also reduce the revenue we generate from our product sales. It is also possible that other legislative proposals having
similar effects will be adopted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Risks
Relating to Competitive Factors</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>We
operate in an environment of intense competition and our products, if approved, will be subject to intense market competition.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">The
biotechnology industry generally and our drug development programs in particular are characterized by intensive competition. Multiple
companies are currently marketing products otherwise being used for indications in which we are developing products. In addition,
many companies, research institutes, hospitals and universities are working to develop products. Many of these entities have substantially
greater financial, technical, manufacturing, marketing, distribution and other resources than we have. Certain of such companies
have experience in undertaking testing and clinical trials of new or improved products for indications in which we are developing
products. In addition, certain competitors have already begun testing biopharmaceuticals for indications in which we are developing
products and may introduce such products before we do.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Risk
Relating to Our Arrangements with Third Parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>If
the collaborators, licensees and others on which we depend do not perform as expected, we may not be able to develop, manufacture
and commercialize drug products.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">If
we cannot maintain our existing collaborative arrangements, product development and license agreements, contract manufacturing
arrangements and other agreements with third parties for services we need on acceptable terms, or at all, and/or enter into new
arrangements, then we will experience delays, added costs and missed opportunities in the development, manufacture or sale of
our proposed products. In particular, we have limited capability to discover or conduct pre-clinical development of new products,
and therefore rely on collaborators, partners, or licensors to be the source of our drug development programs.</span></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Our
lack of sales and marketing experience could limit our revenue from any approved drugs.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
have limited experience in sales, marketing or distribution of pharmaceutical and related products. In the event any of our product
candidates receive regulatory approval for commercialization, we intend to pursue third party arrangements regarding the sales
and marketing of any products we develop internationally. We also may pursue such relationships to market our products domestically,
although that is not our current intention. However, we may not be able to establish or maintain such arrangements or have effective
sales forces and distribution systems necessary to make any products commercially viable. To the extent that we decide not to,
or are unable to, enter into third party arrangements with respect to the sales and marketing of our proposed products, significant
capital expenditures, management resources and time will be required to establish and develop our own marketing and sales force
with technical expertise and with supporting distribution capabilities. To the extent that we depend on third parties for marketing
and distribution, any revenues received by us will depend upon the efforts of such third parties, and their efforts may not be
successful. Licensing and purchase agreements pursuant to which we may acquire drug candidate programs may require the consent
of the licensor or seller for sublicenses or other third-party sales, marketing, or drug development arrangements. If licensors
or sellers do not provide such consent, the development and commercialization of our product candidates could be severely impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>We,
currently and in the future will, continue to rely on third parties to conduct our clinical trials. If these third parties do
not successfully carry out their contractual duties or meet expected deadlines, we may not be able to seek or obtain regulatory
approval for or commercialize our product candidates.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
currently, and will in the future, enter into agreements with third-party CROs under which we have delegated to the CROs the responsibility
to coordinate and monitor the conduct of our clinical trials and to manage data for our clinical programs. We, our CROs and our
clinical sites are required to comply with current cGCPs, regulations and guidelines issued by the FDA and by similar governmental
authorities in other countries where we are conducting clinical trials. We have an ongoing obligation to monitor the activities
conducted by our CROs and at our clinical sites to confirm compliance with these requirements. In the future, if we, our CROs
or our clinical sites fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable
and the FDA may require us to perform additional clinical trials before approving our marketing applications. In addition, our
clinical trials must be conducted with product produced under cGMP regulations and will require a large number of test subjects.
Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval
process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 4.95pt; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">If
CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced,
or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols,
regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able
to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and
the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue
could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>We
may need to rely on third parties to market and commercialize our product candidates in international markets.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">In
the future, if appropriate regulatory approvals are obtained, we may commercialize our product candidates in international markets.
However, we have not decided how to commercialize our product candidates in those markets. We may decide to build our own sales
force or sell our products through third parties. If we decide to sell our product candidates in international markets through
a third party, we may not be able to enter into any marketing arrangements on favorable terms or at all. In addition, these arrangements
could result in lower levels of income to us than if we marketed our product candidates entirely on our own. If we are unable
to enter into a marketing arrangement for our product candidates in international markets, we may not be able to develop an effective
international sales force to successfully commercialize those products in international markets. If we fail to enter into marketing
arrangements for our products and are unable to develop an effective international sales force, our ability to generate revenue
would be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Risks
Relating to Protecting Our Intellectual Property</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>It
is difficult and costly to protect our proprietary rights, and we may not be able to ensure protection of such rights.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">Our
commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of our product
candidates, and the methods used to manufacture them, as well as successfully defending these patents against third-party challenges.
We will only be able to protect our product candidates from unauthorized making, using, selling and offering to sell or importation
by third parties to the extent that we have rights under valid and enforceable patents or trade secrets that cover these activities
or from orphan status designations from regulatory authorities in certain markets.</span></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>If
we are unable to protect our proprietary rights, we may not be able to compete effectively or operate profitably.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Our
success will depend, in part, on our ability to obtain patents and maintain trade secrets, both in the United States and other
countries. Patent matters in the biotechnology and pharmaceutical industries can be highly uncertain and involve complex legal
and factual questions. Accordingly, the validity, breadth and enforceability of our patents and the existence of potentially blocking
patent rights of others cannot be predicted, either in the United States or in other countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
may not be able to develop patentable products or processes or have patents issue from any of the currently pending patent applications,
and the claims granted on issued patents may not be sufficient to protect our technology or adequately cover the actual products
we may eventually sell. Potential competitors or other researchers in the field may have filed patent applications, been issued
patents, published articles or otherwise created prior art that could restrict or block our efforts to obtain additional patents.
Our issued patents or pending patent applications if issued, may be challenged, invalidated, rendered unenforceable or circumvented
or the rights granted thereunder might not provide us with adequate proprietary protection or competitive advantages. Our patent
rights also depend on our compliance with technology and patent licenses upon which our patent rights are based and upon the validity
of assignments of patent rights from consultants, licensors and other inventors that were, or are, not employed by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 4.9pt; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">In
addition, competitors may manufacture and sell our potential products in those foreign countries where we have not filed for patent
protection or where patent protection may be unavailable, not obtainable or, ultimately, not enforceable. Even where patent protection
is obtained, third-party competitors may challenge our patent claims in the various patent offices, for example via opposition
in the European Patent Office or reexamination or interference proceedings in the USPTO. The ability of such competitors to sell
such products in the United States or in foreign countries where we have obtained patents is usually governed by the patent laws
of the countries in which the product is sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
will incur significant ongoing expenses in maintaining our patent portfolio. Should we lack the funds to maintain our patent portfolio
or to enforce our rights against infringers, we could be adversely impacted. Litigation, which could result in substantial costs
to us (even if determined in our favor), may also be necessary to enforce any patents and patent applications issued or licensed
to us or to determine the scope and validity of the proprietary rights of others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Intellectual
property rights do not necessarily address all potential threats to our competitive advantage.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have
limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples
are illustrative:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Others
                                         may be able to make products that are similar to our product candidates but that are
                                         not covered by the claims of the patents that we own.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 10pt"><span style="font-size: 10pt">We
                                         or our licensors or strategic collaborators might not have been the first to make the
                                         inventions covered by the issued patent or pending patent application that we own.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">We
                                         or our licensors or strategic collaborators might not have been the first to file patent
                                         applications covering certain of our inventions.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 10.1pt"><span style="font-size: 10pt">Others
                                         may independently develop similar or identical products to our product candidates or
                                         alternative technologies or duplicate any of our technologies without infringing our
                                         intellectual property rights.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 9.65pt"><span style="font-size: 10pt">Our
                                         pending patent applications may not lead to issued patents or patents with claims that
                                         are sufficiently broad to adequately protect our products and technologies.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 9.95pt"><span style="font-size: 10pt">Issued
                                         patents and patent applications we own or have exclusively licensed may not provide us
                                         with any competitive advantages, or may be held invalid or unenforceable, as a result
                                         of legal challenges by our competitors.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 10.05pt"><span style="font-size: 10pt">Our
                                         competitors might conduct research and development activities in countries where we do
                                         not have patent rights and then use the information learned from such activities to develop
                                         competitive products for sale in our major commercial markets.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">We
                                         may not develop additional proprietary technologies that are patentable.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">The
                                         patents of others may have an adverse effect on our business.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Should
any of these events or others occur, they could significantly harm our ability to sell products and earn revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Patent
reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement
or defense of our issued patents.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">The
Leahy-Smith Act, which was signed into law in September 2011, includes a number of significant changes to U.S. patent law. These
include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. Although
the USPTO has developed some regulations and procedures to govern administration of the Leahy-Smith Act, uncertainty remains as
to how some aspects of the Act and regulations will be interpreted and applied by the USPTO. Accordingly, it is not clear what,
if any, impact the Leahy-Smith Act will have on the operation of our business, our current and pending patent portfolio and future
intellectual property strategy. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs
surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could
have a material adverse effect on our business.</span></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>We
may be subject to litigation with respect to the ownership and use of intellectual property that will be costly to defend or pursue
and uncertain in its outcome.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Our
success also will depend, in part, on our refraining from infringing patents or otherwise violating intellectual property owned
or controlled by others. Pharmaceutical companies, biotechnology companies, universities, research institutions and others may
have filed patent applications or have received, or may obtain, issued patents in the United States or elsewhere relating to aspects
of our intellectual property. It is uncertain whether the issuance of any third-party patents will require us to alter our products
or processes, obtain licenses, or cease certain activities. Some third-party applications or patents may conflict with our issued
patents or pending applications. Any such conflict could result in a significant reduction of the scope or value of our issued
or licensed patents. Even if claims of infringement are without merit, any such action could divert the time and attention of
management and impair our ability to access additional capital and/or cost us significant funds to defend.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">In
addition, if patents issued to other companies contain blocking, dominating or conflicting claims and such claims are ultimately
determined to be valid, we may be required to obtain licenses to these patents or to develop or obtain alternative non-infringing
technology and cease manufacturing or selling any products deemed to infringe those patents. If any licenses are required, we
may not be able to obtain any such licenses on commercially favorable terms, if at all, and if these licenses are not obtained,
we might be prevented from pursuing the development and commercialization of certain of our potential products. Our failure to
obtain a license on favorable terms to any technology that we may require to commercialize our products could prevent us from
earning revenue on a product that we developed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">In
addition, if our competitors file or have filed patent applications in the United States or other countries that claim technology
also claimed by us, we may have to participate in interference proceedings to determine priority of invention. These proceedings,
if initiated by the USPTO or by foreign patent agencies, could result in substantial costs to us, even if the eventual outcome
is favorable to us. Such proceedings can be lengthy, are costly to defend and involve complex questions of law and fact, the outcomes
of which are difficult to predict. Moreover, we may have to participate in post-grant proceedings or third-party <i>ex parte </i>or
<i>inter partes </i>reexamination proceedings under the USPTO or foreign patent agencies. An adverse outcome with respect to a
third-party claim or in an interference proceeding could subject us to significant liabilities, require us to license disputed
rights from third parties, or require us to cease using such technology, any of which could substantially increase our expenses
and impair or delay our ability to earn revenue from product sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>If
we cannot adequately protect our trade secrets, we could lose potential competitive advantage.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
also rely on trade secrets to protect technology, especially where patent protection is not believed to be appropriate or obtainable
or where patents have not issued. For example, our manufacturing process involves a number of trade secret steps, processes, and
conditions. We attempt to protect our proprietary technology and processes, in part, with confidentiality agreements and assignment
of invention agreements with our employees and confidentiality agreements with our consultants and certain contractors. However,
these agreements may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may become
known or be independently discovered by competitors. We may fail in certain circumstances to obtain the necessary confidentiality
agreements, or their scope or term may not be sufficiently broad to protect our interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">If
our trade secrets or other intellectual property become known to our competitors, it could result in a material adverse effect
on our business. To the extent that we or our consultants or research collaborators use intellectual property owned by others
in work for us, disputes may also arise as to the rights to related or resulting know- how and inventions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0"><span style="font-size: 10pt"><b>If
our licensors do not adequately prosecute and protect patents we rely on, then our product development could be impaired.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">While
we normally seek and gain the right to fully prosecute the patents and patent applications relating to our product candidates,
there may be times when platform technology patents or product-specific patents that relate to our product candidates are controlled
by our licensors. In addition, our licensors and/or licensees may have back-up rights to prosecute patent applications if we do
not do so or choose not to do so, and our licensees may have the right to assume patent prosecution rights after certain milestones
are reached. If any of our licensing collaborators fails to appropriately prosecute and maintain patent protection for patents
covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected
and we may not be able to prevent competitors from making, using and selling competing products.</span></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Our
patent portfolio may be incomplete or inadequate.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Although
our patent portfolio consists of issued patents and patent applications and includes composition of matter patents and method/use
patents and patent applications, it may not be adequate to protect our products. We do not know if our current or future patent
applications will be approved or if our existing patents or patents issue in the future will adequately protect our products and
technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submissions, fee payment and other
requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance
with these requirements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">The
USPTO and various foreign governmental patent agencies require compliance with a number of procedural documentaries, fee payment
and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse
of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such
an event, competitors might be able to enter the market earlier than would otherwise have been the case.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Confidentiality
agreements with employees and others may not adequately prevent disclosure of our trade secrets and other proprietary information
and may not adequately protect our intellectual property, which could limit our ability to compete.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Because
we operate in the highly technical field of research and development of biopharmaceutical drugs, we rely in part on trade secret
protection to protect our proprietary trade secrets and unpatented know-how. However, trade secrets are difficult to protect,
and we cannot be certain that others will not develop the same or similar technologies on their own. We have taken steps, including
entering into confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers
and other advisors, to protect our trade secrets and unpatented know-how. These agreements generally require that the other party
keep confidential and not disclose to third parties all confidential information developed by the party or made known to the party
by us during the party’s relationship with us. We also typically obtain agreements from these parties that provide that
inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements
may not be honored and may not effectively assign intellectual property rights to us. Enforcing a claim that a party illegally
obtained and is using our trade secrets or know-how is difficult, expensive and time consuming, and the outcome is unpredictable.
In addition, courts outside the United States may be less willing to protect trade secrets or know-how. The failure to obtain
or maintain trade secret protection could adversely affect our competitive position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Risks
Relating to Our Exposure to Litigation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>We
are exposed to potential product liability or similar claims, and insurance against these claims may not be available to us at
a reasonable rate in the future.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Our
business exposes us to potential liability risks that are inherent in the testing, manufacturing and marketing of human therapeutic
products. Clinical trials involve the testing of product candidates on human subjects or volunteers under a research plan and
carry a risk of liability for personal injury or death to patients due to unforeseen adverse side effects, improper administration
of the product candidate, or other factors. Many of these patients are already seriously ill and are therefore particularly vulnerable
to further illness or death.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
currently carry liability insurance in the amount of $1,000,000 million in the aggregate, but we may not be able to maintain such
insurance or the amount of such insurance may not be adequate to cover claims. We could be materially and adversely affected if
we were required to pay damages or incur defense costs in connection with a claim outside the scope of indemnity or insurance
coverage, if the indemnity is not performed or enforced in accordance with its terms, or if our liability exceeds the amount of
applicable insurance. In addition, insurance may not continue to be available on terms acceptable to us, if at all, or if obtained,
the insurance coverage may be insufficient to cover any potential claims or liabilities. Similar risks, but with larger potential
liability amounts, would exist upon the commercialization or marketing of any products by our collaborators or us. Regardless
of their merit or eventual outcome, product liability claims may result in:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">decreased
                                         demand for our products;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">injury
                                         to our reputation and significant negative media attention;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">withdrawal
                                         of clinical trial volunteers;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">costs
                                         of litigation;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">distraction
                                         of management; and</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">substantial
                                         monetary awards to plaintiffs.</span></td></tr></tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify"><span style="font-size: 10pt">Should
any of these events occur, it could have a material adverse effect on our reputation and financial condition.</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Claims
for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against
us and may reduce the amount of money available to us.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Our
amended and restated certificate of incorporation provides that we will indemnify our directors to the fullest extent permitted
by Nevada law. In addition, as our bylaws provide, we may enter into indemnification agreements with our directors and executive
officers. If we are required to indemnify one or more of our directors or executive officers, it may reduce our available funds
to satisfy successful third-party claims against us, may reduce the amount of money available to us and may have a material adverse
effect on our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Risks
Related to this Offering of Common Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>The
price of our Common Stock may fluctuate substantially.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">You
should consider an investment in our Common Stock to be highly risky, and you should invest in our Common Stock only if you can
withstand a significant or entire loss and wide fluctuations in the market value of your investment. Some factors that may cause
the market price of our Common Stock to fluctuate, in addition to the other risks mentioned in this “Risk Factors”
section and elsewhere in this prospectus, are:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">sales
                                         of our Common Stock by our stockholders, executives, and directors;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">volatility
                                         and limitations in trading volumes of our shares of Common Stock;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 10pt"><span style="font-size: 10pt">our
                                         ability to obtain financings to conduct and complete research and development activities
                                         including, but not limited to, our current and proposed clinical trials, and other business
                                         activities;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 10.15pt"><span style="font-size: 10pt">the
                                         timing and success of introductions of new applications or our competitors or any other
                                         change in the competitive dynamics of our industry, including consolidation among competitors,
                                         customers or strategic partners;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">network
                                         outages or security breaches;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">our
                                         ability to secure resources and the necessary personnel to conduct clinical trials on
                                         our desired schedule;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">commencement,
                                         enrollment or results of our clinical trials for our drug candidates or any future clinical
                                         trials we may conduct;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">changes
                                         in the development status of our drug candidates;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">any
                                         delays or adverse developments or perceived adverse developments with respect to the
                                         FDA’s review of our planned preclinical and clinical trials;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 9.6pt"><span style="font-size: 10pt">any
                                         delay in our submission for studies or drug approvals or adverse regulatory decisions,
                                         including failure to receive regulatory approval for our drug candidates;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">unanticipated
                                         safety concerns related to the use of our drug candidates;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">failures
                                         to meet external expectations or management guidance;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">changes
                                         in our capital structure or dividend policy, future issuances of securities, sales of
                                         large blocks of Common Stock by stockholders;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">our
                                         cash position;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">announcements
                                         and events surrounding financing efforts, including debt and equity securities;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">our
                                         inability to enter into new markets and/or obtain and/or develop new drug candidates;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">reputational
                                         issues;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">competition
                                         from existing technologies and drugs or new technologies and drugs that may emerge;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">announcements
                                         of acquisitions, partnerships, collaborations, joint ventures, new drugs, capital commitments,
                                         or other events by us or our competitors;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">changes
                                         in general economic, political and market conditions in or any of the regions in which
                                         we conduct our business;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">changes
                                         in industry conditions or perceptions;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">changes
                                         in valuations of similar companies or groups of companies;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">analyst
                                         research reports, recommendation and changes in recommendations, price targets, and withdrawals
                                         of coverage;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">departures
                                         and additions of key personnel;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">disputes
                                         and litigations related to intellectual properties, proprietary rights, and contractual
                                         obligations;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">changes
                                         in applicable laws, rules, regulations, or accounting practices and other dynamics;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">possible
                                         delays in the expected recognition of revenue due to lengthy and sometimes unpredictable
                                         sales timelines;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">the
                                         lack of market acceptance and sales growth for our drug candidates, if any, that receive
                                         sales and marketing approval; and</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">other
                                         events or factors, many of which may be unforeseeable and/or out of our control.</span></td></tr></tbody></table>



<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">In
addition, if the market for stocks in biotechnology and/or pharmaceutical companies in general or in related industries or the
stock market in general experiences a loss of investor confidence, the trading price of our Common Stock could decline for reasons
unrelated to our business, financial condition and results of operations. If any of the foregoing occurs, it could cause the trading
price of the shares of our Common Stock price to fall as well, which could expose us to lawsuits that, even if unsuccessful, could
be costly to defend and a distraction to our management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>We
are authorized to issue 300,000,000 shares of Common Stock and 50,000,000 shares of “blank check” preferred stock,
the issuance of which could, among other things, reduce the proportionate ownership interests of current shareholders.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">We
are authorized to issue 300,000,000 shares of Common Stock and 50,000,000 shares of “blank check” preferred stock.
As of September 30, 2020, there were 59,570,666 shares of Common Stock issued, (excluding 11,536,500 shares issuable upon exercise
of all issued and outstanding stock options and warrants, and 2,344,784 shares issuable on the conversion of all outstanding Convertible
Notes). No shares of preferred stock were issued and outstanding as of September 30, 2021. Our board of directors has the ability,
without seeking shareholder approval, to issue additional shares of Common Stock and/or to designate, establish the terms and
conditions of, and issue shares of preferred stock for such consideration, if any, as the board of directors may determine. Any
such shares of preferred stock could have dividend, liquidation, conversion, voting or other rights, which could adversely affect
the voting power or other rights of the holders of shares of Common Stock. In the event of such issuance, the preferred stock
could, among other items, be used as a method of discouraging, delaying or preventing a change in control of our Company, which
could have the effect of discouraging bids for our Company and thereby prevent security-holders from receiving the maximum value
for their shares of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Our
Common Stock is currently traded on the OTC pink sheets and is subject to additional trading restrictions as a “penny stock,”
which could adversely affect the liquidity and price of such stock. If our Common Stock remains subject to the SEC’s penny
stock rules, broker-dealers may experience difficulty in completing customer transactions and trading activity in our securities
may be adversely affected.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">Our
Common Stock currently trades on the OTC pink sheets. The OTC pink sheets may be viewed by investors as a less desirable, and
less liquid, marketplace. As a result, an investors may find it more difficult to purchase, dispose of or obtain accurate quotations
as to the value of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">Because
our Common Stock is not listed on any national securities exchange, such shares will also be subject to the regulations regarding
trading in “penny stocks,” which are those securities trading for less than $5.00 per share, and that are not otherwise
exempted from the definition of a penny stock under other exemptions provided for in the applicable regulations. The following
is a list of the general restrictions on the sale of penny stocks:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 31.5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Before
                                         the sale of penny stock by a broker-dealer to a new purchaser, the broker-dealer must
                                         determine whether the purchaser is suitable to invest in penny stocks. To make that determination,
                                         a broker-dealer must obtain, from a prospective investor, information regarding the purchaser’s
                                         financial condition and investment experience and objectives. Subsequently, the broker-dealer
                                         must deliver to the purchaser a written statement setting forth the basis of the suitability
                                         finding and obtain the purchaser’s signature on such statement.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 31.5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
                                         broker-dealer must obtain from the purchaser an agreement to purchase the securities.
                                         This agreement must be obtained for every purchase until the purchaser becomes an “established
                                         customer.”</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 31.5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
                                         Exchange Act requires that before effecting any transaction in any penny stock, a broker-dealer
                                         must provide the purchaser with a “risk disclosure document” that contains,
                                         among other things, a description of the penny stock market and how it functions and
                                         the risks associated with such investment. These disclosure rules are applicable to both
                                         purchases and sales by investors.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 31.5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
                                         dealer that sells penny stock must send to the purchaser, within 10 days after the end
                                         of each calendar month, a written account statement including prescribed information
                                         relating to the security.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">These
requirements can severely limit the liquidity of securities in the secondary market because fewer brokers or dealers are likely
to be willing to undertake these compliance activities. As a result of our Common Stock not being listed on a national securities
exchange and the rules and restrictions regarding penny stock transactions, an investor’s ability to sell to a third party
and our ability to raise additional capital may be limited. We make no guarantee that market-makers will make a market in our
Common Stock, or that any market for our Common Stock will continue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>We
may acquire other companies or technologies, which could divert our management’s attention, result in dilution to our stockholders
and otherwise disrupt our operations and adversely affect our operating results.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">We
may in the future seek to acquire or invest in businesses, applications and services or technologies that we believe could complement
or expand our current product portfolio, enhance our technical capabilities or otherwise offer growth opportunities. The pursuit
of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating
and pursuing suitable acquisitions, whether or not they are consummated.</span></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">In
addition, we do not have any experience in acquiring other businesses. If we acquire additional businesses, we may not be able
to integrate the acquired personnel, operations and technologies successfully or effectively manage the combined business following
the acquisition. We also may not achieve the anticipated benefits from the acquired business due to a number of factors, including:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">inability
                                         to integrate or benefit from acquired technologies or services in a profitable manner;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">unanticipated
                                         costs or liabilities associated with the acquisition;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">difficulty
                                         integrating the accounting systems, operations and personnel of the acquired business;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">difficulties
                                         and additional expenses associated with supporting legacy pharmaceutical products and
                                         hosting infrastructure of the acquired business;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">diversion
                                         of management’s attention from other business concerns;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">adverse
                                         effects to our existing business relationships with business partners and customers as
                                         a result of the acquisition;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">the
                                         potential loss of key employees;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">use
                                         of resources that are needed in other parts of our business; and</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">use
                                         of substantial portions of our available cash to consummate the acquisition.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">In
addition, a significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other
intangible assets, which must be assessed for impairment at least annually. In the future, if our acquisitions do not yield expected
returns, we may be required to take charges to our operating results based on this impairment assessment process, which could
adversely affect our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Acquisitions
could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our operating
results. In addition, if an acquired business fails to meet our expectations, our operating results, business and financial position
may suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Market
and economic conditions may negatively impact our business, financial condition and share price.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Concerns
over inflation, energy costs, geopolitical issues, the U.S. mortgage market and a declining real estate market, unstable global
credit markets and financial conditions, and volatile oil prices have led to periods of significant economic instability, diminished
liquidity and credit availability, declines in consumer confidence and discretionary spending, diminished expectations for the
global economy and expectations of slower global economic growth going forward, increased unemployment rates, and increased credit
defaults in recent years. Our general business strategy may be adversely affected by any such economic downturns, volatile business
environments and continued unstable or unpredictable economic and market conditions. If these conditions continue to deteriorate
or do not improve, it may make any necessary debt or equity financing more difficult to complete, more costly, and more dilutive.
Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our
growth strategy, financial performance, and share price and could require us to delay or abandon development or commercialization
plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>If
securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business,
our stock price and trading volume may decline.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Any
future trading market for our Common Stock will rely in part on the research and reports that industry or financial analysts publish
about us, our business, our markets and our competitors. We do not control these analysts. If securities analysts do not cover
our Common Stock, the lack of research coverage may adversely affect the market price of our Common Stock. Furthermore, if one
or more of the analysts who do cover us downgrade our Common Stock or if those analysts issue other unfavorable commentary about
us or our business, the market price of the shares of our Common Stock would likely decline. If one or more of these analysts
cease coverage of us or fails to regularly publish reports on us, we could lose visibility in the market and interest in our Common
Stock could decrease, which in turn could cause the market price of, or the trading volume in, the shares of Common Stock to decline
and may also impair our ability to expand our business with existing customers and attract new customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b>We
currently are wholly dependent on John Arnone and Anthony Dudzinski, Conflicts of Interest.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">We
currently are wholly dependent on John Arnone and Anthony Dudzinski, our only executive officers and directors. Our future performance
will depend on the continued services of such persons and our ability to retain such persons and to hire additional qualified
persons. The loss of either of Mr. Arnone or Mr. Dudzinski, or both, would materially and adversely affect our proposed business.
There are no assurances they will continue to do so. The employment agreements among other terms permit each of Mr. Arnone and
Mr. Dudzinski to conduct other business activities outside of their employment with us. Each such employment agreement has been
extended to 2025.We have not obtained any “key-man” life insurance policies, nor do we presently plan to obtain or
maintain any such policies on Mr. Arnone, Mr. Dudzinski or any other of our employees.</span></p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Mr.
Arnone and Mr. Dudzinski collectively beneficially own in excess of 50.1% of our issued and outstanding voting stock and as a
result have the ability to directly and/or indirectly make all decisions for us. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">Mr.
Arnone owns the majority of the issued and outstanding voting stock of Personal Cell Sciences Corporation, a Florida corporation
(“<span style="text-decoration: underline">PCS</span>”). PCS is in the cosmetic business and has entered into a contract manufacturing and royalty agreement
with the company to manufacture conditioned medium. We also receive a royalty of 10% of the gross sales of any autologous products
sold by PCS containing the conditioned medium that we manufacture. Mr. Arnone is also the CEO of Regenerative BioTherapy Corp.
Regenerative BioTherapy Corp, a Florida corporation which entered into a licensing Agreement with the Company in September of
2014. The licensing agreement Permits Regenerative BioTherapy the use of the Company’s Standard Operating Procedures, Quality
Management and General Operations procedures and process for the Company’s product lines and IP; to construct and operate
a laboratory and treatment facility in the Caribbean. We may in the future seek to expand our business relationship with, and/or
acquire PCS and/or Regenerative BioTherapy Corp. Management cannot assure you that any such business relationship or acquisition,
if consummated, would be on terms favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 2pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Because
certain of our stockholders control a significant number of shares of our Common Stock, they may have effective control over actions
requiring stockholder approval.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Our
directors, executive officers and principal stockholders, and their respective affiliates, beneficially own approximately 51.09%
of our outstanding shares of Common Stock. In particular, AMCY, our largest stockholder of record, owns approximately 33.40% of
our issued and outstanding shares of Common and John Arnone, CEO and Chairman beneficially own approximately 40.59% of our issued
and outstanding shares of Common Stock and Anthony Dudzinski, COO and director will beneficially own approximately 40.38 % of
our issued and outstanding Common Stock. As a result, these stockholders, acting together, have the ability to control the outcome
of matters submitted to our stockholders for approval, including the election of directors and any merger, consolidation or sale
of all or substantially all of our assets. In addition, these stockholders, acting together, have the ability to control the management
and affairs of our company. Accordingly, this concentration of ownership might harm the market price of our Common Stock by:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">delaying,
                                         deferring or preventing a change in corporate control;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">impeding
                                         a merger, consolidation, takeover or other business combination involving us; or</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">discouraging
                                         a potential acquirer from making a tender offer or otherwise attempting to obtain control
                                         of us.</span></td></tr></tbody></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Future
sales and issuances of shares of our Common Stock could result in additional dilution of the percentage ownership of our stockholders
and could cause our share price to fall.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">We
expect that significant additional capital will be needed in the future to continue our planned operations, including increased
marketing, hiring new personnel, commercializing our drugs, and continuing activities as an operating public company. To the extent
we raise additional capital by issuing equity securities; our stockholders may experience substantial dilution. We may sell
Common Stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine
from time to time. If we sell Common Stock, convertible securities or other equity securities in more than one transaction, investors
may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and
new investors could gain rights superior to our existing stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>We
do not intend to pay cash dividends on our shares of our Common Stock so any returns will be limited to the value of our shares.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">We
currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not
anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited
to the increase, if any, of our share price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>Our
ability to use our net operating loss carry-forwards and certain other tax attributes is limited by Sections 382 and 383 of the
Internal Revenue Code.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">Net
operating loss carryforwards allow companies to use past year net operating losses to offset against future years’ profits,
if any, to reduce future tax liabilities. Sections 382 and 383 of the Internal Revenue Code of 1986 limit a corporation’s
ability to utilize its net operating loss carryforwards and certain other tax attributes (including research credits) to offset
any future taxable income or tax if the corporation experiences a cumulative ownership change of more than 50% over any rolling
three-year period. State net operating loss carryforwards (and certain other tax attributes) may be similarly limited. An ownership
change can therefore result in significantly greater tax liabilities than a corporation would incur in the absence of such a change
and any increased liabilities could adversely affect the corporation’s business, results of operations, financial condition
and cash flow. Even if another ownership change has not occurred and does not occur as a result of this offering, additional ownership
changes may occur in the future as a result of additional equity offerings or events over which we will have little or no control,
including purchases and sales of our equity by our five percent security holders, the emergence of new five percent security holders,
redemptions of our securities or certain changes in the ownership of any of our five percent security holders.</span></p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>We
are an “emerging growth company” and a “smaller reporting company” and intend to avail ourselves of reduced
disclosure requirements applicable to emerging growth companies, which could make our Common Stock less attractive to investors.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
are an “emerging growth company,” as defined in the JOBS Act, and we intend to take advantage of certain exemptions
from various reporting requirements that are applicable to other public companies that are not “emerging growth companies”
including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act,
reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from
the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
payments not previously approved. In addition, Section 107 of the JOBS Act also provides that an “emerging growth company”
can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with
new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We are not electing to delay such adoption
of new or revised accounting standards, and as a result, we will comply with new or revised accounting standards on the relevant
dates on which adoption of such standards is required for non-emerging growth companies. We cannot predict if investors will find
our Common Stock less attractive because we rely on these exemptions. If some investors find our Common Stock less attractive
as a result, there may be a less active trading market for our Common Stock and our stock price may be more volatile. We may take
advantage of these reporting exemptions until we are no longer an “emerging growth company.” We will remain an “emerging
growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of
$1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion
of an offering; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three
years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
are also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after
we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting
companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting (of which we
have none at this time) Common Stock held by non-affiliates is less than $250 million measured on the last business day of our
second fiscal quarter, or our annual revenue is less than $100 million during the most recently completed fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>We
may be at risk of securities class action litigation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">We
may be at risk of securities class action litigation. In the past, biotechnology and pharmaceutical companies have experienced
significant stock price volatility, particularly when associated with binary events such as clinical trials and drug approvals.
If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources,
which could harm our business and results in a decline in the market price of our Common Stock.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Our
amended and restated certificate of incorporation, our bylaws, may have anti-takeover effects that could discourage, delay or
prevent a change in control, which may cause the market price of the shares of our Common Stock to decline.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.4pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">Our
amended and restated certificate of incorporation and our bylaws may make it more difficult for a third-party to acquire us, even
if closing such a transaction would be beneficial to our stockholders. We will be authorized to issue up to 50 million shares
of preferred stock upon the completion of this offering and the filing of our amended and restated certificate of incorporation
with the State of Nevada. This preferred stock may be issued in one or more series, the terms of which may be determined at the
time of issuance by our board of directors without further action by stockholders. The terms of any series of preferred stock
may include voting rights (including the right to vote as a series on particular matters), preferences as to dividend, liquidation,
conversion and redemption rights and sinking fund provisions. No preferred stock is currently outstanding. The issuance of any
preferred stock could materially adversely affect the rights of the holders of our Common Stock, and therefore, reduce the value
of our Common Stock. In particular, specific rights granted to future holders of preferred stock could be used to restrict our
ability to merge with, or sell our assets to, a third-party and thereby preserve control by the present management.</span></p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Provisions
of our amended and restated certificate of incorporation and our bylaws also could have the effect of discouraging potential acquisition
proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider
favorable. Such provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. For
example, our amended and restated certificate of incorporation, bylaws and provisions of the DGCL, as applicable, among other
things:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">provide
                                         the board of directors with the ability to alter the bylaws without stockholder approval;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">establishing
                                         advance notice requirements for nominations for election to the board of directors or
                                         for proposing matters that can be acted upon at stockholder meetings; and</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">provide
                                         that vacancies on the board of directors may be filled by a majority of directors in
                                         office, although less than a quorum.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Financial
reporting obligations of being a public company in the United States require well defined disclosure and financial controls and
procedures that we did not have as a private company and that are expensive and time-consuming requiring our management to devote
substantial time to compliance matters.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">These
reporting obligations associated with being a public company in the United States require significant expenditures and will place
significant demands on our management and other personnel, including costs resulting from our reporting obligations under the
Exchange Act, the rules and regulations regarding corporate governance practices, including those under the Sarbanes-Oxley Act, the (the “Dodd-Frank Act”), and the listing requirements of the stock exchange on which our securities may be listed.
These rules require the establishment and maintenance of effective disclosure and financial controls and procedures, internal
control over financial reporting and changes in corporate governance practices, among many other complex rules that are often
difficult to implement, monitor and maintain compliance with. Moreover, despite recent reforms made possible by the JOBS Act,
the reporting requirements, rules, and regulations will make some activities more time-consuming and costly, particularly after
we are no longer an “emerging growth company.” In addition, we expect these rules and regulations to make it more
difficult and more expensive for us to obtain director and officer liability insurance. Our management and other personnel will
need to devote a substantial amount of time to ensure that we comply with all these requirements and to keep pace with new regulations,
otherwise we may fall out of compliance and risk becoming subject to litigation or being delisted, among other potential problems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">If
we fail to comply with the rules under the Sarbanes-Oxley Act related to accounting controls and procedures in the future, or,
if we discover additional material weaknesses and other deficiencies in our internal control and accounting procedures, our stock
price could decline significantly and raising capital could be more difficult.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">Section
404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial
reporting after a transition period ending with our second annual report on Form 10-K filed under Section 13(a) of the Exchange
Act. If we fail to comply with the rules under the Sarbanes-Oxley Act related to disclosure controls and procedures in the future,
or, if in the future we discover additional material weaknesses and other deficiencies in our internal control and accounting
procedures, our stock price could decline significantly and raising capital could be more difficult.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Risks
related to COVID-19</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.35pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>Our
business may be materially adversely affected by the recent coronavirus (COVID-19) outbreak.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">The
development of our drug candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic
or outbreak of an infectious disease like the recent outbreak of COVID-19. For example, as a result of measures imposed by the
governments in regions affected by COVID-19 businesses and schools have been suspended due to quarantines or “stay at home”
orders intended to contain this outbreak. Furthermore, many patients had concerns about making hospital and physician office visits
for fear of contracting the virus. These factors had an direct adverse impact on our ability to enroll participants in our clinical
trial programs. In addition, travel restrictions, stay-in-place orders and other measures imposed by governmental agencies and
health organizations to prevent the spread of COVID-19 and protect the citizenry, have had an adverse impact on the flow of goods
and services between nations. The supply disruptions have resulted in shortages of goods and materials. This could also impact
our ability to produce the products we need to conduct our clinical trials. In addition, these measures have resulted in delays
to the regulatory process, which may also have an adverse impact on our business. Finally, initially, the outbreak of COVID-19
led to steep declines in the Dow Industrial Average and other domestic and international stock indices at the end of February
and during March and April 2020. While the markets have rebounded nicely since then, recent concerns over the “Delta variant”
and the impact it may have on the U.S. and global economies, have led to “risk-off” sessions in the global markets.
We are still assessing our business plans and the impact COVID-19 may have on our ability to advance the development of our drug
candidates or to raise financing to support the development of our drug candidates, we cannot assure you that we will be able
to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment
generally or in our sector in particular.</span></p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt">SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">This
report including the sections titled “Prospectus Summary,” “Risk Factors,” “Use of Proceeds,”
“Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Business,”
contains forward-looking statements about us and our industry. These statements involve known and unknown risks, uncertainties
and other factors which may cause our actual results, performance or achievements to be materially different from any future results,
performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but
are not limited to, the factors described in the section captioned “Risk Factors” below. In some cases, you can identify
forward-looking statements by terms such as “anticipate,” “believe,” “could,” “estimate,”
“expect,” “intend,” “seek,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “would,” and similar expressions intended to identify
forward-looking statements. Forward- looking statements reflect our current views with respect to future events and are based
on assumptions and subject to risks and uncertainties. You should read these factors and the other cautionary statements made
in this report and in the documents we incorporate by reference into this report as being applicable to all related forward-looking
statements wherever they appear in this report or the documents we incorporate by reference. If one or more of these factors materialize,
or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any
future results, performance or achievements expressed or implied by these forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: justify"><span style="font-size: 10pt">Given
these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements
include, among other things, statements relating to:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">our
                                         plans to develop and commercialize our product candidates;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 22.65pt"><span style="font-size: 10pt">our
                                         ability to timely secure sufficient funding for our current and proposed operations,
                                         including funding necessary for the development and commercialization of our product
                                         candidates and to complete additional product candidates;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">our
                                         anticipated growth strategies and our ability to manage the expansion of our business
                                         operations effectively;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">future
                                         agreements with third parties in connection with the commercialization of our product
                                         candidates;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">the
                                         success, cost and timing of our product candidate development activities and planned
                                         clinical trials;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.95pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.3pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 14.6pt"><span style="font-size: 10pt">our
                                         expectations regarding the impact of the COVID-19 pandemic and its potentially material
                                         adverse impact on our business, the economy, and the execution of our clinical trials;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">the
                                         rate and degree of market acceptance and clinical utility of our product candidates;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">our
                                         commercialization, marketing and manufacturing capabilities and strategy;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">the
                                         success of competing therapies that are or may become available;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">our
                                         ability to attract and retain key management and technical personnel;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">our
                                         expectations regarding our ability to obtain, maintain and enforce intellectual property
                                         protection for our product candidates;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">our
                                         ability to diversify our product offerings and capture new market opportunities;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">our
                                         use of our existing cash and cash equivalents and the net proceeds from this offering;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">our
                                         estimates regarding expenses, future revenue, capital requirements and needs for additional
                                         financing; and</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 25.9pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14.35pt"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">the
                                         possibility that we in the future may acquire certain businesses and/or additional drug
                                         candidates.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Also, forward-looking statements
represent our estimates and assumptions only as of the date of this prospectus. You should read this prospectus and the documents
that we reference and file as exhibits to this prospectus completely and with the understanding that our actual future results
may be materially different from what we expect. Except as required by law, we assume no obligation to update any forward-looking
statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking
statements, even if new information becomes available in the future.</span></p>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="acryoa004"></span>Item
1B. Unresolved Staff Comments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Not applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="acryoa005"></span>Item
2. Description of Property</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We currently
rent office space at 1 Meridian Road, Eatontown, NJ 07724 for our corporate offices, and we rent laboratory space in Monmouth
Junction, New Jersey. During 2018, the Company constructed a new Clean Room designed specifically for cellular expansion, medium
filling and tissue processing at the Laboratory in Monmouth Junction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><span id="acryoa006"></span>Item
3. Legal Proceedings</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are currently
not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations.
There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory
organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened
against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries’
officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt"><span id="acryoa007"></span>Item
4. Mine Safety Disclosures</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Not applicable.</span></p>




<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><span id="acryoa008"></span>PART
II</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt"><span id="acryoa009"></span>Item
5. Market for Common Equity and Related Stockholder Matters</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>(a) Market
Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our common stock
is listed on the OTC pink sheets under the symbol “CRYO” The following table shows the reported high and low closing
prices per share for our common stock for each quarterly period as noted. The over-the-counter market quotations set forth for
our common stock reflect interdealer prices, without retail mark-up, mark-down or commission and may not necessarily represent
actual transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
<tbody><tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left; padding-bottom: 1pt">Quarter ended</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">High</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Low</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 34%; text-align: justify">December 31, 2020</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">0.42</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">0.25</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">March 31, 2021</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.11</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.26</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: justify">June 30, 2021</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.74</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.25</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">September 30, 2021</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.36</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left">&nbsp;</td></tr>
</tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>(b) Holders
of Common Equity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of
September 30, 2020, there were approximately 473 holders of record of our common stock. This figure does not take into
account those shareholders whose certificates are held in the name of broker-dealers or other nominees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><b><i>(c)
Dividend Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have never
paid any cash dividends on our common shares, and we do not anticipate that we will pay any dividends with respect to those securities
in the foreseeable future. Our current business plan is to retain any future earnings to finance the expansion development of
our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>d) Sales
of Unregistered Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
issued shares of common stock to pay professional services bills valued at $60,000 in Fiscal 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
issued shares of common stock to pay for consulting services valued at $97,500 in Fiscal 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
issued 150,000 shares of common stock in settlement of a service contract in Fiscal 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
issued shares of common stock to pay interest expense on the convertible notes and bridge notes of $57,849 in Fiscal 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The Company issued shares of
common stock and received $143,000 in Fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The Company issued shares
of common stock for a prepaid expense of $75,000 in Fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The Company issued shares
of common stock for services provided in the amount of $258,500 in Fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The Company issued shares of
common stock to pay interest due of $48,546 to holders of the bridge notes and convertible notes in Fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>(e) <b>Securities
Authorized For Issuance Under Equity Compensation Plans</b></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
applies ASC 718, “Accounting for Stock-Based Compensation” to account for its option issues. Accordingly, all options
granted are recorded at fair value using a generally accepted option pricing model at the date of the grant. For purposes of determining
the option value at issuance, the fair value of each option granted is measured at the date of the grant by the option pricing
model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair values
generated by option pricing model may not be indicative of the future values, if any, that may be received by the option holder.</span></p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
normally issues options to its key personnel and consultants at the end of each fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair value
of the options issued in Fiscals 2021 and 2020 was calculated using the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 56%; margin-right: auto">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>&nbsp;</b></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&nbsp;</b></span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>2021</b></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&nbsp;</b></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&nbsp;</b></span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>2020</b></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&nbsp;</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"><span style="font-size: 10pt">Dividend
    yield</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">0.00</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">0.00</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Risk free interest rate</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.78%
                                         and 0.79</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">0.125</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Volatility</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">175.29</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">146.37</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Share Price</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.25
                                         and $0.30</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">0.20</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Term</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">5
                                         years</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">5
                                         years</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
</tbody></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Using the Black-Sholes
valuation method, the Company issued options and recorded stock compensation expenses of $902,853 for Fiscal 2021 and $320,042
in fiscal year 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Transfer
Agent </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our transfer
agent is Olde Monmouth Stock Transfer Co., Inc. located at 200 Memorial Parkway, Atlantic Highlands, New Jersey 07716. Its contact
phone is 732-872-2727.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><span id="acryoa010"></span>Item
6. Selected Financial Data</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Not applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt"><span id="acryoa011"></span>Item
7. Management’s Discussion and Analysis of Financial Condition and Results of Operations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This annual
report on Form 10-K and other reports filed by American CryoStem Corporation (the “Company”) from time to time with
the U.S. Securities and Exchange Commission (the “SEC”) contain or may contain forward-looking statements and information
that are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and
assumptions made by Company’s management. Readers are cautioned not to place undue reliance on these forward-looking
statements, which are only predictions and speak only as of the date hereof. When used in the filings, the words “anticipate,”
“believe,” “estimate,” “expect,” “future,” “intend,” “plan,”
or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify
forward-looking statements. Such statements reflect the current view of the Company with respect to future events and
are subject to risks, uncertainties, assumptions, and other factors, including the risks contained in the “Risk Factors”
section of this Annual Report on Form 10-K., relating to the Company’s industry, the Company’s operations and results
of operations, and any businesses that the Company may acquire. Should one or more of these risks or uncertainties
materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended, or planned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Although the
Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee
future results, levels of activity, performance, or achievements. Except as required by applicable law, including the
securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these
statements to actual results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our financial
statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”).
These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments
and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments
and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and
liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods
presented. Our financial statements would be affected to the extent there are material differences between these estimates and
actual results. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does
not require management’s judgment in its application. There are also areas in which management’s judgment in selecting
any available alternative would not produce a materially different result. The following discussion should be read in conjunction
with our consolidated financial statements and notes thereto appearing elsewhere in this report.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Background</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We were incorporated
in the State of Nevada on March 13, 2009. On April 20, 2011, we acquired, through our wholly owned subsidiary American CryoStem
Acquisition Corporation, substantially all of the assets from, and assumed substantially all of the liabilities of, ACS Global,
Inc. (“ACS”) in exchange for our issuance of 21,000,000 shares of our common stock, par value $0.001 per share, to
ACS (the “Asset Purchase”). We filed a Current Report on Form 8-K with the Securities and Exchange Commission on April
27, 2011 disclosing the Asset Purchase and certain related matters including, but not limited to, the appointment of our present
officers and directors as well as the resignation by the former chief executive officer and sole director. Our fiscal year ends
September 30 of each calendar year.</span></p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Overview</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">American CryoStem
Corporation; (CRYO) founded in 2008, has evolved to become a biotechnology pioneer, standardizing adipose tissue derived technologies
(Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. These standardized technologies which include granted
patents, are the basis for our chemistry, manufacturing, and control (cGMP Manufacturing) of our ATCell product for clinical use
in clinical investigations for Biologic License Applications with the US Food and Drug Administration. Our laboratory stem cell
products are characterized adult human Mesenchymal Stem Cell (MSC’s) derived from adipose tissue that work in conjunction
with our patented (non-animal) medium lines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
filed its first Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) for our ATCELL cellular
therapy product. The IND filing is titled “ATCell™ Expanded Autologous Adipose Derived Mesenchymal Stem Cells deployed
via Intravenous Infusion for the Treatment of Post Concussion Syndrome (PCS) in Retired Athletes and Military Personnel”
File number 19089 was approved by the FDA on September 17, 2020. Post-Concussion Syndrome is an incurable condition affecting
a significant number of athletes involved in contact sports such as football, boxing, soccer, and other sports with a significant
number of participants have suffered one or more concussions. In addition, published research has indicated that up to 30% of
all military personal, active and retired, may suffer from this condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
built and validated a new cGMP clean room processing and manufacturing area at our facility in Monmouth Junction NJ, implemented
and validated cGMP Standard Operating Procedures (SOPs) and installed a new Quality Management System to support its increased
focus on patent and product development and support additional clinical activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
has built a domestic and international patent portfolio consisting of 32 patents. Our 4 primary operating patents regarding the
“collection – processing – storage and return to point of care” of adipose stem cells have been granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is expanding its efforts in attracting and developing collaborative partners to accelerate its development efforts of products
derived from our processing platform that incorporate our completed processing products and provide opportunities for rapid expansion
of our platform. The R&amp;D efforts are focused on university and private collaborations to discover, develop, and commercialize
our cellular therapies and laboratory products and combinations with synergistic technologies to create regenerative medicine
applications and new intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Cash Requirements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We will require
additional capital to fund marketing, operational expansion, processing staff training, as well as for working capital. We are
attempting to raise sufficient funds would enable us to satisfy our cash requirements for a period of the next 12 to 24 months.
In order to finance further market development with the associated expansion of operational capabilities for the time period discussed
above, we will need to raise additional working capital. However, we cannot assure you we can attract sufficient capital to enable
us to fully fund our anticipated cash requirements during this period. In addition, we cannot assure you that the requisite financing,
whether over the short or long term, will be raised within the necessary time frame or on terms acceptable to us, if at all. Should
we be unable to raise sufficient funds we may be required to curtail our operating plans if not cease them entirely. As a result,
we cannot assure you that we will be able to operate profitably on a consistent basis, or at all, in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In order to
move our Company through its next critical growth phase of development and commercialization and to ensure we are in position
to support our research collaborations and market penetration strategies, Management continues to seek new investment into the
Company from existing and new investors with particular emphasis on identifying the best deal structure to attract and retain
meaningful capital sponsorship from both the retail and institutional investing communities, while limiting dilution to our current
shareholders. Management also focuses its efforts on increasing sales and licensing revenue and reducing expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Fiscal 2020
Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In Fiscal
2021, The Company's Total Revenue decreased to $20,590 from $557,903 in Fiscal 2020, due to the adjustment of the revenue recognition
related to our agreement with Baoxin (see Note 3, 13 and 14 of the Financial Statements). Accounts Receivable decreased to $78,782
in Fiscal 2021 from $500,000 in Fiscal 2020 due to the billing of Annual Storage Fees due to the adjustment of Accounts Receivable
related to our Agreement with Baoxin (See Note 3, 13 and 14 of the Financial Statements). In Fiscal 2021, Licensing Fees and Royalties
decreased to $0 from $523,333 in Fiscal 2020. In Fiscal 2021, Tissue Processing &amp; Storage increased to $19,830 from $11,900
in Fiscal 2020. Short term liabilities increased to $1,630,908 in Fiscal 2021 from $1,049,634 in Fiscal 2020. Long term debt increased
to $1,272,901 in 2021 from $848,414 in 2020; due to increases in Accrued Executive Compensation a new convertible note, finance
lease and an increase to the note to the related party. Cost of Sales decreased to $13,573 in Fiscal 2021 from $43,837 in Fiscal
2020. Research and Development increased to $374,284 in Fiscal 2021 from $19,176 in 2020, since the company’s primary focus
in 2021 was clinical studies for its current and planned IND filings. Stock Compensation increased to $902,853 in Fiscal 2021
from $417,542, due to stock options granted. Bad Debt Expense increased to $860,933 in Fiscal 2021 from $326,650 in Fiscal 2020
(See Note 14 of the Financial Statements.) Management increased its allowance for Bad Debt by $542,370. The majority of the increase
in Bad Debt Allowance was caused by Management’s concern for its International Partner, Baoxin’s ability to pay caused
by the continuing affects of the COVID-19 Pandemic See Note 13 and 14 of the Financial Statements.</span></p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Going
Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of the date
of this annual report, there is substantial doubt regarding our ability to continue as a going concern as we have not generated
sufficient cash flow to fund our proposed business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have suffered
recurring losses from operations since our inception. In addition, we have yet to generate an internal cash flow from our business
operations or successfully raised the financing required to expand our business. As a result of these and other factors, our independent
auditor has expressed substantial doubt about our ability to continue as a going concern. Our future success and viability, therefore,
are dependent upon our ability to generate capital financing. The failure to generate sufficient revenues or raise additional
capital may have a material and adverse effect upon us and our shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our plans with
regard to these matters encompass the following actions: (i) obtaining funding from new investors to alleviate our working capital
deficiency, and (ii) implementing a plan to generate sales of our proposed products. Our continued existence is dependent upon
our ability to resolve our liquidity problems and achieve profitability in our current business operations. However, the outcome
of management’s plans cannot be ascertained with any degree of certainty. Our financial statements do not include any adjustments
that might result from the outcome of these risks and uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Liquidity
and Capital Resources</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of the fiscal
year ended September 30, 2021, the Company had a cash balance of $8,244 and net accounts receivable of $78,782. Our sources of
funds in 2021, were tissue processing and storage fees, and financing
activities. In Fiscal 2021, we used $303,920 of net cash for Operations, and $91,345 for investment activities, including Patent
Development, and the establishment of a new finance lease for laboratory equipment. Additionally, the Company generated $361,749
from financing activities, which included issuance of convertible notes, issuance of common stock, a finance lease and proceeds
from a related party note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
will continue to focus on its financing and investment activities but should we be unable to raise sufficient funds, we will be
required to curtail our operating plans if not cease them entirely. We cannot assure you that we will generate the necessary funding
to operate or develop our business. Please see “Cash Requirements” above for our existing plans with respect to raising
the capital we believe will be required. In the event that we are able to obtain the necessary financing to move forward with
our business plan, we expect that our expenses will increase significantly as we attempt to grow our business. Accordingly, the
above estimates for the financing required may not be accurate and must be considered in light these circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There was no
significant impact on the Company’s operations as a result of inflation for the fiscal year ended September 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>Off Balance Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have no off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in
financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are
material to investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Critical
Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We prepare financial
statements in conformity with U.S. generally accepted accounting principles (“GAAP”), which requires us to make estimates
and assumptions that affect the amounts reported in our combined and consolidated financial statements and related notes. We periodically
evaluate these estimates and assumptions based on the most recently available information, our own historical experience and various
other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. Since the use of estimates
is an integral component of the financial reporting process, actual results could differ from those estimates. Some of our accounting
policies require higher degrees of judgment than others in their application. We believe the following accounting policies involve
the most significant judgments and estimates used in the preparation of our financial statements. See Note 1 and Note 3 of the
Financial Statements for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Basis of
Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our financial
statements are presented on the accrual basis of accounting in accordance with generally accepted accounting principles in the
United States of America, whereby revenues are recognized in the period earned and expenses when incurred.</span></p>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Management’s
Use of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The preparation
of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting periods. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Long-Lived
Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We review and
evaluate our long-lived assets for impairment whenever events or changes in circumstances indicate that their net book value may
not be recoverable. When such factors and circumstances exist, we compare the assets’ carrying amounts against the estimated
undiscounted cash flows to be generated by those assets over their estimated useful lives. If the carrying amounts are greater
than the undiscounted cash flows, the fair values of those assets are estimated by discounting the projected cash flows. Any excess
of the carrying amounts over the fair values are recorded as impairments in that fiscal period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Statement
of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">For purposes
of the statement of cash flows, we consider all highly liquid investments (i.e., investments which, when purchased, have original
maturities of three months or less) to be cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Fair Value
of Financial Instruments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our financial
instruments consist of cash and cash equivalents. The fair value of cash and cash equivalents approximates the recorded amounts
because of the liquidity and short-term nature of these items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Recent Accounting
Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The
FASB recently issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging
– Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s
Own Equity, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The
guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing
the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial
conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The
guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated
from the host contract and accounted for as derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In
addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments
and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing
certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments
qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring
separate accounting from the host contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The
amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted
earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share
settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The
amendments in ASU 2020-06 are effective for our company for fiscal years beginning after December 15, 2023, with early adoption
permitted. The Company is currently assessing the impact of these amendments on its future financial reporting.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">In June
2016, the FASB issued ASU No. 2016-13 <i>Financial Instruments-Credit Losses</i>. The new guidance provides better representation
about expected credit losses on financial instruments. This Update requires the use of a methodology that reflects expected losses
and requires consideration of a broader range of reasonable and supportive information to inform credit loss estimates. This ASU is effective for reporting periods beginning after December 15, 2022, with early adoption permitted. The company
is studying the impact of adopting the ASU in fiscal year 2024, and what effect it could have. The Company believes the accounting
change would not have a material effect on the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Related
Party Transactions. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">At
September 30, 2021, the Company was indebted to a company that is majority owned by the Company’s two chief executive officers
for $147,775.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><span id="acryoa012"></span>Item
7A. Quantitative and Qualitative Disclosures about Market Risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We do not hold
any derivative instruments and do not engage in any hedging activities.</span></p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="acryoa013"></span>Item
8. Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our financial
statements are contained in pages F-1 through F-20 which appear at the end of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><span id="acryoa014"></span>Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company’s
Accountants (Fruci &amp; Associates) are unchanged for Fiscal 2021. There were no disagreements with our Accountants on Accounting
or Financial Disclosure for Fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt"><span id="acryoa015"></span>Item
9A. Controls and Procedures</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>(a) Evaluation
of Disclosure and Control Procedures</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company’s
disclosure controls and procedures are designed to ensure (i) that information required to be disclosed by the Company in the
reports the Company files or submits under the Exchange Act are recorded, processed, summarized, and reported within the time
periods specified in the SEC’s rules and forms; and (ii) that information required to be disclosed by the Company in the
reports it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including
its principal executive officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required
disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our principal
executive officer and principal financial officer evaluated the effectiveness of the design and operation of our disclosure controls
and procedures as of September 30, 2021, and concluded that the disclosure controls and procedures were effective as a whole.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>(b)</i><b>&nbsp;</b><i>Management’s
Report on Internal Control over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company’s
management is responsible for establishing and maintaining an adequate system of internal control over financial reporting, as
defined in Rule 13a-15(f) under the Exchange Act. The Company’s internal control over financial reporting is
designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
in accordance with Generally Accepted Accounting Principles (“GAAP”).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Because of its
inherent limitations, a system of internal control over financial reporting can provide only reasonable assurance of such reliability
and may not prevent or detect misstatements. Also, projection of any evaluation of effectiveness to future periods
is subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Management has
conducted, with the participation of our Chief Executive Officer and our Principal Accounting Officer, an assessment of the effectiveness
of our internal control over financial reporting as of September 30, 2020. Management’s assessment of internal
control over financial reporting used the criteria set forth in SEC Release 33-8810 based on the framework established by the
Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in <i>Internal Control over Financial Reporting
– Guidance for Smaller Public Companies</i> (2013). Based on this evaluation, Management concluded that our system of internal
control over financial reporting was effective as of September 30, 2020, based on these criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>(c) Changes
in Internal Control over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There were no
changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act,
during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>(d) Attestation
Report of the Registered Public Accounting Firm</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This annual
report does not include an attestation report of our independent registered public accounting firm regarding internal control
over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant
to an exemption for smaller reporting companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt"><span id="acryoa016"></span>Item
9B.Other Information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">None.</span></p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><span id="acryoa017"></span>PART
III</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt"><span id="acryoa018"></span>Item
10. Directors, Executive Officers, and Corporate Governance</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following
table and biographical summaries set forth information, including principal occupation and business experience, about our directors
and executive officers at September 30, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 46%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Position</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Officer
    and/or </b></span><span style="font-size: 10pt"><br>
    <span style="font-family: Times New Roman, Times, Serif"><b>Director Since</b></span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEECC">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">John
    Arnone</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Chairman
    and Chief Executive Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2011</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Anthony
    F. Dudzinski</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Operating Officer and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2011</span></td></tr>
</tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>John Arnone
– Chairman and Chief Executive Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Mr. Arnone has
been the Chairman of American CryoStem since 2008 and Chief Executive Officer since 2011. Mr. Arnone is also Chairman and CEO
of Personal Cell Sciences, Inc., a private Company that markets the U-Autologous line of skin care products. Prior to his involvement
in the life sciences/biotechnology industries, he spent 25 years in the investment banking/financial services industry as an investment
banker and a proactive investor. Over a 25 year period and holding NASD licenses, Mr. Arnone founded, managed and operated two
general securities broker-dealers based in New York specializing in strategic planning, corporate structure, financial planning
and new business development. Over the years, he has provided advisory and business management services as a founder, officer,
director and/or shareholder to both mid-level and development stage private and public companies. Mr. Arnone also co-founded and
operated a global entertainment distribution corporation with 120 employees, and under his guidance the Company was voted medium
wholesaler of the year in the music industry (1997, 1998 and 2000) by the National Association of Recording Merchants. Since 2002
Mr. Arnone is the founder and owner of Maestro Entertainment Corp. a music catalog holding company, Mr. Arnone is a co-founder
and Director of DigiTrax Entertainment Inc. an Artificial Intelligence based Music Company located in Knoxville, Tennessee. Mr.
Arnone holds a degree in Business Administration and a Bachelors of Art in Economics from Kean University in New Jersey.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Anthony F.
Dudzinski − Chief Operating Officer and Director</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Mr. Dudzinski
is a founder of American CryoStem as well as its Chief Operating Officer. He is primarily focused on building and maintaining
the Company’s operational and laboratory infrastructure and their compliance with current regulations. Mr. Dudzinski has
been in the life sciences and biotechnology sector for more than eight years and has more than 25 years of experience in areas
of senior management with a variety of public and private companies. Beginning in the securities industry with a focus on regulatory
compliance and operations, he combined this experience with the biotechnology industry while building new investment vehicles
focused on life sciences and biotechnology companies in 2004. Mr. Dudzinski’s past positions include Chief Executive Officer,
President, Chief Operating Officer and Director of small and medium-sized organizations, including a publicly traded company with
approximately 300 employees. He was also the President and Chief Operating Officer of a privately operated, registered broker-dealer
with more than 175 sales associates. In addition to this experience, he was a founder and Chief Executive Officer of a number
of publicly available exchange traded funds; and the Founder, Chairman and Chief Operating Officer of a target date fund complex
and a registered investment company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Compliance
with Section 16(A) of the Exchange Act</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Section 16(a)
of the Exchange Act requires the Company’s directors, executive officers and persons who beneficially own 10% or more of
a class of securities registered under Section 12 of the Exchange Act to file reports of beneficial ownership and changes in beneficial
ownership with the SEC. Directors, executive officers and greater than 10% stockholders are required by the rules and regulations
of the SEC to furnish the Company with copies of all reports filed by them in compliance with Section 16(a).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Based solely
on our review of certain reports filed with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities
Exchange Act of 1934, as amended, the reports required to be filed with respect to transactions in our common stock during the
fiscal year ended September 30, 2021, were timely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Code of Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">We
have not adopted a Code of Ethics.</span></p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="acryoa019"></span>Item
11. Executive Compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following
table sets forth compensation information for services rendered by certain of our executive officers in all capacities during
the last two completed fiscal years. The following information includes the dollar value of base salaries and certain
other compensation, if any, whether paid or deferred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Summary Compensation
Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Name and Position(s)</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Salary($)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accrued<br>
 Salary($)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bonus</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock<br>
 Awards</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Option<br>
 Awards<sup>1</sup></b></span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total <br>
Compensation</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 10%; font-weight: bold; text-align: left; padding-left: 0.75pt">John S. Arnone</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">2020</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">7,000</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">120,000</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right"><span style="font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right"><span style="font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">90,000</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">217,000</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.75pt">President and CEO</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2021</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">N/A</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">N/A</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">180,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">313,000</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.75pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; font-weight: bold; text-align: left; padding-left: 0.75pt">Anthony F. Dudzinski</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2020</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">N/A</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">N/A</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">80,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">207,000</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left; padding-left: 0.75pt">Chief Operating Officer</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2021</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">N/A</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">N/A</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">180,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">313,000</td><td style="text-align: left">&nbsp;</td></tr>
</tbody></table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><sup>1</sup>This
column represents the aggregate grant-date fair value of the awards computed in accordance with FASB ASC Topic 718. These amounts
represent the accounting value for these awards and do not necessarily correspond to the actual value that may be realized by
the named executive officer. The assumptions used in the calculation of these amounts for the fiscal year ended September 30,
2021 are described in the Notes to our financial statements included in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We do not anticipate
increasing the annual salaries paid to our officers until we have adequate funds to do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Compensation
of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">We do
not compensate any of our directors for their services as directors other than stock for their time. However, we do reimburse
our directors for expenses incurred in attending board meetings and issue stock for their time. During Fiscals 2021 and 2021 no
stock was issued or expenses reimbursed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><span id="acryoa020"></span>Item
12. Security Ownership of Certain Beneficial Owners and Management</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following
table sets forth certain information regarding the beneficial ownership of our Common Stock by: (i) each person who, to our knowledge,
beneficially owns 5% or more of our Common Stock and (ii) each of our directors and officers. Unless otherwise indicated, each
of the stockholders listed below has sole voting and investment power over its shares of Common Stock beneficially owned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tbody><tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Name and Address of Beneficial Owner</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br> Shares</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Percent</b><br> <b>of Class <sup>1</sup></b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Directors and Named Executive Officers <sup>2</sup>:</b></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 54%; text-align: left"><span style="font-size: 10pt">John S. Arnone <sup>3</sup></span></td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">26,030,000</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">40.59</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left"><span style="font-size: 10pt">Anthony Dudzinski <sup>4</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">25,830,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">40.38</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">All directors and named executive officers as a group (2 persons)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Other 5% or Greater Beneficial Owners</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">ACS Global, Inc.</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">20,500,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">33.40</td><td style="text-align: left">%</td></tr>
</tbody></table>













<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><sup>1</sup>Beneficial
ownership is calculated based on 61,374,524 shares of Common Stock issued and outstanding as of September 30, 2021 together with
securities exercisable or convertible into shares of Common Stock within sixty (60) days of the date hereof for each stockholder.
Beneficial ownership is determined in accordance with Rule 13d-3 of the Commission. The number of shares of Common Stock beneficially
owned by a person includes shares of Common Stock issuable upon conversion of securities and subject to options or warrants held
by that person that are currently convertible or exercisable or convertible or exercisable within sixty (60) days of the date
hereof. The shares of Common Stock issuable pursuant to those convertible securities, options or warrants are deemed outstanding
for computing the percentage ownership of the person holding such convertible securities, options or warrants but are not deemed
outstanding for the purposes of computing the percentage ownership of any other person. The above calculations include an adjustment
as required to include all vested options granted to John Arnone and Anthony Dudzinski.</span></p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><sup>2</sup>Unless
otherwise specified, the address for the directors and officers is c/o American CryoStem Corporation at 1 Meridian Road, Eatontown,
NJ 07724.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><sup>3</sup>Mr.
Arnone presently owns 18,250,000 shares of Common Stock of ACS Global and has the right to receive an additional 12,000,000 such
shares upon the conversion of Series C Preferred Stock of ACS Global owned by him. As a result, he beneficially owns 43.74% percent
of the ACS Global Common Stock. Mr. Arnone is also an officer and a director of ACS Global. Consequently, Mr. Arnone is a control
person of ACS Global and may as such be deemed to “beneficially own” the 20,500,000 shares of Common Stock owned by
ACS Global. Mr. Arnone, however, disclaims beneficial ownership of all such shares. Mr. Arnone also holds, 2,780,000 shares of
the Company’s Common Stock and 4,000,000 options (of which 2,250,000 are vested) to purchase the Company’s Common
Stock, 1,000,000 which expire on July 10, 2022, 1,000,000 will expire on September 15, 2025, 1,000,000 will expire on June 30,
2026 and 1,000,000 which expire on September 3, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><sup>4</sup>Mr.
Dudzinski presently owns 6,020,000 shares of ACS Global Common Stock and has the right to receive an additional 12,000,000 such
shares upon the conversion of ACS Global preferred stock owned by him. As a result, he beneficially owns 22.20% percent of the
ACS Global Common Stock. Mr. Dudzinski is also an officer and a director of ACS Global. Consequently, Mr. Dudzinski is a control
person of ACS Global and may as such be deemed to “beneficially own” the 20,500,000 shares of Common Stock owned by
ACS Global. Mr. Dudzinski, however, disclaims beneficial ownership of all such shares. Mr. Dudzinski also holds 2,645,000 shares
of the Company’s Common Stock and 3,000,000 options (of which 2,250,000 are vested) to purchase the Company’s Common
Stock, 1,000,000 which expire on July 10, 2022, 1,000,000 will expire on September 15, 2025, 1,000,000 will expire on June 30,
2026 and 1,000,000 which expire on September 3, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Description
of Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are
authorized to issue 300,000,000 shares of Common Stock, par value $0.001 per share and 50,000,000 shares of preferred stock, par
value $0.0001 per share. As of September 30, 2021, there were 61,374,524 shares of Common Stock and no shares of preferred stock
issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>Outstanding Equity Awards at Fiscal
Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following
table sets forth information with respect to the outstanding equity awards to our named executive officers during fiscal 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Option Awards</td><td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center">&nbsp;</td><td style="white-space: nowrap; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Name</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br>
securities<br>
 underlying<br>
 unexercised <br>
options (#)<br>
Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br>
    securities <br> underlying<br>  unexercised <br>
options (#)<br>
 Unexercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity <br> incentive <br>
    plan awards: <br> Number of<br>  securities<br>  underlying <br> unexercised <br> options (#)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option<br>
 exercise<br>
 price ($)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option<br>
 expiration<br>
 date</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 35%; text-align: left">John S. Arnone</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">1,000,000</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">0</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">1,000,000</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">0.40</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right"><span style="font-size: 10pt">7/10/2022</span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">750,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">250,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">9/15/2025</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">500,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">500,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.25</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">6/30/2026</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">500,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">500,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">9/3/2026</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Anthony Dudzinski</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">0</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.40</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">7/10/2022</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">750,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">250,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">9/15/2025</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">500,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">500,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.25</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">6/30/2026</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">500,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">500,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">9/3/2026</span></td><td style="text-align: left">&nbsp;</td></tr>
</tbody></table>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Option Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On September
18, 2011 our Board of Directors approved the “American CryoStem Corporation Incentive Stock Option Plan” (the “2011
Plan”). Under the Plan, officers, directors, employees and consultants to the Company may be granted options to purchase
shares of the Company’s common stock, par value $0.001 per share. There are 3,000,000 shares of common stock reserved for
issuance under the Plan. The Plan is administered under the authority of the Stock Option Plan Committee (the “Committee”).
The Company issued 2,910,000 of the Options available under the 2011 Plan in Fiscal 2012. To date 2,185,000 options from the 2011
Plan have been exercised, 725,000 have expired, and a total of 0 remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On May 1, 2013
our Board of Directors approved the 2013 American CryoStem Corporation Incentive Stock Option Plan (the “2013 Plan)”.
Under the Plan, officers, directors, employees and consultants to the Company may be granted options to purchase shares of the
Company’s common stock, par value $0.001 per share. There are 5,000,000 shares of common stock reserved for issuance under
the Plan. The Plan is administered under the authority of the Stock Option Plan Committee (the “Committee”). During
2013 the Company granted a total of 3,740,000 at a weighted average price of $0.18 to certain employees, advisory board members
and consultants. To date 2,175,000 Options issued under the plan have been exercised, 1,565,000 have expired, and 0 remain outstanding.</span></p>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On
September 21, 2014 our Board of Directors approved the 2014 American CryoStem Corporation Incentive Stock Option Plan (the
“2014 Plan”). Under the Plan, officers, directors, employees and consultants to the Company may be granted
options to purchase shares of the Company’s common stock, par value $0.001 per share. There are 4,000,000 shares of
common stock reserved for issuance under the Plan. The Plan is administered under the authority of the Stock Option Plan
Committee (the “Committee”). During 2014 the Company granted a total of 3,495,000 at a weighted average price of
$0.21 to certain employees, advisory board members and consultants. To date 350,000 Options issued under the plan have been
exercised, 3,145,000 have expired, and 0 remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On
September 20, 2015 our Board of Directors approved the 2015 American CryoStem Corporation Incentive Stock Option Plan
(the “2015 Plan”). Under the Plan, officers, directors, employees and consultants to the Company may be granted
options to purchase shares of the Company’s common stock, par value $0.001 per share. There are 4,000,000 shares of
common stock reserved for issuance under the Plan. The Plan is administered under the authority of the Stock Option Plan
Committee (the “Committee”). During 2015 the Company granted a total of 3,550,000 at a weighted average price of
$0.21 to certain employees, advisory board members and consultants. To date 2,450,000 Options issued under the plan have
been exercised, 1,025,000 have expired, 75,000 have been forfeited and 0 remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On September
20, 2016 our Board of Directors approved the 2016 American CryoStem Corporation Incentive Stock Option Plan (the “2016 Plan”).
Under the Plan, officers, directors, employees and consultants to the Company may be granted options to purchase shares of the
Company’s common stock, par value $0.001 per share. There are 4,000,000 shares of common stock reserved for issuance under
the Plan. The Plan is administered under the authority of the Stock Option Plan Committee (the “Committee”). During
2016 the Company granted a total of 3,050,000 at a weighted average price of $0.21 to certain employees, advisory board members
and consultants. To date 100,000 Options issued under the plan have been exercised, 2,800,000 have expired, 150,000 have been
forfeited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On July
10, 2017 our Board of Directors approved the 2017 American CryoStem Corporation Incentive Stock Option Plan (the “2017
Plan”). Under the Plan, officers, directors, employees and consultants to the Company may be granted options to
purchase shares of the Company’s common stock, par value $0.001 per share. There are 4,000,000 shares of common stock
reserved for issuance under the Plan. The Plan is administered under the authority of the Stock Option Plan Committee (the
“Committee”). During 2017 the Company granted a total of 2,770,000 at a weighted average price of $0.40 to
certain employees, advisory board members and consultants. To date 20,000 Options issued under the plan have been exercised,
0 have expired, 100,000 have been forfeited and 2,650,000 remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On September
15, 2020 our Board of Directors approved the 2020 American CryoStem Corporation Incentive Stock Option Plan (the “2017 Plan”).
Under the Plan, officers, directors, employees and consultants to the Company may be granted options to purchase shares of the
Company’s common stock, par value $0.001 per share. There are 5,000,000 shares of common stock reserved for issuance under
the Plan. The Plan is administered under the authority of the Stock Option Plan Committee (the “Committee”). During
2020 the Company granted a total of 2,500,000 at a weighted average price of $0.20 to certain employees, advisory board members
and consultants. During 2021, the Company granted a total of 900,000 at a weighted price of $0.22. To date no Options issued under
the plan have been exercised, 0 have expired, 0 have been forfeited and 3,400,000 remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On June 15,
2021 our Board of Directors approved the 2021 American CryoStem Corporation Incentive Stock Option Plan (the “2017 Plan”).
Under the Plan, officers, directors, employees and consultants to the Company may be granted options to purchase shares of the
Company’s common stock, par value $0.001 per share. There are 5,000,000 shares of common stock reserved for issuance under
the Plan. The Plan is administered under the authority of the Stock Option Plan Committee (the “Committee”). During
2021 the Company granted a total of 5,000,000 at a weighted average price of $0.21 to certain employees, advisory board members
and consultants. To date no Options issued under the plan have been exercised, 0 have expired, 0 have been forfeited and 5,000,000
remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our current
Board of Directors serves as the Committee. The Plan further provides for the Committee to set the terms of any Options granted
at the time of the grant and terminates ten years for its effective date and is subject to final shareholder approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On September
18, 2011, our Board of Directors approved the Annual Bonus Performance Plan for Executive Officers. To promote the success of
our Company by providing to participating executives bonus incentives that qualify as performance-based compensation within the
meaning of Section 162(m) of the Internal Revenue Code of 1986 as amended. The plan provides for the granting of up to an aggregate
amount of bonuses awarded to all Participants of up to 10% of our income before taxes. The plan shall be administered by a Committee
currently consisting of our Board of Directors. No bonuses have been granted under this plan during fiscal 2021.</span></p>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><span id="acryoa021"></span>Item
13. Certain Relationships and Related Transactions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On April 20,
2011, we acquired, through our wholly owned subsidiary American CryoStem Acquisition Corporation, substantially all of the assets
from, and assumed substantially all of the liabilities of, ACS Global, Inc. (formerly known as American CryoStem Corporation)
a Nevada corporation (“ACS Global”), in exchange for 21,000,000 shares of our Common Stock. At the time of the acquisition,
John Arnone, our Chairman of the Board, CEO and President was a director and the secretary of ACS Global and Anthony Dudzinski,
one of our directors and our Chief Operating Officer, Treasurer and Secretary was a director, president and secretary of ACS Global.
In addition, Mr. Arnone owns 18,250,000 shares of Common Stock of ACS Global and has the right to receive an additional 12,000,000
such shares upon the conversion of Series C Preferred Stock of ACS Global owned by him and Mr. Dudzinski owns 6,020,000 shares
of ACS Global Common Stock and has the right to receive an additional 12,000,000 such shares upon the conversion of ACS Global
preferred stock owned by him. As a result, assuming the conversion of such preferred stock, Mr. Arnone and Mr. Dudzinski would
have been deemed to be the beneficial owners of approximately 43.74% and 22<i>.</i>20% of the Common Stock of ACS Global, respectively.
Further, Mr. Arnone and Mr. Dudzinski, as control persons of ACS Global may be deemed to beneficially own the 21,000,000 shares
of our Common Stock issued to ACS Global in the acquisition. Each of Mr. Arnone and Mr. Dudzinski disclaim such beneficial ownership.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On
September 15, 2020 the company reached an Agreement with ACS Global, Inc to issue to ACS Global, Inc, 1,000,000 restricted
common shares as payment of $100,000 of the outstanding loan and on October 1, 2020 the Company executed a note with ACS
Global for a principal amount of $99,125.00 representing the outstanding balance (following the September payment) due to ACS
Global. Inc. The Note matures on October 1, 2023 and carries an interest rate of 10% per annum which may be paid in cash or
stock. On March 1, 2021, the note was increased by $49,000. The note may be prepaid at any time by the Company. The principal
balance of the Note is $147,775 at Fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
was indebted to a company that is totally owned by the Company’s Chairman in the amount of $21,875 at September 30, 2021.
The advances were unsecured, carried no interest rate and have subsequently been paid back.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On September
15, 2020, the Company reached an agreement with Mr. Arnone and Mr. Dudzinski to reduce its indebtedness to them of $200,000 each
in exchange for the exercise of certain options held by them resulting in the issuance of 1,000,000 restricted common shares each
to Mr. Arnone and to Mr. Dudzinski.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Mr. Arnone remains
a Director and Secretary of ACS Global and Mr. Dudzinski remains as a Director, President and Treasurer of ACS Global. Mr.
Arnone is also the Chairman and CEO of Personal Cell Sciences, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Director
Independence</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Using the definition
of “independent” using the rules of The NASDAQ Stock Market, we have determined that neither John Arnone nor Anthony
Dudzinski is independent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><span id="acryoa022"></span>Item
14. Principal Accountant Fees and Services</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The
Company’s Board of Directors and management annually reviews its audit needs and the qualifications of its current auditor.
During fiscal 2021 the Company reviewed the services, qualification and retainer agreement of its current Auditor, Fruci
&amp; Associates II, PLLC and approved Fruci &amp; Associates II, PLLC) retention for the Fiscal 2021 audit and for review of
its quarterly filing requirements for Fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Audit Fees</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The aggregate
fees billed by Fruci &amp; Associates II, PLLC, for professional services rendered for the audit of our annual financial statements
for the fiscal year ended September 30, 2021 were $26,500 and $24,000 for the fiscal year ended September 30, 2020. Fruci &amp;
Associates II, PLLC billed the Company a total of $13,000 in Fiscal 2021 for the review of the Company’s quarterly reports,
and $17,500 in Fiscal 2020 for the review of the Company’s quarterly reports.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Audit-Related
Fees</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There were no
other fees billed by Fruci &amp; Associates II, PLLC for professional services rendered, other than as stated under the captions
Audit Fees.</span></p>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Tax Fees</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There were no
other fees billed Fruci &amp; Associates II, PLLC for professional services rendered, other than as stated under the captions
Audit Fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>All Other
Fees</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There were no
other fees billed by Fruci &amp; Associates II, PLLC for professional services rendered, other than as stated under the captions
Audit Fees, Audit-Related Fees, and Tax Fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><span id="acryoa023"></span>PART
IV</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; padding-right: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="acryoa024"></span>Item 15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; padding-right: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Exhibits</span></td></tr>
</tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0; text-align: justify"><span style="font-size: 10pt">(a)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 90%; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1468679/000101905622000053/ex31_1.htm" tabindex="18"><span style="font-size: 10pt">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1468679/000101905622000053/ex31_2.htm" tabindex="18"><span style="font-size: 10pt">Certification of Chief Operating Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1468679/000101905622000053/ex32_1.htm" tabindex="18"><span style="font-size: 10pt">Certification of American CryoStem Corporation’s Chief Executive Officer and Chief Operating Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">XBRL Instance Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">XBRL Taxonomy Extension Schema</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">XBRL Taxonomy Extension Calculation</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">XBRL Taxonomy Extension Definition</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">XBRL Taxonomy Extension Label</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">XBRL Taxonomy Extension Presentation</span></td></tr>
</tbody></table>

<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">52</td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 10pt 0; text-align: justify"><span style="font-size: 10pt">In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 10pt 0; text-align: justify"><span style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0; text-align: justify"><span style="font-size: 10pt"><b></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0; text-align: justify"><span style="font-size: 10pt"><b>AMERICAN
        CRYOSTEM CORPORATION</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0; text-align: justify"><span style="font-size: 10pt"><b></b></span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; padding-right: 0pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-right: 0pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%; padding-right: 0pt"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Dated: January
    13, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    John S. Arnone</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">John
    S. Arnone</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0; text-align: justify"><span style="font-size: 10pt">President, CEO and Chairman of the Board</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0 0; text-align: justify"></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Dated: January
    13, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Anthony F. Dudzinski</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Anthony
    F. Dudzinski</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">COO, Treasurer, Secretary and Director</span></td></tr>
</tbody></table>



<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><span id="acryoa025"></span>PART
F/S</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 10pt; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><span id="acryoa026"></span>INDEX
TO FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 10pt; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><span id="acryoa027"></span>AUDITED
FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Page
    (s)</span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#acryob001" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">F-2</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#acryob002" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Consolidated Balance Sheets</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">F-4</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#acryob003" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Consolidated Statements of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">F-5</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#acryob005" tabindex="18"><span style="font-size: 10pt">Consolidated Statements of Cash Flows</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">F-6</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#acryob006" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">Consolidated Statements of Stockholders’ Deficit</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">F-7</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#acryob007" tabindex="18"><span style="font: 10pt Times New Roman, Times, Serif">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">F-8
    to F-20</span></td></tr>
</tbody></table>


<!-- Field: Page; Sequence: 56; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="acryob001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">&nbsp;</p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: right; text-indent: 0"><img alt="(LOGO)" data-src="https://www.sec.gov/Archives/edgar/data/1468679/000101905622000053/acryo002.jpg" src="https://www.sec.gov/Archives/edgar/data/1468679/000101905622000053/acryo002.jpg">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0"><span style="font-size: 10pt">To
the Board of Directors and Shareholders of American CryoStem Corporation <b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0"><span style="font-size: 10pt"><b>Opinion on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt">We
have audited the accompanying consolidated balance sheets of American CryoStem Corporation (“the Company”) as of September
30, 2021 and 2020, and the related consolidated statements of operations, changes in shareholders’ deficit, and cash flows for
each of the years in the two-year period ended September 30, 2021, and the related notes (collectively referred to as the financial
statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the
Company as of September 30, 2021 and 2020 and the results of its operations and its cash flows for each of the years in the two-year
period ended September 30, 2021, in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><b>Going
Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 2 to the financial statements, the Company has incurred significant losses since inception. This factor raises substantial
doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described
in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt">These
financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but
not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.
Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><b>Critical
Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt">The
critical audit matters communicated below are matters arising from the current period audit of the financial statements that were
communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material
to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of
critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by
communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or
disclosures to which they relate.</span></p>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><b><i>Collectability
of Revenue and Related Receivable</i></b> — <b><i>Refer
to Notes 3, 13, and 14 to the financial statements</i></b></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><i>Critical
Audit Matter Description</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt">The
Company has one large customer which composes substantially all the revenue and accounts receivable balances as of September 30,
2021 and for the year then ended. There has been a significant period since the last collection on the account and there are other
uncertainties related to the external environment, such as continued and new closures in China related to COVID-19. The potential
of collection requires a high degree of judgment, and the evaluation of collectability is subjective; therefore, we assessed valuation
and collectability of the related receivable and revenue a critical audit matter.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><i>How
the Critical Audit Matter Was Addressed in the Audit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt">Our
audit procedures related to evaluating the Company’s valuation of large accounts receivable and revenue included the following,
among others:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; width: 100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><span style="font: 10pt Symbol">·</span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Confirmation
of the outstanding receivable balance.</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; width: 100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><span style="font: 10pt Symbol">·</span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Discussions
with the customer, including observation of their facilities and review of financial information.</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; width: 100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><span style="font: 10pt Symbol">·</span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Obtaining
an understanding of management’s process for their analysis and our testing of underlying information to determine if future
collections appear to be more likely than not to occur.</span></td>
</tr></tbody></table>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><b><i>Accounting
for Investments</i></b> — <b><i>Refer
to Notes 1 and 13 to the financial statements</i></b></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><i>Critical
Audit Matter Description</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt">The
Company holds one investment that is accounted for as an equity investment without a readily determinable fair value. Adjustments
to the cost of the investment is based on significant judgment regarding appropriate valuation and is highly subjective; therefore,
we assessed this as a critical audit matter.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><i>How
the Critical Audit Matter Was Addressed in the Audit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt">Our
audit procedures related to evaluating the Company’s accounting for notes payable and related accounts included the following,
among others:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; width: 100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">·</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Discussions
with the investee, including observation of their facilities.</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; width: 100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify"></td><td style="width: 0.25in; text-align: justify"><span style="font: 10pt Symbol">·</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Obtaining
an understanding of management’s process for their analysis of underlying information to determine the appropriate valuation.
Performing a calculation of our expected valuation and compared to management results.</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; width: 100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify"></td><td style="width: 0.25in; text-align: justify"><span style="font: 10pt Symbol">·</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Independent
assessment of financial information of the investee.</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; width: 100%"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify"></td><td style="width: 0.25in; text-align: justify"><span style="font: 10pt Symbol">·</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Testing
of all transactions related to this matter.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0"><img alt="-s-" data-src="https://www.sec.gov/Archives/edgar/data/1468679/000101905622000053/acryo003.jpg" src="https://www.sec.gov/Archives/edgar/data/1468679/000101905622000053/acryo003.jpg"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0"><span style="font-size: 10pt">We
have served as the Company’s auditor since 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0"><span style="font-size: 10pt">Spokane,
Washington <br>
January 13, 2022</span></p>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>American CryoStem
Corporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><span id="acryob002"></span><b>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>As of September
30, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_111_zx0x0s9vmo49" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" id="xdx_49B_20210930_z8dRkdHDf3ai" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt">&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" id="xdx_495_20200930_zvUfFAiep6He" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&nbsp;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--AssetsAbstract_iB_zQCUMiq3Tlnk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">ASSETS</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">30-Sep-21</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">30-Sep-20</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_404_eus-gaap--AssetsCurrentAbstract_i01B_zil9fLraFcbf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">Current Assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzjud_zJAFLYewBfsj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; padding-left: 17.3pt; text-indent: -8.65pt">Cash</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,244</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,760</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_408_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzjud_ztM7o8UQnqb3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Accounts
Receivable - net of allowance for bad debt</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AccountsReceivableNetCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-35" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78,782</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AccountsReceivableNetCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40B_eus-gaap--InventoryNet_i02I_maCzjud_zUNeqQhr9Mv5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt; text-indent: -8.65pt">Inventory</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:InventoryNet" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,934</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:InventoryNet" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,401</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40C_ecustom--DeferredContractExpense_i02I_maCzjud_zZng105wOtol" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Deferred
Contract Expense</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="cryo:DeferredContractExpense" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">39,370</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0054"><span><ix:nonfraction name="cryo:DeferredContractExpense" contextref="AsOf2020-09-30" id="fact-identifier-40" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0054" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40C_eus-gaap--PrepaidExpenseCurrent_i02I_maCzjud_zP9aQTB6mJj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Prepaid
Expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PrepaidExpenseCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,619</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PrepaidExpenseCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40D_eus-gaap--AssetsCurrent_i02TI_mtCzjud_maCzxym_zIi3g8bVltAa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 34.6pt; text-indent: -8.65pt">Total Current
Assets</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AssetsCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-43" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">196,949</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AssetsCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">567,161</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40A_eus-gaap--OtherAssetsAbstract_i01B_zwkW0BYjn9Ka" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">Other Assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_401_ecustom--InvestmentInJointVentureBaoxin_i02I_maCzxym_z0di88L7NO64" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Investment
in Baoxin</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="cryo:InvestmentInJointVentureBaoxin" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">244,919</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="cryo:InvestmentInJointVentureBaoxin" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">300,000</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40A_eus-gaap--SecurityDeposit_i02I_maCzxym_zOsBpwH2CJRj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Security
Deposit</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:SecurityDeposit" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,540</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:SecurityDeposit" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,540</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40E_eus-gaap--FiniteLivedPatentsGross_i02I_maCzxym_zwPRDNAarp6l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Patents
and Patents Development - net of accumulated amortization</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:FiniteLivedPatentsGross" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-49" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">371,849</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:FiniteLivedPatentsGross" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">365,676</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40B_eus-gaap--AssetsNet_i02I_maCzxym_zQbIlgxvTRf8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Fixed Assets
- net of accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AssetsNet" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">113,483</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AssetsNet" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-52" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">126,591</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40B_eus-gaap--FinanceLeaseRightOfUseAsset_i02I_maCzxym_zbfYRqNk6eD3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Finance
Lease - Right-of-Use-Asset</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">115,516</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85,817</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40F_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzxym_zjMjmwT1xMRi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Operating
Lease Right-of-Use-Asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0080"><span><ix:nonfraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextref="AsOf2021-09-30" id="fact-identifier-55" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0080" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,064</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_401_eus-gaap--Assets_i02TI_mtCzxym_zdasGWUYaPLi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt"><span style="font-size: 10pt">Total Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-57" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,056,256</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,476,849</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z8XNheExrRPe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">LIABILITIES AND
    SHAREHOLDERS’ DEFICIT</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_zgbtO60qoJH3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">Current Liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_407_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maCzPuM_znAzWRxnMpQ9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Accounts
Payable &amp; Accrued Expenses</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-59" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">553,120</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">181,924</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_401_eus-gaap--LitigationReserveCurrent_i02I_maCzPuM_zodgud3v1r3a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Legal &amp;
Accounting Payable</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LitigationReserveCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">97,824</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LitigationReserveCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,568</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_407_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzPuM_zbUUV5vew3S" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Bridge
Notes Payable</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:OtherLiabilitiesCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-63" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">226,500</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:OtherLiabilitiesCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">226,500</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_401_eus-gaap--ConvertibleNotesPayableCurrent_i02I_maCzPuM_zRUyVFEImwF8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Convertible
Notes Payable</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayableCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-65" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">573,500</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayableCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">558,552</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_406_eus-gaap--LoansPayableCurrent_i02I_maCzPuM_zf2lEkJyNjie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">PPP Loan
- Current Portion</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LoansPayableCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,407</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LoansPayableCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,304</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_406_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_maCzPuM_ziBJc1Ymuiy4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Finance
Lease Liability</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-69" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,512</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,722</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzPuM_zxbTvyumijn3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Operating
Lease Liability</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0110"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextref="AsOf2021-09-30" id="fact-identifier-71" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0110" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-72" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,064</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40A_eus-gaap--DeferredRevenue_i02I_maCzPuM_z4HL7SgRlP9j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Deferred
Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DeferredRevenue" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">122,045</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0114"><span><ix:nonfraction name="us-gaap:DeferredRevenue" contextref="AsOf2020-09-30" id="fact-identifier-74" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_405_eus-gaap--LiabilitiesCurrent_i02TI_mtCzPuM_maCzWyA_z1bXbgfnCNgd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt"><span style="font-size: 10pt">Total Current Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LiabilitiesCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,630,908</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LiabilitiesCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-76" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,049,634</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40E_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zNXaELy7DDp4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">Long Term Liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_407_eus-gaap--LongTermLoansPayable_i02I_maCzWyA_zbJp4PESLzVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">PPP Loan</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0122"><span><ix:nonfraction name="us-gaap:LongTermLoansPayable" contextref="AsOf2021-09-30" id="fact-identifier-77" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0122" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LongTermLoansPayable" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-78" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,103</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_402_eus-gaap--AccruedSalariesCurrentAndNoncurrent_i02I_maCzWyA_z6Ft6SyWCyW7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Accrued
Executive Salaries</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AccruedSalariesCurrentAndNoncurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-79" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">980,186</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AccruedSalariesCurrentAndNoncurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-80" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">740,186</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_401_eus-gaap--ConvertibleLongTermNotesPayable_i02I_maCzWyA_zqeqnIH3kQ2j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Convertible
Notes Payable</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ConvertibleLongTermNotesPayable" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">132,631</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0129"><span><ix:nonfraction name="us-gaap:ConvertibleLongTermNotesPayable" contextref="AsOf2020-09-30" id="fact-identifier-82" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0129" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_i02I_maCzWyA_zijiVuRczByk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Finance
Lease Liability</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-83" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,651</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0132"><span><ix:nonfraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextref="AsOf2020-09-30" id="fact-identifier-84" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0132" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40B_eus-gaap--NotesPayableRelatedPartiesNoncurrent_i02I_maCzWyA_z1LDFvHiBZch" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Note Payable
to Related Party</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">147,775</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-86" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">99,125</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40A_eus-gaap--DueToRelatedPartiesNoncurrent_i02I_maCzWyA_zyKuQdo3C5O5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Payable
to Related Party</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DueToRelatedPartiesNoncurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-87" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">658</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0138"><span><ix:nonfraction name="us-gaap:DueToRelatedPartiesNoncurrent" contextref="AsOf2020-09-30" id="fact-identifier-88" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0138" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_402_eus-gaap--Liabilities_i02TI_mtCzWyA_maCzl9l_zJsNYN8P8n2d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt"><span style="font-size: 10pt">Total Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:Liabilities" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,903,809</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:Liabilities" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,898,048</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_408_eus-gaap--CommitmentsAndContingencies_i02I_ztEPbHzSwqI" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">Commitments and Contingencies</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CommitmentsAndContingencies" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CommitmentsAndContingencies" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-92" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_400_eus-gaap--StockholdersEquityAbstract_i01B_zHs916PHzTxa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">Shareholders’ Deficit:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40A_eus-gaap--PreferredStockValue_i02I_z2WkbPuZS5T7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt"><span style="font-size: 10pt">Preferred Stock - $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210930_zVGzd8kGiiEh" title="Preferred Stock, Par Value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20200930_zNpW0Qmgb2N1" title="Preferred Stock, Par Value"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-09-30" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2020-09-30" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">.0001</ix:nonfraction></span></ix:nonfraction></span></span></span> par value, <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_c20210930_zD5qYBRBZ09d"><span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20200930_z5hPAal4khNc"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-95" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span> shares authorized, <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20210930_zN9rYTMTp0Tg"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20200930_zxIx7ZLp8C0e"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20200930_zHSD2bdiZgR7"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_c20210930_zotZCKQoHy3g"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-98" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-99" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-100" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></span></span></span></span> shares issued and outstanding at September 30, 2021 and 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-101" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_400_eus-gaap--CommonStockValue_i02I_maCzfqc_z4yWndCMX7Qi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt"><span style="font-size: 10pt">Common Stock - $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210930_zZvFhxggNNY5" title="Common Stock, Par Value"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20200930_zTwnQ5JfBZK" title="Common Stock, Par Value"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-09-30" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-103" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2020-09-30" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-104" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">.001</ix:nonfraction></span></ix:nonfraction></span></span></span> par value, <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20210930_zM768Ag8zve8"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20200930_zY76ySBoNKJ4"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-105" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-106" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">300,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span> shares
    authorized, <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20210930_zNyt0mr8tsS6"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20210930_zqgMqKjGYAW5"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-107" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-108" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61,374,524</ix:nonfraction></span></ix:nonfraction></span></span></span> shares issued and outstanding at September 30, 2021 and <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20200930_z3d0Nlclilv7"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20200930_zZpEljSOEHd8"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-109" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-110" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,570,666</ix:nonfraction></span></ix:nonfraction></span></span></span> issued
    and outstanding at September 30, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-111" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61,376</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,572</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40D_eus-gaap--AdditionalPaidInCapital_i02I_maCzfqc_z3fmJI91BlCd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Additional
Paid in Capital</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapital" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-113" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,368,836</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapital" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,917,408</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_403_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzfqc_z5jAUte0r1z1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Accumulated
Deficit</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-115" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,277,765</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,398,179</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_402_eus-gaap--StockholdersEquity_i02TI_mtCzfqc_maCzl9l_zRCJ0RX7TZkf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt"><span style="font-size: 10pt">Total Shareholders’ Deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-117" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,847,553</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-118" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">421,199</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtCzl9l_zQVjgYeZ2Vqj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt"><span style="font-size: 10pt">Total Liabilities &amp;
    Shareholders’ Deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-119" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,056,256</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-120" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,476,849</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
</tbody></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">See the
notes to the financial statements.</span></p>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->





<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">American
CryoStem Corporation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="acryob003"></span><span style="font-size: 10pt"><b>Consolidated
Statements of Operations</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">For the
Years Ended September 30, 2021 and 2020</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_113_zvjVHjnPrD9a" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" id="xdx_49C_20201001__20210930_zjQsBs6X2Mea" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">30-Sep-21</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" id="xdx_499_20191001__20200930_z7mXpnyMfCGf" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">30-Sep-20</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--RevenuesAbstract_iB_z3u3tIxZZQc2" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 0.75pt">Revenues</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--HealthCareOtherMember_maCzvdu_zyBFjOfMIaed" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; padding-left: 8.65pt"><span id="xdx_91A_eus-gaap--HealthCareOtherMember_zWxAEy97ub8a">Tissue Processing &amp; Storage</span></td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2020-10-012021-09-30_us-gaap_HealthCareOtherMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-121" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,830</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2019-10-012020-09-30_us-gaap_HealthCareOtherMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-122" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,900</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr id="xdx_406_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_maCzvdu_zE07omTRbdM9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt"><span id="xdx_91B_eus-gaap--ProductMember_z62Wgskyx2vl">Product Sales</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2020-10-012021-09-30_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-123" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">760</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2019-10-012020-09-30_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,670</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_402_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_maCzvdu_zpYbcv3WjFMb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"><span id="xdx_91A_eus-gaap--RoyaltyMember_zmhJWKwQnd5g">Licensing Fees &amp; Royalties</span></td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0198"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2020-10-012021-09-30_us-gaap_RoyaltyMember" id="fact-identifier-125" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0198" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2019-10-012020-09-30_us-gaap_RoyaltyMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-126" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">523,333</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--Revenues_maCzvdu_zzTqoh8vuXXh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Total Revenues</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-127" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,590</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-128" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">557,903</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--CostOfRevenue_iN_di_msCzvdu_zlwL1EFQvb8k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">Less Cost of Revenues</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:CostOfRevenue" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-129" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,573</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:CostOfRevenue" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-130" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">43,837</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.75pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40F_eus-gaap--GrossProfit_iT_mtCzvdu_maCzFqd_zTaoSbtvlZff" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Gross Margin</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:GrossProfit" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-131" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,017</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:GrossProfit" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-132" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">514,066</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.75pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB_zHpGebPhYUji" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.75pt">Operating Expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzBnf_zIhxSMSs3US" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Research &amp; Development</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-133" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">374,284</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-134" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,176</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_ecustom--LaboratoryExpense_i01_maCzBnf_z5dxCy3HgvMb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Laboratory Expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:LaboratoryExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">72,928</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:LaboratoryExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-136" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">74,093</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--SellingAndMarketingExpense_i01_maCzBnf_zbV3xTEYjae8" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Sales &amp; Marketing</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:SellingAndMarketingExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-137" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,059</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:SellingAndMarketingExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-138" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,395</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_401_eus-gaap--ProfessionalFees_i01_maCzBnf_z3DtvtSppwai" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Professional Fees</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProfessionalFees" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-139" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">191,219</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProfessionalFees" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-140" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">111,169</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40E_ecustom--ConsultantsStockForServices_i01_maCzBnf_zBIVzx42aMPe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Consultants - Stock for Services &amp; Option Grants</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:ConsultantsStockForServices" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-141" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,067,734</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:ConsultantsStockForServices" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-142" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">417,542</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_eus-gaap--ProvisionForDoubtfulAccounts_i01_maCzBnf_ztMwsfDHQCO7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Bad Debt Expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProvisionForDoubtfulAccounts" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-143" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">542,370</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProvisionForDoubtfulAccounts" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-144" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">326,650</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzBnf_zp7TlmmIif3e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">General &amp; Administrative</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-145" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,221</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-146" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">439,577</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--OperatingExpenses_i01T_mtCzBnf_msCzFqd_zJgolXc2wWAg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Total Operating Expenses</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-147" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,754,815</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-148" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,414,602</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.75pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingIncomeLoss_i01T_mtCzFqd_maCzpW0_z5ndqiDAi7Q9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.75pt">Net Loss from Operations</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-149" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,747,798</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-150" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">900,536</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.75pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_zCBb6BglTPE8" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 0.75pt">Other Income (Expenses):</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_402_eus-gaap--InterestIncomeDomesticDeposits_i01_maCzpW0_zn4E3Mg2YbQ6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Interest Income</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestIncomeDomesticDeposits" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-151" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestIncomeDomesticDeposits" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-152" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt"><span style="font-size: 10pt">Loss on Investment</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><p style="margin: 0"><span style="font-size: 10pt">(55,081</span></p>


</td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">—</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_402_ecustom--GrantIncome_i01_maCzpW0_ziHsw1U4JbW1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">EIDL Grant</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0247"><span><ix:nonfraction name="cryo:GrantIncome" contextref="From2020-10-01to2021-09-30" id="fact-identifier-153" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0247" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:GrantIncome" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-154" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_eus-gaap--RentalIncomeNonoperating_i01_maCzpW0_zICdiwU6pekf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Laboratory Rent</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:RentalIncomeNonoperating" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-155" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0251"><span><ix:nonfraction name="us-gaap:RentalIncomeNonoperating" contextref="From2019-10-012020-09-30" id="fact-identifier-156" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0251" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_ecustom--GainsLossesOnWriteOffOfLiability_i01_maCzpW0_zOGdL2hNZ805" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Gain on write off of Liability</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:GainsLossesOnWriteOffOfLiability" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-157" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">24,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:GainsLossesOnWriteOffOfLiability" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-158" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">127,667</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--UnrealizedGainLossOnDerivatives_i01_maCzpW0_z13P8KVhVlt3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Gain on Value of Derivative</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0256"><span><ix:nonfraction name="us-gaap:UnrealizedGainLossOnDerivatives" contextref="From2020-10-01to2021-09-30" id="fact-identifier-159" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0256" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:UnrealizedGainLossOnDerivatives" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-160" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,968</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_402_eus-gaap--GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_i01_maCzpW0_zaPeFjaYJZGk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Loss on Debt Settlement</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0259"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" contextref="From2020-10-01to2021-09-30" id="fact-identifier-161" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0259" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-162" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,504</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--TaxesOther_i01N_di_msCzpW0_z7alnPSgFyUi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Foreign Taxes</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262"><span><ix:nonfraction name="us-gaap:TaxesOther" contextref="From2020-10-01to2021-09-30" id="fact-identifier-163" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0262" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:TaxesOther" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-164" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,191</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOtherLoans_i01_maCzpW0_zsmqx9eLGybb" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Loss on Loan Issuance</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0265"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInOtherLoans" contextref="From2020-10-01to2021-09-30" id="fact-identifier-165" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0265" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInOtherLoans" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-166" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">92,951</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--AmortizationOfDebtDiscountPremium_i01N_di_msCzpW0_zjLkc9Rcw3dk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Amortization of Debt Discount</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2020-10-01to2021-09-30" id="fact-identifier-167" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0268" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-168" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">168,000</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--EffectOfExchangeRateOnCashAndCashEquivalents_i01N_di_msCzpW0_zz2cPBcVPC1j" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Exchange Rate</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-169" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">123</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-170" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">476</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--InterestExpense_i01N_di_msCzpW0_zQLTxexHWOv9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Interest Expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:InterestExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-171" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">80,925</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:InterestExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-172" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78,454</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_407_eus-gaap--InterestExpenseOther_i01N_di_msCzpW0_zeFqvktKki63" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Interest Expense (beneficial conversion feature-debenture)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:InterestExpenseOther" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-173" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,912</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:InterestExpenseOther" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-174" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57,764</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_405_ecustom--Penalties_i01N_di_msCzpW0_z1OirhPJvFLl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 8.65pt">Penalties</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280"><span><ix:nonfraction name="cryo:Penalties" contextref="From2020-10-01to2021-09-30" id="fact-identifier-175" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="cryo:Penalties" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-176" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.75pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--NetIncomeLoss_i01T_mtCzpW0_z3jgQBaBrZri" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.75pt">Net Loss</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-177" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,879,586</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-178" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,179,285</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.75pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--EarningsPerShareBasicAndDiluted_i01_zNxzMeoTyzLh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.75pt">Basic &amp; Fully Diluted Net Income (Loss) per Common Share:</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-179" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.05</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-180" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.02</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.75pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i01_zp1ljF8BhAnd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 0.75pt">Weighted Average of Common Shares Outstanding - Basic &amp; fully diluted</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-181" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60,341,578</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-182" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,659,523</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
</tbody></table>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font-size: 10pt"></span><span style="font-size: 10pt">See the
notes to the financial statements.</span></p>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">American
CryoStem Corporation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><span id="acryob005"></span><b>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>For the Years
Ended September 30, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_112_zwCJZe54BMn2" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" id="xdx_490_20201001__20210930_zCtHMMpVeep8" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">30-Sep-21</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" id="xdx_492_20191001__20200930_zowzMUJbjNui" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">30-Sep-20</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
<tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_zNyt0mr8tsS6" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 0.75pt">Operating Activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_zM768Ag8zve8" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; padding-left: 17.3pt">Net loss</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-183" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,879,586</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-184" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,179,285</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zZvFhxggNNY5" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Adjustments to reconcile net loss items not requiring the use of cash:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_ecustom--GainLossOnWriteOffOfLiability_i02N_di_zotZCKQoHy3g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Gain on Write Off of Liability</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="cryo:GainLossOnWriteOffOfLiability" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-185" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">24,000</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302"><span><ix:nonfraction name="cryo:GainLossOnWriteOffOfLiability" contextref="From2019-10-012020-09-30" id="fact-identifier-186" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0302" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_409_eus-gaap--IncreaseDecreaseInDerivativeAssets_i02N_di_zN9rYTMTp0Tg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Derivative change in fair value</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInDerivativeAssets" contextref="From2020-10-01to2021-09-30" id="fact-identifier-187" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0304" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInDerivativeAssets" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-188" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,968</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--IncreaseDecreaseInOtherLoans_i02N_di_zD5qYBRBZ09d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Loss on Loan Issuance</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInOtherLoans" contextref="From2020-10-01to2021-09-30" id="fact-identifier-189" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0307" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInOtherLoans" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-190" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">92,951</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_eus-gaap--AmortizationOfDebtDiscountPremium_i02_zVGzd8kGiiEh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Amortization of Debt Discount</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2020-10-01to2021-09-30" id="fact-identifier-191" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0310" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-192" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">168,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_409_eus-gaap--ProvisionForDoubtfulAccounts_i02_zq8UQnaVFuSh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Bad Debt Expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProvisionForDoubtfulAccounts" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-193" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">542,370</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProvisionForDoubtfulAccounts" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-194" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">326,650</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--InterestExpenseDebt_i02_zHkEQayahblj" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Interest paid in Common Stock</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestExpenseDebt" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-195" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">48,546</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestExpenseDebt" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-196" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57,849</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40E_ecustom--BillPaidWithCommonStock_i02_zRPnBamkvE" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Bills Paid with Common Stock</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319"><span><ix:nonfraction name="cryo:BillPaidWithCommonStock" contextref="From2020-10-01to2021-09-30" id="fact-identifier-197" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:BillPaidWithCommonStock" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-198" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">60,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_ecustom--ContractSettlementWithCommonStock_i02_zyi2xEOgHnK3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Contract Settlement with Common Stock</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322"><span><ix:nonfraction name="cryo:ContractSettlementWithCommonStock" contextref="From2020-10-01to2021-09-30" id="fact-identifier-199" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0322" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:ContractSettlementWithCommonStock" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-200" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">46,500</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_i02_zXsoQHARzhJ1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Stock Compensation Expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-201" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">902,853</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-202" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">417,542</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_zbNhqMvIKaja" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Common Stock for Services</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-203" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">258,500</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329"><span><ix:nonfraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextref="From2019-10-012020-09-30" id="fact-identifier-204" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0329" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--DepreciationDepletionAndAmortization_i02_z0DrLxtbcOR9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Depreciation &amp; Amortization Expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DepreciationDepletionAndAmortization" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-205" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">68,581</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DepreciationDepletionAndAmortization" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-206" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,215</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--InterestExpenseOther_i02_zjONprb4zv1b" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Interest Expense - Beneficial Conversion Feature</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestExpenseOther" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-207" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,912</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestExpenseOther" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-208" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57,764</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_409_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02_zd5RiSBkV0Qk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Gain on Settlement of Debt</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2020-10-01to2021-09-30" id="fact-identifier-209" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0337" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-210" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">174,167</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.75pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_i01B_zDN4DGSkO1Lb" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 0.75pt">Changes in operating assets and liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_zMvcxDJ9TAhe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Accounts Receivable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-211" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">121,152</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-212" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">496,496</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40F_ecustom--IncreaseDecreseInDeferredContract_i02_zvSbD6Cz0ZAb" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Deferred Contract</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="cryo:IncreaseDecreseInDeferredContract" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-213" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">39,370</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347"><span><ix:nonfraction name="cryo:IncreaseDecreseInDeferredContract" contextref="From2019-10-012020-09-30" id="fact-identifier-214" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0347" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_zwHLD6TLUzbi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Prepaid expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-215" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,381</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-216" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 17.3pt">Investment Loss</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><p style="margin: 0">55,081</p>


</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInInventories_i02N_di_zOQ1HTQ1UlB2" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 17.3pt">Inventory</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInInventories" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-217" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,467</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInInventories" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-218" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,454</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_zOYC62Ow96N2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Accounts Payable and Accrued Expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-219" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">469,452</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-220" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">263,676</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--IncreaseDecreaseInEmployeeRelatedLiabilities_i02_zJbT6a1pY3s3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Accrued Executive Compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-221" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">240,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-222" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">160,000</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInDeferredRevenue_i02_zcyzOk6tmGik" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">Deferred Revenue</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-223" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">122,045</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-224" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,333</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02_maCzqgM_zhyrR6PD73xd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 0.75pt">Net cash used by operations</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-225" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">303,920</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-226" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">514,648</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.75pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zHVTPWC5BY5b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Investing activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_ecustom--FinanceLeaseAsset_i01N_di_zz1xp87WYeee" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Finance Lease Asset</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="cryo:FinanceLeaseAsset" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-227" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">48,620</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371"><span><ix:nonfraction name="cryo:FinanceLeaseAsset" contextref="From2019-10-012020-09-30" id="fact-identifier-228" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0371" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_zjhH0YnQkPK9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 17.3pt">Purchase of equipment</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373"><span><ix:nonfraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextref="From2020-10-01to2021-09-30" id="fact-identifier-229" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0373" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-230" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,882</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40B_eus-gaap--IncreaseDecreaseInIntangibleAssetsCurrent_i01N_di_zSsLCrTuqTMh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">Patents development</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-231" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42,725</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-232" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,849</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_maCzqgM_zMfAY2nwC11e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.75pt">Net cash used by investing activities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-233" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">91,345</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-234" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,731</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.75pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zaT3l7riXVFc" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 0pt">Financing activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzBhF_zipjRIH36d6b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 17.3pt">Issuance of Common Shares</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-235" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">143,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-236" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">401,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--ProceedsFromConvertibleDebt_i01_maCzBhF_zCprDFH8cesd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Issuance of Convertible Notes</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-237" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-238" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">168,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--ProceedsFromOtherDebt_i01_maCzBhF_zf4wmV0FFXm2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">PPP Loan</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391"><span><ix:nonfraction name="us-gaap:ProceedsFromOtherDebt" contextref="From2020-10-01to2021-09-30" id="fact-identifier-239" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0391" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromOtherDebt" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-240" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,407</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--RepaymentsOfLongTermCapitalLeaseObligations_i01N_di_msCzBhF_zA46wIjCEVP5" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Finance Lease</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-241" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,441</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-242" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,673</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_i01_maCzBhF_zIx7tjlV1X2i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">Payable to related party</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-243" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">49,308</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-244" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,395</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzBhF_maCzqgM_zRpwSZPC2E8d" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.75pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-245" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">361,749</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-246" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">545,339</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.75pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsPeriodIncreaseDecrease_i01T_mtCzqgM_zONcWZKkKCah" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.75pt">Net change in cash</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-247" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,516</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-248" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,960</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.75pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zchgfNGQnppc" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.75pt">Cash balance at beginning of the period</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-249" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,760</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-250" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,800</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.75pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zXztrDV4sxt4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.75pt">Cash balance at end of the period</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-251" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,244</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-252" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,760</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.75pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zR4cUsh01fXc" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 0.75pt">Supplemental disclosures of cash flow information:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_406_eus-gaap--InterestPaidNet_i01_zMxkNUa56HU8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Interest paid during the period</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestPaidNet" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-253" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,972</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestPaidNet" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-254" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,562</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--IncomeTaxesPaidNet_i01_zV7VEIHjryG9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Income taxes paid during the period</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418"><span><ix:nonfraction name="us-gaap:IncomeTaxesPaidNet" contextref="From2020-10-01to2021-09-30" id="fact-identifier-255" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0418" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419"><span><ix:nonfraction name="us-gaap:IncomeTaxesPaidNet" contextref="From2019-10-012020-09-30" id="fact-identifier-256" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0419" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
</tbody></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"></span><span style="font-size: 10pt">See the
notes to the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>See Note 17 – Noncash Transactions</b></p>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">American
CryoStem Corporation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><span id="acryob006"></span>Consolidated
Statement of Changes in Shareholders’ Deficit</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>For the
Years Ended September 30, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_zD8IaKdyzNMk" summary="xdx: Statement - Consolidated Statement of Changes in Shareholders' Deficit" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common<br>
 Shares</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z1zDHS0dqthe" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Par Value</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zQzMriIBDPA" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Paid in<br>
 Capital</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zvFdgCGLpPsj" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated<br>
 Deficit</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" id="xdx_4BD_zZ37gRyp8HM8" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total<br>
 Deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td></tr>
<tr id="xdx_43C_c20191001__20200930_eus-gaap--StockholdersEquity_iS_zqgebkgC68w4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; width: 50%; padding-left: 8.65pt; text-indent: -8.65pt">Balance at September 30, 2019</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zctnrZJ9jtd7" title="Beginning Balance, Shares" style="width: 6%; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-257" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">49,387,918</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-258" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">49,389</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-259" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,931,500</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-260" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,218,894</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-261" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,238,005</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_43E_c20191001__20200930_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z4ic80uj83Og" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">Issuance of common shares</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrCooH1BVIac" title="Issuance of common shares, Shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-262" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,475,000</ix:nonfraction></span></td><td style="text-align: left"></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-263" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,475</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-264" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">398,525</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0430"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-265" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0430" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-266" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">401,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_43E_c20191001__20200930_ecustom--StockIssuedDuringPeriodValueConversionOfNotesPayable_zmP5cMjMjvY8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Conversion of Note Payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodValueConversionOfNotesPayableInShares_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHodICYRRXW7" title="Conversion of Note Payable, Shares" style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueConversionOfNotesPayableInShares" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-267" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,965,659</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueConversionOfNotesPayable" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-268" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,966</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueConversionOfNotesPayable" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-269" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">430,234</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0437"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueConversionOfNotesPayable" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-270" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0437" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueConversionOfNotesPayable" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-271" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">433,200</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_433_c20191001__20200930_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_znloWL2M9Ho6" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Options Exercised</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdSA7wmf6Pfb" title="Options Exercised, Shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-272" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,400,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-273" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,400</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">477,600</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0444"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-275" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0444" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-276" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">480,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_43A_c20191001__20200930_ecustom--BillPaidWithCommonStock_zH29f1LRf6a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Shares issued to pay bills</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_983_ecustom--SharesIssuedToPayBillsShares_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7GPHhCwtSbj" title="Shares issued to pay bills, Shares" style="text-align: right"><span><ix:nonfraction name="cryo:SharesIssuedToPayBillsShares" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-277" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">300,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:BillPaidWithCommonStock" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-278" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">300</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:BillPaidWithCommonStock" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-279" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">59,700</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451"><span><ix:nonfraction name="cryo:BillPaidWithCommonStock" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-280" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0451" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:BillPaidWithCommonStock" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-281" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">60,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_435_c20191001__20200930_eus-gaap--DebtConversionConvertedInstrumentAmount1_zgZ8PrfvL1A5" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Shares issued to related party to reduce debt</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zt5yrmjW8cZ2" title="Shares issued to related party to reduce debt, Shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-282" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,000,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-283" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-284" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">99,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458"><span><ix:nonfraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-285" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0458" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-286" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_43B_c20191001__20200930_ecustom--ContractSettlementWithCommonStock_zryB8KdZSuM1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">Shares issued as settlement of contract</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98A_ecustom--SharesIssuedAsSettlementOfContractShares_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zThOjsegC8Ni" title="Shares issued as settlement of contract, Shares" style="text-align: right"><span><ix:nonfraction name="cryo:SharesIssuedAsSettlementOfContractShares" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-287" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">150,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:ContractSettlementWithCommonStock" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-288" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">150</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:ContractSettlementWithCommonStock" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-289" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">46,350</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465"><span><ix:nonfraction name="cryo:ContractSettlementWithCommonStock" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-290" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0465" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:ContractSettlementWithCommonStock" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-291" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">46,500</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_433_c20191001__20200930_ecustom--StockIssuedDuringPeriodValueIssuedForInterestDue_z5DGXOw3L5Ai" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Shares issued to pay Interest Due</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesIssuedForInterestDue_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z63e4XBkQnO3" title="Shares issued to pay Interest Due, Shares" style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodSharesIssuedForInterestDue" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-292" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">227,088</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueIssuedForInterestDue" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-293" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">227</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueIssuedForInterestDue" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-294" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">57,622</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueIssuedForInterestDue" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-295" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0472" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueIssuedForInterestDue" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-296" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">57,849</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_436_c20191001__20200930_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zygbiEZ3xN3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Shares issued for services provided</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzKiI7klx9e3" title="Shares issued for services provided, Shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-297" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">665,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-298" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">665</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-299" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">96,835</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0479"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-300" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0479" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-301" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">97,500</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_435_c20191001__20200930_ecustom--StockOptionGranted_zW5HzRIeOZye" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Stock Options Granted</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484"><span><ix:nonfraction name="cryo:StockOptionGranted" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" id="fact-identifier-302" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0484" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:StockOptionGranted" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-303" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">320,042</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486"><span><ix:nonfraction name="cryo:StockOptionGranted" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-304" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0486" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:StockOptionGranted" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-305" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">320,042</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_43B_c20191001__20200930_eus-gaap--NetIncomeLoss_zcNgsbQPVW6e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt; text-indent: -8.65pt">Net loss</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" id="fact-identifier-306" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0489" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-307" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0490" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-308" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,179,285</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-309" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,179,285</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_430_c20201001__20210930_eus-gaap--StockholdersEquity_iS_zJ1kQpY6dyJg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 8.65pt; text-indent: -8.65pt">Balance at September 30, 2020</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9UgngQN82dg" title="Beginning Balance, Shares" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-310" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,570,665</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-311" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,572</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-312" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,917,408</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-313" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,398,179</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-314" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">421,199</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_43F_c20201001__20210930_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zRXIKopPe613" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">Issuance of common shares</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUycqfitBYw6" title="Issuance of common shares, Shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-315" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">640,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-316" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">640</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-317" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">142,360</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-318" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0503" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">143,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_431_c20201001__20210930_ecustom--StockIssuedDuringPeriodValuePrepaidExpenses_z8IfRt5hH2a6" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Shares issued for a prepaid expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesPrepaidExpenses_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgWomcbX4UJ1" title="Shares issued for a prepaid expense, Shares" style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodSharesPrepaidExpenses" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-320" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValuePrepaidExpenses" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-321" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValuePrepaidExpenses" contextref="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-322" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">74,900</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValuePrepaidExpenses" contextref="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-323" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0510" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValuePrepaidExpenses" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-324" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">75,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_439_c20201001__20210930_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zTUdkfJYhDob" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Shares issued for services provided</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmKW9eOuzcad" title="Shares issued for services provided, Shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-325" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">939,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-326" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">939</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-327" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">257,561</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0517"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-328" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0517" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-329" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">258,500</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_435_c20201001__20210930_ecustom--StockIssuedDuringPeriodValueIssuedForInterestDue_zZKehlOrV9X9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Shares issued to pay Interest Due</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_987_ecustom--StockIssuedDuringPeriodSharesIssuedForInterestDue_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcziyK4S4MLa" title="Shares issued to pay Interest Due, Shares" style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodSharesIssuedForInterestDue" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-330" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">124,858</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueIssuedForInterestDue" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-331" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">125</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueIssuedForInterestDue" contextref="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-332" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">48,421</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0524"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueIssuedForInterestDue" contextref="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-333" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0524" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueIssuedForInterestDue" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-334" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">48,546</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_430_c20201001__20210930_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_z0ID2zfH11vj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Issued Convertible Note - Beneficial Conversion Feature</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0529"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" id="fact-identifier-335" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0529" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextref="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-336" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,333</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0531"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextref="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-337" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0531" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-338" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,333</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_43A_c20201001__20210930_eus-gaap--ShareBasedCompensation_zcKAxjFoHEx" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Stock Options Granted</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" id="fact-identifier-339" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0534" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-340" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">902,853</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0536"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-341" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0536" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-342" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">902,853</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_438_c20201001__20210930_eus-gaap--NetIncomeLoss_z1BOkRFhJqCc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt; text-indent: -8.65pt">Net loss</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0539"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" id="fact-identifier-343" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0539" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0540"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-344" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0540" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-345" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,879,586</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-346" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,879,586</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_437_c20201001__20210930_eus-gaap--StockholdersEquity_iE_zEJYRyOdwi9k" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 8.65pt; text-indent: -8.65pt">Balance at September 30, 2021</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztm8zlr3ZEbf" title="Ending Balance, Shares" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-347" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61,374,523</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-348" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61,376</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-349" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,368,836</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-350" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,277,765</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-351" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,847,553</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</tbody></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"></span><span style="font-size: 10pt">See the
notes to the financial statements.</span></p>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>American CryoStem
Corporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><span id="acryob007"></span>Notes to the
Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><span style="font-size: 10pt"><b>September
30, 2021 and 2020</b></span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-352" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80E_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zuUFuYwPnUsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b>NOTE 1. <span id="xdx_820_zNfUHzL9UsQf">Organization of
the Company and Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">American
CryoStem Corporation (the “Company”) is a publicly held corporation formed on March 13, 2009 in the state of Nevada
as R&amp;A Productions Inc. (R&amp;A).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">In
April 2011, R&amp;A purchased substantially all the assets and liabilities of American CryoStem Corporation (ACS) a company formed
in 1987, for 21 million shares of common stock. ACS was deemed to be the accounting acquirer. At the date of the purchase, the
former operations of R&amp;A were discontinued and the name of the Company was changed to American CryoStem Corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The
Company is in the business of collecting adipose tissue, processing it to separate the adult stem cells, preparing such stem cells
for long-term storage and developing autologous mesenchymal stem cell therapies. The process allows individuals to preserve their
stem cells for future personal use in cellular therapy. The adipose derived stem cells are prepared and stored in their raw form
without manipulation, bio-generation or the addition of biomarkers or other materials, making them suitable for use in cellular
treatments and therapies offered by existing and planned treatment centers worldwide. Individualized collection and storage of
adult stem cells provides personalized medicine solutions by making the patient’s own preserved stem cells available for
future cellular therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0; text-align: justify"><span style="font-size: 10pt">The
Company has devoted a significant amount of its time and resources to develop its technologies and intellectual property. These
efforts have resulted in the development of cell lines, cell culture medium, other laboratory products and cellular therapies
which the Company believes are suitable for licensing and distribution by third parties. Additionally, the Company has initiated
a licensing program to license its technologies to laboratories currently processing other types of biologic materials including
cord blood and general blood banks. The Company closed its first licensing agreement in 2014 and intends to pursue additional
licensing partners in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The
accompanying consolidated financial statements include the accounts of American CryoStem Corporation and its wholly owned subsidiaries.
The Company’s subsidiaries are APAC CryoStem Limited, a Hong Kong company and APAC CryoStem (Shenzhen) Ltd. which were established
to support its licensing agreement and operations, and collect the licensing fees in Hong Kong and China. Currently, Mr. Arnone
and Mr. Dudzinski serve as management and directors of both companies. All significant intercompany accounts and transactions have been eliminated in the consolidation. Management believes
all amounts have been adjusted properly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Accounting
policies refer to specific accounting principles and the methods of applying those principles to present fairly the company’s
financial position and results of operations in accordance with generally accepted accounting principles. The policies discussed
below include those that management has determined to be the most appropriate in preparing the company’s financial statements.</span></p>

<span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:UseOfEstimates" inside-table="false" id="fact-identifier-353" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_845_eus-gaap--UseOfEstimates_zvFpAOyHL704" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i><span id="xdx_86D_zS52ms8XUMJ9">Use
of Estimates</span></i> - The preparation of the financial statements in conformity with United States generally accepted accounting
principles (“GAAP”) uniformly applied requires management to make reasonable estimates and assumptions that affect
the reported amounts of the assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts
of revenues and expenses at the date of the financial statements and for the period they include. Actual results may differ from
these estimates.</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-354" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zUaeA0G23rTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i><span id="xdx_867_zXB21WPpkb2d">Cash</span>
</i>- For the purpose of calculating changes in cash flows, cash includes all cash balances and highly liquid short-term investments
with an original maturity of three months or less. Occasionally, the Company maintains cash balances at financial institutions
that exceed federally insured limits.</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:InvestmentPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-355" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84A_eus-gaap--InvestmentPolicyTextBlock_zM9KgRfzBc8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i><span id="xdx_86E_zUlkejeKXJSf">Accounting
for Investments</span></i> - The Company accounts for investments based upon the type and nature of the investment and the availability
of current information to determine its value. Investments in marketable securities in which there is a trading market will be
valued at market value on the nearest trading date relative to the Company’s financial reporting requirements. Investments
which there is no trading market from which to obtain recent pricing and trading data for valuation purposes will be valued based
upon management’s review of available financial information, disclosures related to the investment and recent valuations
related to the investment’s fundraising efforts.</span></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" inside-table="false" id="fact-identifier-356" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_z1xAbomqmLdl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i><span id="xdx_866_zKjpyW1Jgbn5">Research
and Development</span> - </i>Research and development expenses include both external and internal expenses. External expenses primarily
include costs of intellectual property development, clinical trial development, fees paid for third party testing services, clinical
supply and manufacturing expenses, regulatory filing fees, consulting and professional fees as well as other general costs related
to the execution of research and development activities. Internal expenses primarily include compensation of employees engaged
in research and development activities. Research and development expenses are expensed as incurred. Manufacturing costs are generally
expensed as incurred.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23D_z79jm9B99bA6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>American
CryoStem Corporation</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zz4kvjuA92s5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to
the Consolidated Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zU8PzErAEwZ4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: center"><span style="font-size: 10pt"><b>September
30, 2021 and 2020</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zRTWBihHxmNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
1. Organization of the Company and Significant Accounting Policies (continued)</b></span></p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-357" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_849_eus-gaap--RevenueRecognitionPolicyTextBlock_zOxcAG4QguM6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i><span id="xdx_863_zWngOKigd6x1">Revenue Recognition</span>
</i>- Effective October 1, 2018, we adopted ASC 606, Revenue from Contracts with Customers (“ASC 606”), using the
modified retrospective transition method. The comparative information has not been restated and continues to be reported under
the accounting standards in effect for the periods presented. This standard applies to all contracts with customers, except for
contracts that are within the scope of other standards, such as leases, insurance, certain collaboration arrangements and financial
instruments. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. The standard
also requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with
customers. The adoption of ASC 606 did not have an impact on the amount of reported revenues. See Note 3 “Revenue Recognition”
for additional information.</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-358" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_842_eus-gaap--AdvertisingCostsPolicyTextBlock_zE02eLki7s4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i><span id="xdx_868_zjyTVrvsRnS2">Advertising</span>
</i>– Advertising Costs are expensed as they are incurred. Advertising Costs were $<span id="xdx_907_eus-gaap--AdvertisingExpense_c20201001__20210930_zopvMR7ErHr7"><span><ix:nonfraction name="us-gaap:AdvertisingExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-359" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">814</ix:nonfraction></span></span> for Fiscal 2021 and $<span id="xdx_908_eus-gaap--AdvertisingExpense_c20191001__20200930_zWniCIVy4n12"><span><ix:nonfraction name="us-gaap:AdvertisingExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-360" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span> for Fiscal
2020, which is in Sales and Marketing Expenses within the Consolidated Statements of Operations.</span></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" inside-table="false" id="fact-identifier-361" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84A_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zboTiHkKZ17g" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i><span id="xdx_862_zM7klYbtsb37">Bad
Debt Expense</span></i> - The Company provides, through charges to income or loss, a charge for bad debt expense, which is based upon
management’s evaluation of numerous factors. These factors include economic conditions prevailing, a predictive analysis
of the outcome of the current portfolio by client, and prior credit loss experience of each client. The Company uses the information
from this analysis to develop an estimate of bad debt reserve based upon the amount of accounts receivable by client at the balance
sheet date. The Allowance for Doubtful Accounts was $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20210930_zwptOf0lqHJ1"><span><ix:nonfraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-362" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">860,933</ix:nonfraction></span></span> at September 30, 2021 and $<span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20200930_zx3rzvMSPPId"><span><ix:nonfraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-363" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">337,515</ix:nonfraction></span></span> at September 30, 2020. (See Note
3 for additional information)</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:InventoryPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-364" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zZUPeJwnxSWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i><span id="xdx_860_zDJ9r7mAs93f">Inventory</span>
</i>- Inventory is valued at lower of cost or market using the first in, first out method. Inventory consists of the disposables
and materials used to create production kits, for processing of adipose tissue and cellular samples, the manufacture of Medias
used to prepare the samples and cryoprotectant for the storage of the samples.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Inventory
was composed of Raw Materials and Finished Goods, which was valued at $<span id="xdx_900_eus-gaap--InventoryNet_iI_c20210930_zNXVdRldUZ3d"><span><ix:nonfraction name="us-gaap:InventoryNet" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-365" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,934</ix:nonfraction></span></span> at September 30, 2021 and $<span id="xdx_905_eus-gaap--InventoryNet_iI_c20200930_zN6YWs4MhwIf"><span><ix:nonfraction name="us-gaap:InventoryNet" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-366" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,401</ix:nonfraction></span></span> at September 30,
2020.</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-367" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z6e7kH8iA7J3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i><span id="xdx_86E_zrsYaQxna9Ec">Long
Lived Assets</span></i> - The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash
flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount.</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-368" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zFss3fuljtS6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i><span id="xdx_86C_z0Yhl0g2kAld">Fixed
Assets</span></i> – Fixed assets are stated at cost. Depreciation expense is computed using the straight-line method over
the estimated useful life of the assets, which is estimated as follows:</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-369" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zDMrTlhFq0ol" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BF_z82upBhAPb31" style="display: none">Schedule
of Fixed Assets, Useful Life of Assets</span></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="cryo:DisclosureOrganizationOfTheCompanyAndSignificantAccountingPoliciesDetailsAbstract" inside-table="false" id="fact-identifier-370" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellspacing="0" cellpadding="0" id="xdx_882_ecustom--DisclosureOrganizationOfTheCompanyAndSignificantAccountingPoliciesDetailsAbstract_zj5NgbfVxWli" summary="xdx: Disclosure - Organization of the Company and Significant Accounting Policies (Details)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 40%; border-collapse: collapse; margin-right: auto">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 0.8pt"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 0.8pt; text-align: right"></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 65%; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Office
    Equipment</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 35%; padding-right: 0.8pt; text-align: right"><span id="xdx_986_eus-gaap--PropertyPlantAndEquipmentUsefulLife_c20201001__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zHpGebPhYUji" style="font: 10pt Times New Roman, Times, Serif"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_us-gaap_OfficeEquipmentMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" inside-table="true" id="fact-identifier-371" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5 years</ix:nonnumeric></span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Lab
    Equipment &amp; Furniture</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: right"><span id="xdx_984_eus-gaap--PropertyPlantAndEquipmentUsefulLife_c20201001__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndFurnitureMember_zTaoSbtvlZff" style="font: 10pt Times New Roman, Times, Serif"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_custom_LabEquipmentAndFurnitureMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" inside-table="true" id="fact-identifier-372" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7 years</ix:nonnumeric></span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Lab
    Software</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: right"><span id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_c20201001__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zlwL1EFQvb8k" style="font: 10pt Times New Roman, Times, Serif"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" inside-table="true" id="fact-identifier-373" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5 years</ix:nonnumeric></span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Leasehold
    Improvements</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: right"><span id="xdx_983_eus-gaap--PropertyPlantAndEquipmentUsefulLife_c20201001__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zzTqoh8vuXXh" style="font: 10pt Times New Roman, Times, Serif"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" inside-table="true" id="fact-identifier-374" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15 years</ix:nonnumeric></span></span></td></tr>
</tbody></table></ix:nonnumeric></span>
<p id="xdx_8A6_zeLJJtHyNNU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><i>&nbsp;</i></span></p>
</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-375" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zTUExgscxpib" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0; text-align: justify"><span style="font-size: 10pt"><i><span id="xdx_869_zA9KIHiydQEd">Income
taxes</span> - </i>The Company accounts for income taxes in accordance with generally accepted accounting principles which require an
asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities
are computed annually for differences between financial statement and income tax bases of assets and liabilities that will result
in taxable income or deductible expenses in the future based on enacted tax laws and rates applicable to the periods in which
the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred
tax assets and liabilities to the amount expected to be realized. Income tax expense is the tax payable or refundable for the
period adjusted for the change during the period in deferred tax assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
follows the accounting requirements associated with uncertainty in income taxes using the provisions of Financial Accounting Standards
Board (FASB) ASC 740, Income Taxes. Using that guidance, tax positions initially need to be recognized in the financial statements
when it is more likely than not the positions will be sustained upon examination by the tax authorities. It also provides guidance
for derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As of September
30, 2021 and September 30, 2020, the Company has no uncertain tax positions that qualify for either recognition or disclosure
in the financial statements. All tax returns from fiscal years 2015 to 2020 are subject to IRS and State of New Jersey audit.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_239_z2N1wHrET7L8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>American
CryoStem Corporation</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zSHTODysRC28" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to
the Consolidated Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_236_z5zzfSr5CjZh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: center"><span style="font-size: 10pt"><b>September
30, 2021 and 2020</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_234_z0VlZInbetCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
1. Organization of the Company and Significant Accounting Policies (continued)</b></span></p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-376" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zTd1B1bAh3pa" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i><span id="xdx_86B_zAdI5baiElUa">Recently
Issued Accounting Pronouncements</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The FASB recently issued ASU 2020-06,
Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s
Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to reduce
complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The guidance in ASU 2020-06 simplifies
the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20,
Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion
features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible
instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted
for as derivatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In addition, the amendments revise
the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that
are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required
for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity
classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting
from the host contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The amendments in ASU 2020-06 further
revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible
instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating
diluted EPS when an instrument may be settled in cash or shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The amendments in ASU 2020-06 are
effective for our company for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is currently
assessing the impact of these amendments on its future financial reporting.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In June
2016, the FASB issued ASU No. 2016-13 <i>Financial Instruments-Credit Losses</i>. The new guidance provides better representation
about expected credit losses on financial instruments. This Update requires the use of a methodology that reflects expected losses
and requires consideration of a broader range of reasonable and supportive information to inform credit loss estimates. This ASU is effective for reporting periods beginning after December 15, 2022, with early adoption permitted. The company
is studying the impact of adopting the ASU in fiscal year 2024, and what effect it could have. The Company believes the accounting
change would not have a material effect on the financial statements.</span></p>



</ix:nonnumeric></span></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80D_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zXPaZeNErJD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
2. <span id="xdx_824_zDSXWac9eh5h">Going Concern </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The accompanying
consolidated financial statements have been presented in accordance with generally accepted accounting principles in the U.S.,
which assume the continuity of the Company as a going concern. However, the Company has incurred significant losses since its
inception which raises substantial doubt about the Company’s ability to continue as a going concern. Management has made
this assessment for the period one year from date of the issuance of this report. Management’s plans with regard to this
matter are to continue to fund its operations through fundraising activities in fiscal 2022 for future operations and business
expansion. The Company has executed a firm Letter of Intent (LOI) for a $10 million financing with EF Hutton in 2022.</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-378" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_805_eus-gaap--RevenueFromContractWithCustomerTextBlock_zXTwDcCtJWl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
3. <span id="xdx_820_zkmV2n5M3jmf">Revenue Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Under ASC 606, we recognize revenue
when our customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to
receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within
the scope of ASC 606, we perform the following five steps:</span></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">a.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Identify the contract(s) with a customer;</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">b.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Identify the performance obligations in the contract;</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">c.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Determine the transaction price;</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">d.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Allocate the transaction price to the performance obligations in the contract; and</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">e.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Recognize revenue when (or as) the performance obligations are satisfied.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We only apply the five step model
to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services
we transfer to the customer. At contract inception, if the contract is determined to be within the scope of ASC 606, we assess
the goods or services promised within each contract, determine those that are performance obligations, and assess whether each
promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the
respective performance obligation when (or as) the performance obligation is satisfied.</span></p>





<ix:exclude><!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_231_zhqyqJuX9AC" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>American
CryoStem Corporation</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zagGO91xBqz9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to
the Consolidated Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zMZwZ1c14No2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: center"><span style="font-size: 10pt"><b>September
30, 2021 and 2020</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_znydffOpNiR4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: left"><span style="font-size: 10pt"><b>NOTE
3. Revenue Recognition (continued)</b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our major sources
of revenue during the reporting periods were 1. Tissue Collection, Processing and Storage revenue from various customers; 2. Annual
Storage Fees for our ATGRAFT and ATCELL products, from customers who have had stored in our laboratory facility; 3. Licensing
and other fees from Baoxin, Cell Source, CRYOVIVA, Pepro-Tech and Personal Cell Sciences; and 4. Products sales revenues from
Baoxin and CRYOVIVA. The adoption of ASC 606 did not have an impact on the pattern or timing of recognition of our Tissue Processing,
Storage Fees or Product Sales Revenue, since:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Tissue
                                         Collection, Processing &amp; Storage Revenue is recognized on the date the process is
                                         completed and stored in our facility.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Storage
                                         Fees are charged annually. </span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">3.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Licensing
                                         and other Fees - This is based on the passage of time and as the customer has access
                                         to the license. The Company reviewed and analyzed the contract with Baoxin. Management’s
                                         judgments are:</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">a.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Baoxin
                                         qualifies as a customer since American CryoStem does not take significant risks or receive
                                         significant gains from the agreement.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">b.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The
                                         right to use the license does not have significant standalone functionality because consulting
                                         is required by American CryoStem in order for the customer to be able to use the license.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">c.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The
                                         Company has determined as of the date of this report, due to Baoxin’s payment history
                                         during the COVID pandemic, to make an adjustment for recognition of the Baoxin revenue.
                                         The Company considered during its review Baoxin’s most recent audited financial
                                         statements, documentation provided by Baoxin concerning the completion of their new 100,000
                                         sq. ft facility in 2021, the uncertainty of the timing for restarting their tissue processing
                                         operations in the new facility, and the ongoing uncertainties regarding the continuing
                                         effects of the COVID-19 pandemic in China. (See Notes 13 and 14 for additional information)
                                         </span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">4.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The
                                         majority of our Product Sales Revenue continues to be recognized when the customer takes
                                         control of the product. </span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Revenue
and Allowances</b></span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-379" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_893_eus-gaap--DisaggregationOfRevenueTableTextBlock_zXrLPFLg6RRc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following
table provides <span id="xdx_8BF_zOp3g7zEWWWc">information about Fees and Product Sales Revenue</span> for the years ended September 30, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>



</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="cryo:DisclosureRevenueRecognitionDetailsAbstract" inside-table="false" id="fact-identifier-380" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureRevenueRecognitionDetailsAbstract_zQZ1jB5CGDc5" summary="xdx: Disclosure - Revenue Recognition (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tbody><tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">9/30/2021</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">9/30/2020</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Licensing &amp; Other Fees</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 54%; padding-left: 8.65pt">Baoxin</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_c20201001__20210930__srt--ProductOrServiceAxis__us-gaap--RoyaltyMember__dei--LegalEntityAxis__custom--BaoxinMember_zwBLwLFIRR5f" style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0610"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2020-10-012021-09-30_us-gaap_RoyaltyMember_custom_BaoxinMember" id="fact-identifier-381" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0610" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20191001__20200930__srt--ProductOrServiceAxis__us-gaap--RoyaltyMember__dei--LegalEntityAxis__custom--BaoxinMember_zRQ1DTYjLkwi" style="width: 8%; text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2019-10-012020-09-30_us-gaap_RoyaltyMember_custom_BaoxinMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-382" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Cell Source</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--Revenues_d0_c20201001__20210930__srt--ProductOrServiceAxis__us-gaap--RoyaltyMember__dei--LegalEntityAxis__custom--CellSourceMember_zCZOHmmXXgac" style="text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2020-10-012021-09-30_us-gaap_RoyaltyMember_custom_CellSourceMember" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-383" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--Revenues_c20191001__20200930__srt--ProductOrServiceAxis__us-gaap--RoyaltyMember__dei--LegalEntityAxis__custom--CellSourceMember_zeGW7r0kdSXd" style="text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2019-10-012020-09-30_us-gaap_RoyaltyMember_custom_CellSourceMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-384" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,333</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">Totals</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_c20201001__20210930__srt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zQat9nyUqRI8" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0614"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2020-10-012021-09-30_us-gaap_RoyaltyMember" id="fact-identifier-385" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0614" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--Revenues_c20191001__20200930__srt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zq2HpMb2Noi1" style="text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2019-10-012020-09-30_us-gaap_RoyaltyMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-386" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">523,333</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Product Sales</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Baoxin</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_c20201001__20210930__srt--ProductOrServiceAxis__us-gaap--ProductMember__dei--LegalEntityAxis__custom--BaoxinMember_zUMlPc0aYng3" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0616"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2020-10-012021-09-30_us-gaap_ProductMember_custom_BaoxinMember" id="fact-identifier-387" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0616" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_c20191001__20200930__srt--ProductOrServiceAxis__us-gaap--ProductMember__dei--LegalEntityAxis__custom--BaoxinMember_zlSxJzVVUC5b" style="text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2019-10-012020-09-30_us-gaap_ProductMember_custom_BaoxinMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-388" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,680</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">CryoViva</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_986_eus-gaap--Revenues_c20201001__20210930__srt--ProductOrServiceAxis__us-gaap--ProductMember__dei--LegalEntityAxis__custom--CryoVivaMember_zV2mVl6LQdch" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0618"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2020-10-012021-09-30_us-gaap_ProductMember_custom_CryoVivaMember" id="fact-identifier-389" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0618" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--Revenues_c20191001__20200930__srt--ProductOrServiceAxis__us-gaap--ProductMember__dei--LegalEntityAxis__custom--CryoVivaMember_zlLw0rKCCVMg" style="text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2019-10-012020-09-30_us-gaap_ProductMember_custom_CryoVivaMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-390" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,060</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Science Diagnostics</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--Revenues_c20201001__20210930__srt--ProductOrServiceAxis__us-gaap--ProductMember__dei--LegalEntityAxis__custom--ScienceDiagnosticMember_zGBhCIQZpa63" style="text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2020-10-012021-09-30_us-gaap_ProductMember_custom_ScienceDiagnosticMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-391" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">760</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--Revenues_c20191001__20200930__srt--ProductOrServiceAxis__us-gaap--ProductMember__dei--LegalEntityAxis__custom--ScienceDiagnosticMember_zE0w7H9W8l1b" style="text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2019-10-012020-09-30_us-gaap_ProductMember_custom_ScienceDiagnosticMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-392" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">930</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Totals</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--Revenues_c20201001__20210930__srt--ProductOrServiceAxis__us-gaap--ProductMember_z4A7DFH15GEg" style="text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2020-10-012021-09-30_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-393" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">760</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20191001__20200930__srt--ProductOrServiceAxis__us-gaap--ProductMember_zdyMbZvpoA6g" style="text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2019-10-012020-09-30_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-394" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,670</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
</tbody></table></ix:nonnumeric></span>




<p id="xdx_8A5_zXOUc7dyYhji" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Tissue Processing
and Storage was not included in the table since this revenue was provided by customers who were individuals rather than corporate
partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Performance
Obligations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">At contract
inception, we assess the goods and services promised in our contracts and identify the performance obligations for each promise
to transfer to the customer goods or to provide the customer with a service that is distinct. To identify the performance obligations,
we consider all of the goods and services promised in the contract regardless of whether they are specifically stated or are implied
by customary business practices. We determined that the following distinct goods or services represent separate performance obligations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">ATGRAFT
                                         and ATCELL Customer Tissue Processing Fees</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">ATGRAFT
                                         and ATCELL Customer Storage Fees</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Licensing
                                         and other Fees</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">·</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Supply
                                         of our Tissue Collection, Processing and Storage Products to our customers.<span style="font-family: Arial, Helvetica, Sans-Serif">
                                         </span></span></td></tr></tbody></table>



<ix:exclude><!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23F_zi36N1E8dufk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>American
CryoStem Corporation</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_z4MYyxpAlWnl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to
the Consolidated Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zMdMTqqdAXTb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: center"><span style="font-size: 10pt"><b>September
30, 2021 and 2020</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_ztmSLbUBkiC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
3. Revenue Recognition (continued)</b></span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">We principally
sell our products to end users, who have agreements with us to utilize our processing and storage technology. We provide processing
and storage services to individual customers, physicians and clinics. We charge various fees for consulting services or licensing
of our technologies; which includes processing and storage agreements, arrangements with biotechnology processing facilities for
the provision of our services within a limited geographic area.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">For the
customers that purchase our Tissue Collection, Processing and Storage Products we transfer control at the point in time when the
goods are shipped from our facility, shipping costs are paid by the customer and these costs are not accrued when the related
revenue is recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i>Variable
Consideration</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Under
ASC 606, we are required to make estimates of the net sales price, including estimates of variable consideration (such as rebates
and discounts) and recognize the estimated amount as revenue when we transfer control of the product or provide the service to
our customers. Variable Consideration must be determined using either an “expected value” or a “most likely
amount” method. At the current time the Company does not offer rebates or discounts on our provision of ATGRAFT and ATCELL
customer processing and storage fees; Licensing and other Fees; and offer Tissue Collection, Processing and Storage products;
therefore we have not made any provisions for variable consideration related to discounts or rebates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i>Product
Returns</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">We only
offer product returns in the event a delivered product is found to be defective for which we offer replacement only. The Company
has not had any product returned based upon a defective product claim however return experience may change over time.</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:EarningsPerShareTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-395" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80B_eus-gaap--EarningsPerShareTextBlock_zu7m6wy4oWMj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
4. <span id="xdx_825_zGfNlLgAy2Ub">Loss per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
applies ASC 260, “Earnings<i> per Share”</i> to calculate loss per share. In accordance with ASC 260, basic and fully
diluted net loss per share has been computed based on the weighted average of common shares outstanding during the years. The
dilutive effects of the convertible notes and the options outstanding are not included in the calculation of loss per share since
their inclusion would be anti-dilutive.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
had <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zfVyTgGjj4Ng"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-396" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,536,500</ix:nonfraction></span></span> and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20191001__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zb72iJqS37Y7"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2019-10-012020-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-397" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,936,500</ix:nonfraction></span></span> shares of Common Stock issuable upon exercise of all outstanding stock options and warrants for Fiscal
Years 2021 and 2020, respectively; and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20201001__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zO6zzsTXpAv4"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-10-012021-09-30_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-398" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,334,784</ix:nonfraction></span></span> and <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20191001__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zB3CE8EGBSWc"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2019-10-012020-09-30_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-399" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,134,784</ix:nonfraction></span></span> shares issuable on the conversion of outstanding Convertible Notes
for Fiscal Years 2021 and 2020, respectively.</span></p>



<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-400" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z2EyUFtVNFpb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B9_ztrmPBZJCPw3">Net Loss per
share for the Fiscal Years is computed below:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="cryo:DisclosureLossPerShareDetailsAbstract" inside-table="false" id="fact-identifier-401" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureLossPerShareDetailsAbstract_zxPC3q67MLrk" summary="xdx: Disclosure - Loss Per Share (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" id="xdx_491_20201001__20210930_zcsTyY1Jwqvd" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">30-Sep-21</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" id="xdx_490_20191001__20200930_zylBX6Hi3lYl" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">30-Sep-20</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_404_eus-gaap--NetIncomeLoss_zDQcN5R3Zh81" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-size: 10pt">Net Loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-402" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,879,586</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-403" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,179,285</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_404_eus-gaap--EarningsPerShareBasicAndDiluted_zoJGsHuVXSdf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Basic &amp; Fully Diluted
    Net Income (Loss) per Common Share:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-404" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.05</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-405" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.02</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_401_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_zPoRhTiyYzpe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Weighted Average of Common Shares Outstanding
    - Basic &amp; fully diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-406" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60,341,578</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-407" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,659,523</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
</tbody></table></ix:nonnumeric></span>



<p id="xdx_8AD_z8KhkpgXQhHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>



</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-408" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zr74kFJPBl83" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
5. <span id="xdx_82A_zioTyZ0Zlyk8">Fixed Assets</span></b></span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-409" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zhZESjsR9EW" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-size: 10pt">The <span id="xdx_8BB_zTZIhRWDR3te">fixed
assets accounts of the Company</span> are comprised as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-size: 10pt"></span></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="cryo:DisclosureFixedAssetsDetailsAbstract" inside-table="false" id="fact-identifier-410" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureFixedAssetsDetailsAbstract_zaifnaidwipc" summary="xdx: Disclosure - Fixed Assets (Details)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 90%">
<tbody><tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" id="xdx_491_20210930_zOmoGVWg1N53" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">9/30/2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" id="xdx_497_20200930_zrBh2gv201Zc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">9/30/2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zpeVFpRUnVN8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-size: 10pt">Laboratory
    Equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2021-09-30_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-411" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">257,905</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2020-09-30_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-412" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">257,905</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryLeaseholdImprovementsMember_zzweU96xSXU3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Laboratory
    Leasehold Improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2021-09-30_custom_LaboratoryLeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-413" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">110,286</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2020-09-30_custom_LaboratoryLeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-414" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">110,286</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryFurnitureMember_zQ9brBji4ccj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Laboratory
    Furniture</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2021-09-30_custom_LaboratoryFurnitureMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-415" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,841</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2020-09-30_custom_LaboratoryFurnitureMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-416" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,841</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zUzvUPhsQsl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Office
    Equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2021-09-30_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-417" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,869</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2020-09-30_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-418" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,869</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeLeaseholdImprovementsMember_z1r1LcKv6Ou3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Office Leasehold Improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2021-09-30_custom_OfficeLeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-419" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,650</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2020-09-30_custom_OfficeLeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-420" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,650</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureMember_zWEgw4W3HfCc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Office
    Furniture</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2021-09-30_custom_OfficeFurnitureMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-421" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,812</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentGross" contextref="AsOf2020-09-30_custom_OfficeFurnitureMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-422" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,812</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zfLteZFAaZPc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Accumulated
    Depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-423" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">288,880</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-424" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">275,772</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iI_zi08MomYXy2f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Net
    Property and Equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentNet" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-425" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">113,483</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentNet" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-426" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">126,591</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
</tbody></table></ix:nonnumeric></span>





<p id="xdx_8AF_zF1VUOhoEw87" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Depreciation
expense for Fiscal Years 2021 and 2020 is $<span id="xdx_90A_eus-gaap--Depreciation_c20201001__20210930_zthmhoU1hF53"><span><ix:nonfraction name="us-gaap:Depreciation" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-427" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,109</ix:nonfraction></span></span> and $<span id="xdx_908_eus-gaap--Depreciation_c20191001__20200930_zh3BwYxu3qJk"><span><ix:nonfraction name="us-gaap:Depreciation" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-428" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,170</ix:nonfraction></span></span>, respectively.</span></p>

</ix:nonnumeric></span><p id="xdx_817_zsRPvyjlDCj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p id="xdx_23C_zAMeJMs2js8g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>American
CryoStem Corporation</b></span></p>

<p id="xdx_235_zL0e6RcAU6O5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to
the Consolidated Financial Statements</b></span></p>

<p id="xdx_237_zcELOSSjIkF3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: center"><span style="font-size: 10pt"><b>September
30, 2021 and 2020</b></span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-429" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_808_eus-gaap--IntangibleAssetsDisclosureTextBlock_zoLniS728xt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 6. <span id="xdx_827_zT7muxpo2L9">Patent &amp; Patents Filings</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0; text-align: justify"><span style="font-size: 10pt">The patent
and patents development are recorded at cost and are being amortized on a straight line basis over a period of seventeen years.
The company capitalizes Legal and Administrative Fees incurred in the process of filing for its patents. The Company has only
been amortizing the patents issued. Amortization Expense for Fiscal Year 2021 was $36,552 and $5,663 for Fiscal 2020. The Company
reviewed its current patent assets in Fiscal 2021 and determined that no impairment was required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Patents still
in the application process and Trademarks have not been amortized. The unamortized costs of patents in the application process
are $<span id="xdx_90E_ecustom--UnamortizedCostsOfPatents_iI_c20210930_z85LccNUFnqg"><span><ix:nonfraction name="cryo:UnamortizedCostsOfPatents" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-430" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">164,194</ix:nonfraction></span></span> for Fiscal 2021. Amortizable Patent Costs were $<span id="xdx_906_ecustom--AmortizablePatentCosts_iI_c20210930_zLg6JGa72Xwk"><span><ix:nonfraction name="cryo:AmortizablePatentCosts" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-431" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">238,172</ix:nonfraction></span></span> at Fiscal Year Ended 2021. The following is the minimum expected
amortization expense for these patents for the next 5 years:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-432" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_899_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zZ0SgkigSce5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zvyvWgtJ6NI9" style="display: none">Schedule of patent amortization</span></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="cryo:DisclosurePatentAndPatentsFilingsDetails" inside-table="false" id="fact-identifier-433" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--DisclosurePatentAndPatentsFilingsDetails_z8TYhkmjzNCk" summary="xdx: Disclosure - Patent &amp; Patents Filings (Details)" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; border-collapse: collapse; width: 30%">
<tbody><tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td></td><td></td>
    <td style="text-align: left"></td><td id="xdx_499_20210930_zNL4pTGFQeKh" style="text-align: right"></td><td style="text-align: left"></td></tr>
<tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zPc2PPyXEsi8" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 17%">Fiscal 2022</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-434" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,010</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zg3FS3zLPzd5" style="vertical-align: bottom; background-color: White">
    <td>Fiscal 2023</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-435" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,010</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_z7GtkeATeazl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Fiscal 2024</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-436" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,010</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zPkHT6yqBgL" style="vertical-align: bottom; background-color: White">
    <td>Fiscal 2025</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-437" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,010</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zEEUm1mwSr25" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Fiscal 2026</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-438" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,010</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
</tbody></table></ix:nonnumeric></span>


<p id="xdx_8AD_zN0MUORpBWr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following
is a description of the Company’s patent assets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On August 2,
2011, the Company was awarded U.S. Patent No. US 7,989,205 B2, titled Cell Culture Media, Kits, and Methods of Use. The Patent
is for cell culture media kits for the support of primary culture of normal non-hematopoietic cells of mesodermal origin suitable
for both research and clinical applications. The Company filed and maintains a continuation (U.S. Serial No. 13/194,900) and additional
claims were granted on November 8, 2016 under patent Number 9,487,755. The Company filed an additional continuation on November
7, 2016 as part of our overall patent strategy and to cover expanded modifications of the original patent grant, US Patent Application
No. 15/344,805.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On July 3, 2018,
the Company was awarded U. S. Patent No. US 10,014,079 B2 titled “Business Method for Collection, Cryogenic Storage and
Distribution of a Biologic Sample Material originally filed as US Serial No 13/702,304 filed June 6, 2011 with a priority date
of June 6, 2010. The patent covers the Company’s comprehensive business method for collecting, processing, cryogenic storage
and distribution of a biologic sample material. The Company has filed a continuation of the patent to cover addition claims and
will file additional Continuation in Part claims for improvements that it has developed since the original patent filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On December
18, 2018, the Company was awarded US Patent No. US 10,154,664 B2 titled “Systems and Methods for the Digestion of Adipose
Tissue Samples Obtained from a Client for Cryopreservation” U.S. Serial No. 13/646,647 filed October 5, 2012 with a priority
date of October 6, 2011.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
has filed the following additional patents to extend its intellectual property to encompass additional aspects of the Company’s
platform processing technologies. To date the following additional patent filings have been made:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">A business method
for Collection, Cryogenic Storage and Distribution of a Biologic Sample Material US Serial No 13/702,304 filed June 6, 2011 with
a priority date of June 6, 2010.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Additionally,
this patent has been filed European Union Application No. EPI3800847.9 and China Application No. 2013800391988.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Human Serum
for Cell Culture Medium for Clinical Growth of Human Adipose Stromal Cells, International PCT filing PCT/US/68350 filed December
31, 2015 with a priority date of December 31, 2014. During 2017 the Company extended the filing into China, the EU, India, Japan,
the Kingdom of Saudi Arabia, Canada and Mexico.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is currently developing additional US and foreign patent applications and expects to file a number of additional provisional and
PCT patent applications in Fiscal 2022</span></p>

</ix:nonnumeric></span><p id="xdx_815_zatDhVq1F4fe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->


<p id="xdx_23F_zQhr2jDiNyq1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>American
CryoStem Corporation</b></span></p>

<p id="xdx_239_zZEuJsLbit1l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to
the Consolidated Financial Statements</b></span></p>

<p id="xdx_231_zQEaDj75y0Vj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: center"><span style="font-size: 10pt"><b>September
30, 2021 and 2020</b></span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:DebtDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-439" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zBbOsXoUJ7r" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE
7. <span id="xdx_82F_z5Et5mwqXrR3">Debt</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-440" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_891_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zOszHsccBj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The <span id="xdx_8B7_z7IN0OW1hMB9">following
table describes the Company’s debt outstanding</span> as of September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="cryo:DisclosureDebtDetailsAbstract" inside-table="false" id="fact-identifier-441" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureDebtDetailsAbstract_zDGRR2saEaci" summary="xdx: Disclosure - Debt (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"><b>Debt</b></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&nbsp;</b></span></td>
    <td colspan="2" id="xdx_48B_eus-gaap--DebtInstrumentCarryingAmount_iI_zv1MuTa9LmY1" style="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Carrying
    Value</b></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&nbsp;</b></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span style="font-size: 10pt">&nbsp;</span></b></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><b>&nbsp;</b></td>
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Maturity</b></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&nbsp;</b></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span style="font-size: 10pt">&nbsp;</span></b></td>
    <td colspan="2" id="xdx_48A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_zieC3it7uEs9" style="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Rate</b></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&nbsp;</b></span></td></tr>
<tr id="xdx_410_20210930__us-gaap--LongtermDebtTypeAxis__custom--BridgeNoteMember_zKFAMCwNh7w9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: justify"><span style="font-size: 10pt">Bridge
    Notes</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentCarryingAmount" contextref="AsOf2021-09-30_custom_BridgeNoteMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-442" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">226,500</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_98D_eus-gaap--DebtInstrumentMaturityDateDescription_c20201001__20210930__us-gaap--LongtermDebtTypeAxis__custom--BridgeNoteMember_zDVzv5dTvkKe" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: left"><span style="font-size: 10pt"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_custom_BridgeNoteMember" name="us-gaap:DebtInstrumentMaturityDateDescription" inside-table="true" id="fact-identifier-443" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Demand</ix:nonnumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2021-09-30_custom_BridgeNoteMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-444" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.00</ix:nonfraction></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt"></span></td></tr>
<tr id="xdx_41E_20210930__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_zfYr4KZlDBc6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Convertible Notes
    @ 75 cents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentCarryingAmount" contextref="AsOf2021-09-30_custom_ConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-445" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_98F_eus-gaap--DebtInstrumentMaturityDateDescription_c20201001__20210930__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_zD0u5vGLOWU2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_custom_ConvertibleNotesMember" name="us-gaap:DebtInstrumentMaturityDateDescription" inside-table="true" id="fact-identifier-446" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Fiscal 2023</ix:nonnumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2021-09-30_custom_ConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-447" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.00</ix:nonfraction></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"></span></td></tr>
<tr id="xdx_41F_20210930__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotes2Member_zyiTta5A8Fol" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Convertible Notes
    @ 40 cents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentCarryingAmount" contextref="AsOf2021-09-30_custom_ConvertibleNotes2Member" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-448" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_985_eus-gaap--DebtInstrumentMaturityDateDescription_c20201001__20210930__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotes2Member_zb7RApnH5xRc" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_custom_ConvertibleNotes2Member" name="us-gaap:DebtInstrumentMaturityDateDescription" inside-table="true" id="fact-identifier-449" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Demand</ix:nonnumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2021-09-30_custom_ConvertibleNotes2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-450" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.00</ix:nonfraction></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"></span></td></tr>
<tr id="xdx_410_20210930__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotes3Member_zYsk140ZAFj2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Convertible Notes
    @ 35 cents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentCarryingAmount" contextref="AsOf2021-09-30_custom_ConvertibleNotes3Member" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-451" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">83,500</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_984_eus-gaap--DebtInstrumentMaturityDateDescription_c20201001__20210930__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotes3Member_z5blPXuuUm68" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_custom_ConvertibleNotes3Member" name="us-gaap:DebtInstrumentMaturityDateDescription" inside-table="true" id="fact-identifier-452" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Demand</ix:nonnumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2021-09-30_custom_ConvertibleNotes3Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-453" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.00</ix:nonfraction></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"></span></td></tr>
<tr id="xdx_413_20210930__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotes4Member_zhj0seFarjA5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Convertible Notes
    @ 33 cents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentCarryingAmount" contextref="AsOf2021-09-30_custom_ConvertibleNotes4Member" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-454" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_983_eus-gaap--DebtInstrumentMaturityDateDescription_c20201001__20210930__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotes4Member_zpyJjbDeh5Ib" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_custom_ConvertibleNotes4Member" name="us-gaap:DebtInstrumentMaturityDateDescription" inside-table="true" id="fact-identifier-455" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Demand</ix:nonnumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2021-09-30_custom_ConvertibleNotes4Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-456" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.00</ix:nonfraction></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"></span></td></tr>
<tr id="xdx_41F_20210930__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotes5Member_zitJE5twg0sc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Convertible Notes
    @ 30 cents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentCarryingAmount" contextref="AsOf2021-09-30_custom_ConvertibleNotes5Member" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-457" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45,000</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_98B_eus-gaap--DebtInstrumentMaturityDateDescription_c20201001__20210930__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotes5Member_zynzpsTQsmeb" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_custom_ConvertibleNotes5Member" name="us-gaap:DebtInstrumentMaturityDateDescription" inside-table="true" id="fact-identifier-458" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Demand</ix:nonnumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2021-09-30_custom_ConvertibleNotes5Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-459" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.00</ix:nonfraction></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"></span></td></tr>
<tr id="xdx_419_20210930__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotes6Member_zJtjFwXGMlgg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Convertible Notes
    @ 20 cents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentCarryingAmount" contextref="AsOf2021-09-30_custom_ConvertibleNotes6Member" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-460" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">155,000</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_983_eus-gaap--DebtInstrumentMaturityDateDescription_c20201001__20210930__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotes6Member_zXirToMLyLF6" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_custom_ConvertibleNotes6Member" name="us-gaap:DebtInstrumentMaturityDateDescription" inside-table="true" id="fact-identifier-461" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Demand</ix:nonnumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2021-09-30_custom_ConvertibleNotes6Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-462" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.00</ix:nonfraction></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"></span></td></tr>
<tr id="xdx_417_20210930__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotes7Member_zz0ZN3XAO2i3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Convertible Notes
    @ 15 cents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentCarryingAmount" contextref="AsOf2021-09-30_custom_ConvertibleNotes7Member" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-463" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,000</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_98C_eus-gaap--DebtInstrumentMaturityDateDescription_c20201001__20210930__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotes7Member_z2rmKUuwahA3" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_custom_ConvertibleNotes7Member" name="us-gaap:DebtInstrumentMaturityDateDescription" inside-table="true" id="fact-identifier-464" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Demand</ix:nonnumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2021-09-30_custom_ConvertibleNotes7Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-465" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.00</ix:nonfraction></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"></span></td></tr>
<tr id="xdx_416_20210930__us-gaap--LongtermDebtTypeAxis__custom--PPPLoanMember_zYhSBGlbK71b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">PPP Loan</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentCarryingAmount" contextref="AsOf2021-09-30_custom_PPPLoanMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-466" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,407</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_981_eus-gaap--DebtInstrumentMaturityDateDescription_c20201001__20210930__us-gaap--LongtermDebtTypeAxis__custom--PPPLoanMember_zLYVNCWgo83i" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_custom_PPPLoanMember" name="us-gaap:DebtInstrumentMaturityDateDescription" inside-table="true" id="fact-identifier-467" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Monthly
                                         Installments through Fiscal 2022</ix:nonnumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2021-09-30_custom_PPPLoanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-468" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.00</ix:nonfraction></span></span>%</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"></span></td></tr>
<tr id="xdx_41A_20210930__us-gaap--LongtermDebtTypeAxis__custom--FinanceLeaseMember_zWqXBZMF0zy5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Finance Lease</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentCarryingAmount" contextref="AsOf2021-09-30_custom_FinanceLeaseMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-469" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,163</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_98A_eus-gaap--DebtInstrumentMaturityDateDescription_c20201001__20210930__us-gaap--LongtermDebtTypeAxis__custom--FinanceLeaseMember_zOkRKutdZBNg" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_custom_FinanceLeaseMember" name="us-gaap:DebtInstrumentMaturityDateDescription" inside-table="true" id="fact-identifier-470" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Monthly Installments through Fiscal 2023</ix:nonnumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2021-09-30_custom_FinanceLeaseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-471" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14.00</ix:nonfraction></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"></span></td></tr>
</tbody></table></ix:nonnumeric></span>

<p id="xdx_8A7_zSp90e6QbUB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The convertible
notes are exercisable at any time and have exercise prices ranging from $0.15 to $0.75 with the amount of shares exercisable based
on the face value of the convertible note. The holders of the bridge notes were issued an option to purchase shares of the Company
at $0.05 per share with the number of shares dependent upon the face value of the bridge note. As of the date of this report,
36,500 of these options remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On April 6,
2018, the Company issued a debenture and received proceeds of $100,000. The debenture matured in March 2020 and has an exercise
price of $.40 with interest at 8%. The entire Carrying Value of $100,000 was due in March 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a result
of the issue, the Company recognized interest expense of $100,000 as a beneficial conversion feature of the debenture which has
been amortized over the life of the note. The Interest Expense due to the Beneficial Conversion Feature for the Year Ended September
30, 2020 was $25,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In April 2019,
the Company issued debentures and received proceeds of $150,000. The debentures have matured in 2021 and had an
exercise price of $0.33 with interest at 5%. The entire Carrying Value of $150,000 are currently past due and are due on demand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a result
of the issue, the Company recognized interest expense of $61,364 as a beneficial conversion feature of the debenture which has
been amortized over the life of the note. The Interest Expense due to the Beneficial Conversion Feature for the Year Ended September
30, 2021 and 2020 was $14,948 and $32,764, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In March 2021,
the Company issued debentures and received proceeds of $150,000. The debentures mature in December 2022 and have an exercise price
of $0.75 with interest at 5%. The entire Carrying Value of $150,000 is due in Fiscal 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a result
of the issue, the Company recognized interest expense of $25,333 as a beneficial conversion feature of the debentures, which has
been amortized over the lives of the notes. The Interest Expense due to the Beneficial Conversion Feature for Fiscal Year 2021
was $7,964.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="cryo:ExecutiveCompensationDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-472" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_80A_ecustom--ExecutiveCompensationDisclosureTextBlock_zfoC37RbbU6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 8. <span id="xdx_825_zgsc2mP2WiL5">Executive
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The company
accrues Executive Salary for its two Officers at a rate of $10,000 per month for each or $<span id="xdx_901_eus-gaap--OfficersCompensation_c20201001__20210930__srt--TitleOfIndividualAxis__custom--OfficerOneMember_zpwISLmX1pv4" title="Accured Salary"><span id="xdx_906_eus-gaap--OfficersCompensation_c20201001__20210930__srt--TitleOfIndividualAxis__custom--OfficerTwoMember_zMir7QqUGqYl" title="Accured Salary"><span><ix:nonfraction name="us-gaap:OfficersCompensation" contextref="From2020-10-012021-09-30_custom_OfficerOneMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-473" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:OfficersCompensation" contextref="From2020-10-012021-09-30_custom_OfficerTwoMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-474" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">120,000</ix:nonfraction></span></ix:nonfraction></span></span></span> annually. Management has decided
to pay these salaries in the future as cash flow permits. Management controls the collection of these accrued salaries and does
not plan to demand payment in Fiscal 2022.</span></p>

</ix:nonnumeric></span><p id="xdx_81D_zX2hFwOUqmye" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p id="xdx_23A_zo90s0R5voa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>American
CryoStem Corporation</b></span></p>

<p id="xdx_232_zaP9mhu6vmQ4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to
the Consolidated Financial Statements</b></span></p>

<p id="xdx_23C_zTXcttfw6Dta" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: center"><span style="font-size: 10pt"><b>September
30, 2021 and 2020</b></span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-475" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z18E5dEqRTga" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
9. <span id="xdx_825_zBDnD1l451B1">Common Stock Issuances</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
fiscal 2020, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd58kSds4LG2"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-476" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,475,000</ix:nonfraction></span></span> shares and received $415,000. The share price was determined by agreement with the purchasers,
based upon the current market price less a discount for purchasing restricted securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
fiscal 2020, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlXtmhbY6pae"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-477" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,965,659</ix:nonfraction></span></span> shares for the conversion of a note along with interest and fees totaling $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20191001__20200930_zS8HGoGZcoW8"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-478" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">180,217</ix:nonfraction></span></span>.
The share price was determined based upon the original note agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
fiscal 2020, the Company issued <span id="xdx_90F_ecustom--SharesIssuedToPayBillsShares_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDxHYrjN9afi"><span><ix:nonfraction name="cryo:SharesIssuedToPayBillsShares" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-479" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">300,000</ix:nonfraction></span></span> shares to pay bills of $<span id="xdx_904_ecustom--BillPaidWithCommonStock_c20191001__20200930_zjOGYVbuwC7k"><span><ix:nonfraction name="cryo:BillPaidWithCommonStock" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-480" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">60,000</ix:nonfraction></span></span>. The share price was determined by agreement with the creditors,
based upon the current market price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
fiscal 2020, the Company issued <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcOHSQ7jLzD3"><span><ix:nonfraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-481" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,000,000</ix:nonfraction></span></span> shares to pay a portion of its debt $<span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20191001__20200930_zNxWnStnWNna"><span><ix:nonfraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-482" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span>, to its parent company. The share price
was determined based upon the current market price less a discount for accepting restricted securities as payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During fiscal
2020, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHGyiBxmzmr5"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-483" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">665,000</ix:nonfraction></span></span> shares for services of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20191001__20200930_zlHEGqZG1GS7"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-484" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">97,500</ix:nonfraction></span></span>. The share price was determined by agreement with the service
providers, based upon the current market price.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
fiscal 2020, the Company issued <span id="xdx_908_ecustom--SharesIssuedAsSettlementOfContractShares_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJOVoPS10Hej"><span><ix:nonfraction name="cryo:SharesIssuedAsSettlementOfContractShares" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-485" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">150,000</ix:nonfraction></span></span> shares in settlement of a contract. The share price was determined by the market price
on the date of the settlement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
fiscal 2020, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT0IytuCYvud"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-486" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,400,000</ix:nonfraction></span></span> shares for stock options exercised for $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20191001__20200930_zkBRFN1OBzn7"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-487" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">480,000</ix:nonfraction></span></span>. The share price was determined based
upon the option price for the plan year for which the options were exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
fiscal 2020, the Company issued <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesIssuedForInterestDue_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl0V1Yq3K9G1"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodSharesIssuedForInterestDue" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-488" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">227,088</ix:nonfraction></span></span> shares to pay interest due to holders of the bridge notes and convertible notes. The value
of the interest paid was $<span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueIssuedForInterestDue_c20191001__20200930_z0acArUzNkT"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueIssuedForInterestDue" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-489" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">57,849</ix:nonfraction></span></span>. The share prices were determined by the aggregate market price for the week in which the shares
were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
fiscal 2021, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0CHYAHGNdx5"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-490" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">640,000</ix:nonfraction></span></span> shares and received $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20201001__20210930_zVTCLGc2QUC9"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-491" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">143,000</ix:nonfraction></span></span>. The share price was determined by agreement with the purchasers,
based upon the current market price less a discount for purchasing restricted securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">During fiscal
2021, the Company issued <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesPrepaidExpenses_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJgRl9m3PIQ9"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodSharesPrepaidExpenses" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-492" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100,000</ix:nonfraction></span></span> shares for a prepaid expense of $<span id="xdx_908_ecustom--StockIssuedDuringPeriodValuePrepaidExpenses_c20201001__20210930_zPhySCxZflx9"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValuePrepaidExpenses" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-493" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">75,000</ix:nonfraction></span></span>. The share price was determined by agreement with the
service provider, based upon the current market price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">During fiscal
2021, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7iAwvjrSdy6"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-494" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">939,000</ix:nonfraction></span></span> shares for services provided in the amount of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20201001__20210930_zLCBLxZCXaDi"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-495" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">258,500</ix:nonfraction></span></span>. The share price was determined by agreement
with the service provider, based upon the current market price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
fiscal 2021, the Company issued <span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesIssuedForInterestDue_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8WtMiHMJkc"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodSharesIssuedForInterestDue" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-496" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">124,858</ix:nonfraction></span></span> shares to pay interest due to holders of the bridge notes and convertible notes. The value
of the interest paid was $<span id="xdx_905_ecustom--StockIssuedDuringPeriodValueIssuedForInterestDue_c20201001__20210930_zXfjxekAiC31"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueIssuedForInterestDue" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-497" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">48,546</ix:nonfraction></span></span>. The share prices were determined by the aggregate market price for the week in which the shares
were issued.</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-498" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_800_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zurvSZ1zrpfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
10. <span id="xdx_821_zjotIQeshwua">Option Issuances</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
applies ASC 718, “Accounting for Stock-Based Compensation” to account for its option issues. Accordingly, all options
granted are recorded at fair value using a generally accepted option pricing model at the date of the grant. The Company uses
the Black-Sholes option pricing model to measure the fair values of its option grants. For purposes of determining the option
values at issuance, the fair value of each option granted is measured at the date of the grant by the option pricing model using
the parameters of the volatility of the Company’s share prices and the risk free interest rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 10pt; text-align: justify"><span style="font-size: 10pt">The
Company normally issues options to its key personnel and consultants at the end of each fiscal year or as may be included in retainer
or employment agreements. The Company prepares an option agreement for each option grant that includes the date of the grant,
the vesting schedule, the expiration date and other terms of the granted options. The Company’s option plan calls
for the immediate expiration and cancellation of the granted options in the event of the termination of employment or the contract
associated with the original option grant except for certain circumstances including retirement or disability. The Company’s
method for exercising options is to require delivery of the executed option agreement with the payment of the option price to
the Company by the option holder. Upon receipt and confirmation of payment of the exercise price by Company management, the Company
prepares board minutes and instructs the transfer agent to issue the requisite number of shares underlying the option exercise.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_239_zVDXSnWHj9Cg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>American
CryoStem Corporation</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_z1Se959ipcG1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to
the Consolidated Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zWamHsHlIU2f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: center"><span style="font-size: 10pt"><b>September
30, 2021 and 2020</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zvDSr4CsvhF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
10. Option Issuances (continued)</b></span></p></ix:exclude>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-499" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zjt8PxyFpF85" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Using
the Black-Sholes valuation method the company issued options and recorded compensation of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20201001__20210930_zTRHjYHJBHg2">902,853</span> for Fiscal 2021 and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20191001__20200930_zQxuQKFfgQx9">320,042</span>
for Fiscal 2020. The fair value of the options issued in Fiscal 2021 was calculated using the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="display: none; font-size: 10pt">Schedule
of Assumption of Fair Value of Options Issued&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"></span></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="cryo:DisclosureOptionIssuancesDetailsAbstract" inside-table="false" id="fact-identifier-500" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--DisclosureOptionIssuancesDetailsAbstract_zch5geVjjE3c" summary="xdx: Disclosure - Option Issuances (Details)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"><span style="font-size: 10pt">Dividend
    yield</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-size: 10pt">0.00%</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Risk free interest
    rate</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20201001__20210930__srt--RangeAxis__srt--MinimumMember_zlebfMkATJE6"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2020-10-012021-09-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-501" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.78</ix:nonfraction></span>%</span>
                                         and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20201001__20210930__srt--RangeAxis__srt--MaximumMember_zNszAFXXspHb"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2020-10-012021-09-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-502" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.79</ix:nonfraction></span>%</span></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Volatility</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_c20201001__20210930_zmq9EOvchn0l"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-503" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">175.29</ix:nonfraction></span>%</span></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Share Price</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">$<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210930__srt--RangeAxis__srt--MinimumMember_zkrL40mZLYPh"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2021-09-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-504" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.25</ix:nonfraction></span></span>
                                         and $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210930__srt--RangeAxis__srt--MaximumMember_zMvqNqMwkZNk"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2021-09-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-505" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.30</ix:nonfraction></span></span></span></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Term</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dt_c20201001__20210930_zKYAGLIAUMM5"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-506" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5
                                         years</ix:nonnumeric></span></span></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
</tbody></table></ix:nonnumeric></span>



<p id="xdx_8A5_zq7KG1A6iR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&nbsp;</span></p>



<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-507" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zvmdblXN8krc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following
is a summary of common stock options outstanding at September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span id="xdx_8B1_zMAp3Aeq7Epl">Schedule of Stock Option Outstanding&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="cryo:DisclosureOptionIssuancesDetails2Abstract" inside-table="false" id="fact-identifier-508" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--DisclosureOptionIssuancesDetails2Abstract_zEdh3pFXKNYb" summary="xdx: Disclosure - Option Issuances (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Amount</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Exercise<br>
    Price Range</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Weighted
    <br>
    Average<br>
    Exercise<br>
    Price</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Weighted
    <br>
    Average<br>
    Remaining<br>
    Term (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-size: 10pt">Outstanding at September 30,
    2019</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20191001__20200930_z2ueanObBH19" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-509" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,761,500</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20191001__20200930__srt--RangeAxis__srt--MinimumMember_zUONPeND9mhj"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2019-09-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-510" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.05</ix:nonfraction></span></span>
                                         - $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20191001__20200930__srt--RangeAxis__srt--MaximumMember_zMZRQWXWAsEb"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2019-09-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-511" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.40</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20191001__20200930_z39r3W02MJud" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-512" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.26</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dxH_c20191001__20200930_zqPLPbXvz4ae" title="::XDX::P1Y10M6D" style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">1.85</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191001__20200930_zfJhV1uwfB7d" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-513" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,500,000</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930_zFoM3ORP6WQc"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-514" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.20</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross_c20191001__20200930_zixzpmbX9XP2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="cryo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="Shares" inside-table="true" id="fact-identifier-515" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,400,000</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930_za1k8CrJTQY5"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-516" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.20</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20191001__20200930_zZgcgqhrU6Dj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="Shares" inside-table="true" id="fact-identifier-517" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">925,000</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20191001__20200930_zaCEoTxmdr0l"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-518" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.20</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20191001__20200930_znhzb0mwXG0h" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0803"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextref="From2019-10-012020-09-30" id="fact-identifier-519" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0803" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Outstanding at September 30, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210930_zehc6JSAe0a7" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-520" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,936,500</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__srt--RangeAxis__srt--MinimumMember_zrkc0LqZiLVf"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2020-09-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-521" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.05</ix:nonfraction></span></span>
                                         - $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__srt--RangeAxis__srt--MaximumMember_zNwL70jCKGCh"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2020-09-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-522" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.40</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930_zdQMlQnBN2Mh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-523" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.26</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dxH_c20201001__20210930_zOaeGHrEcTra" title="::XDX::P2Y3M29D" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210930_zmuw4K4pbHuh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-524" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,400,000</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210930__srt--RangeAxis__srt--MinimumMember_zqcjhti60hX7"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2020-10-012021-09-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-525" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.22</ix:nonfraction></span></span>
                                         - $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210930__srt--RangeAxis__srt--MaximumMember_zy5D9IRkoK83"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2020-10-012021-09-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-526" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.25</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930_z5l81MSX0q98" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-527" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.25</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross_c20201001__20210930_zunpXMQGcNrj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0813"><span><ix:nonfraction name="cryo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross" contextref="From2020-10-01to2021-09-30" id="fact-identifier-528" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0813" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20201001__20210930_zhHIiTbjuM8a" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="Shares" inside-table="true" id="fact-identifier-529" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,800,000</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20201001__20210930_zPemFy34vvgk"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-530" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.20</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20201001__20210930_zSKhL3GcguJ" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0816"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextref="From2020-10-01to2021-09-30" id="fact-identifier-531" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0816" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Outstanding at September 30, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20201001__20210930_z16TPEldSv5" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-532" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,536,500</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20201001__20210930__srt--RangeAxis__srt--MinimumMember_zbP1EEdjI0G9"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-09-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-533" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.05</ix:nonfraction></span></span>
                                         - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20201001__20210930__srt--RangeAxis__srt--MaximumMember_z2WiHtp22sF2"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-09-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-534" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.40</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20201001__20210930_z9dGmoy8OzEc" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-535" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.26</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxH_c20201001__20210930_zhh87h74c9Vf" title="::XDX::P3Y8M23D" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">3.73</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Vested at September 30, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210930_zsRe9zv9b2S" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-536" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,711,500</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20210930__srt--RangeAxis__srt--MinimumMember_zyOfICCSqh4i"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-09-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-537" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.05</ix:nonfraction></span></span>
                                         - $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20210930__srt--RangeAxis__srt--MaximumMember_zgMnMQpbwgvj"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-09-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-538" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.40</ix:nonfraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20210930_zhqIJteKW7C8" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-539" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.28</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxH_c20201001__20210930_zHWeDyJCkgaa" title="::XDX::P3Y2M26D" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">3.24</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
</tbody></table></ix:nonnumeric></span>







<p id="xdx_8A1_zo0STzcOHTXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Option
Forfeitures are recorded as they occur. The intrinsic value of the outstanding common stock options is $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20210930_zt8fYg2j0H2f"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-540" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">421,125</ix:nonfraction></span></span> and the intrinsic
value of the outstanding vested stock options is $<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210930_z1cQod0wOTM6"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-541" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">147,625</ix:nonfraction></span></span>.</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-542" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80C_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zB6GgWKnXwFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE 11. <span id="xdx_824_zewbrNMaWGNh">Fair Values of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Fair Value
Measurements under generally accepted accounting principles clarifies the principle that fair value should be based on the assumptions
market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information
used to develop those assumptions. Under the standard, fair value measurements are separately disclosed by level within the fair
value hierarchy as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Level
1 - Quoted prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Level
2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets
with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant
inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full
term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Level
3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">To the
extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of
fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the
fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value
measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">The
Company valued Accounts Receivable, Bridge Notes and Convertible Notes at cost. Financial instruments’ carrying value approximates
fair value. Stock Options are valued using level 3 of the fair value hierarchy.</span></p>

</ix:nonnumeric></span><p id="xdx_817_z7SAaJyzrxVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p id="xdx_234_zOV6zcgT7DK" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>American
CryoStem Corporation</b></span></p>

<p id="xdx_230_zlZ3adP4VzB6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to
the Consolidated Financial Statements</b></span></p>

<p id="xdx_238_zHbpfnMlL0Sf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>September
30, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-543" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80C_eus-gaap--LeasesOfLesseeDisclosureTextBlock_ziw1AinjZLci" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
12. <span id="xdx_82F_zzbhyaHbQFD5">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-size: 10pt">The Company
determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification
criteria of finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments
to present value; however, one of the Company’s leases does not provide a readily determinable implicit rate. Therefore,
the Company must discount lease payments based on an estimate of its incremental borrowing rate which is based on the interest
rate of similar debt outstanding. Effective October 1, 2019, the Company adopted the provision of ASC 842 Leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Finance
Lease</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
leases Equipment at its laboratory from NFS Leasing, Inc. Lease payments are $2,993.62 per month for eighteen (18) months. The
final lease payment is scheduled for January 1, 2023. When the final payment is made, the Company will own the equipment. The
table below presents the lease related asset and liability recorded on the Company’s consolidated balance sheets as of September
30, 2021:</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:LesseeFinanceLeasesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-544" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_896_eus-gaap--LesseeFinanceLeasesTextBlock_zyz4WAHySfI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BF_zdvfW32lnRj6" style="display: none">Schedule of Finance Lease related Assets and Liability</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="cryo:DisclosureLeasesDetailsAbstract" inside-table="false" id="fact-identifier-545" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--DisclosureLeasesDetailsAbstract_zhTJAXL7Mdg" summary="xdx: Disclosure - Leases (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Classification
    on Balance Sheet</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" id="xdx_49B_20210930_zu9gcbHFXji7" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">September
    30, 2021</span></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_407_ecustom--FinanceLeaseRightOfUseAssetAbstract_iB_zbP4uSEt0lSl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Assets</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40A_eus-gaap--FinanceLeaseRightOfUseAsset_i01I_z2T7I6KKbtPc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"><span style="font-size: 10pt">Finance
    Lease Asset</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 38%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Finance
                                         lease right of use asset</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-546" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">115,516</ix:nonfraction></span></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_408_eus-gaap--FinanceLeaseRightOfUseAsset_i01TI_z13gibmAKPIh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total
    Finance lease assets</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-547" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">115,516</ix:nonfraction></span></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityAbstract_iB_z9vTrGzcINPd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Liabilities</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_406_ecustom--FinanceLeaseLiabilityCurrentAbstract_i01B_zvgVYOZTABY6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Current Liabilities</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_404_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_maFLLzcyc_zTYDHUjWGsI8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt"><span style="font-size: 10pt">Finance
    lease liability</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Current
                                         finance lease liability</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-548" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,512</ix:nonfraction></span></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_409_ecustom--FinanceLeaseLiabilityNoncurrentAbstract_i01B_zgjNZL2opajj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Noncurrent liabilities</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityNoncurrent_i02I_maFLLzcyc_zE1n66YkcfZf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"><span style="font-size: 10pt">Finance
    lease liability</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">Long-Term
                                         finance lease liability</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-549" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,651</ix:nonfraction></span></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_403_eus-gaap--FinanceLeaseLiability_i01TI_mtFLLzcyc_zXGYRx06Q2e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total
    operating lease liability</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="white-space: nowrap; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="white-space: nowrap; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:FinanceLeaseLiability" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-550" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,163</ix:nonfraction></span></span></td><td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
</tbody></table></ix:nonnumeric></span>
<p id="xdx_8A5_zZRBiZumhTSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-551" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_89D_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zTXQ8tRfbge4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Lease
obligations at September 30, 2021:</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span id="xdx_8B4_zv5QVA8zCuGh">Schedule of Finance Lease Obligation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="cryo:DisclosureLeasesDetails2Abstract" inside-table="false" id="fact-identifier-552" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureLeasesDetails2Abstract_z8tuViadOwx8" summary="xdx: Disclosure - Leases (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
<tbody><tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td></td><td></td>
    <td style="text-align: left"></td><td id="xdx_499_20210930_zInVKUReLNF1" style="text-align: right"></td><td style="text-align: left"></td></tr>
<tr id="xdx_40B_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDz6Fh_zcWmQEo1Q8T3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 47%">Fiscal 2022</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span><ix:nonfraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-553" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38,917</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDz6Fh_zkmQtlLpgPd3" style="vertical-align: bottom; background-color: White">
    <td>Fiscal 2023</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-554" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,975</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDz6Fh_maFLLzU62_zoH3NfRHfk39" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Total Payments</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-555" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,892</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iI_maFLLzU62_zBDceQTvR3I7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amount representing interest</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-556" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,729</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--FinanceLeaseLiability_iTI_mtFLLzU62_zK0fLzFsG9G2" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Finance lease obligation, net</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FinanceLeaseLiability" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-557" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,163</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityCurrent_iI_zlJyS6dPxnge" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance lease obligation, current portion</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-558" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,512</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zrsV1i3b4UVb" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Finance lease obligation, long-term</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-559" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,651</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
</tbody></table></ix:nonnumeric></span>





<p id="xdx_8A2_zjP3qHlJped8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The lease expense
for the Fiscal Years 2021 and 2020 was $<span id="xdx_901_ecustom--FinanceLeaseExpense_c20201001__20210930_zBDjLw4uDuUk"><span><ix:nonfraction name="cryo:FinanceLeaseExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-560" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20,892</ix:nonfraction></span></span> and $<span id="xdx_90F_ecustom--FinanceLeaseExpense_c20191001__20200930_zMmazeBAOM16"><span><ix:nonfraction name="cryo:FinanceLeaseExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-561" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">42,235</ix:nonfraction></span></span>, which consisted of amortization expenses of $<span id="xdx_905_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20201001__20210930_zcJ9hQmerH4f"><span><ix:nonfraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-562" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,921</ix:nonfraction></span></span> and $<span id="xdx_90C_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20191001__20200930_ziInEJK1Cyoa"><span><ix:nonfraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-563" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,673</ix:nonfraction></span></span> along
with interest expenses of $<span id="xdx_90E_eus-gaap--InterestPaidNet_c20201001__20210930_z8fvnmRUziHk"><span><ix:nonfraction name="us-gaap:InterestPaidNet" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-564" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,972</ix:nonfraction></span></span> and $<span id="xdx_90C_eus-gaap--InterestPaidNet_c20191001__20200930_z3Ib1PEVCHI6"><span><ix:nonfraction name="us-gaap:InterestPaidNet" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-565" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,562</ix:nonfraction></span></span>, respectively. At September 30, 2021, the remaining lease term was 1.42 years (<span id="xdx_902_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20210930_zktRb0ISECna"><span><ix:nonnumeric contextref="AsOf2021-09-30" format="ixt-sec:durwordsen" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" inside-table="false" id="fact-identifier-566" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17
months</ix:nonnumeric></span></span>) and the discount rate was <span id="xdx_901_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_c20210930_zPEH79qG9IRf"><span><ix:nonfraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-567" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13.25</ix:nonfraction></span>%</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Operating Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
leases its office facility, in Eatontown, New Jersey, from Eaton Holdings LLC. The lease expired on April 30, 2021 and the Company
can exercise a renewal option for an additional three years. The company has not exercised its option to renew for 36 months at
$2,650 per month. The company is renting month to month at $2,650 per month, while management evaluates whether it will renew
the lease. Since the lease obligation is less than twelve months, the Company does not report a lease related asset or liability
for this lease. The lease expense for Fiscal 2021 and 2020 was $<span id="xdx_905_eus-gaap--OperatingLeaseExpense_c20201001__20210930_zRRpDEgNGp9j"><span><ix:nonfraction name="us-gaap:OperatingLeaseExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-568" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,800</ix:nonfraction></span></span> and $<span id="xdx_903_eus-gaap--OperatingLeaseExpense_c20191001__20200930_z9c9iRpytQK9"><span><ix:nonfraction name="us-gaap:OperatingLeaseExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-569" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,800</ix:nonfraction></span></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; margin-bottom: 0"><span style="font-size: 10pt">The
Company leases its laboratory facility, in Monmouth Junction, New Jersey, from Princeton Corporate Plaza LLC. The Company renewed
its lease on April 1, 2021 for an additional 12 months and pays $2,462 per month. Since the lease obligation is less than twelve
months, the Company does not report a lease related asset or liability for this lease. Rent paid for the laboratory facility for
Fiscal 2021 and 2020 was $<span id="xdx_90E_eus-gaap--OperatingLeasesRentExpenseNet_c20201001__20210930_zhCv5b4X6zsd"><span><ix:nonfraction name="us-gaap:OperatingLeasesRentExpenseNet" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-570" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,116</ix:nonfraction></span></span> and $<span id="xdx_90D_eus-gaap--OperatingLeasesRentExpenseNet_c20191001__20200930_zD60lXvtuTk2"><span><ix:nonfraction name="us-gaap:OperatingLeasesRentExpenseNet" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-571" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,668</ix:nonfraction></span></span>, respectively.</span></p>

</ix:nonnumeric></span><p id="xdx_810_zrKCHn0BFEod" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p id="xdx_230_zsKocynPHYe4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>American
CryoStem Corporation</b></span></p>

<p id="xdx_232_zuZa9Jis1PTc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to
the Consolidated Financial Statements</b></span></p>

<p id="xdx_238_zOpShXTIVzfd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: center"><span style="font-size: 10pt"><b>September
30, 2021 and 2020</b></span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-572" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80F_eus-gaap--EquityMethodInvestmentsDisclosureTextBlock_zEeZyakNDjMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
13. <span id="xdx_820_zQaD1LqBYV4k">Investments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
the first quarter of 2018, the Company invested $300,000 in Baoxin Ltd., a Chinese company that is involved in tissue storage
and processing in Baoxin, China. Baoxin is not a publically traded corporation and the investment is carried at the lower of cost
or market value. The Company annually reviews its investments for impairment. After reviewing the status of Baoxin’s Financial
Condition, as stated in Note 14, the Company has determined that based on Baoxin’s 2020 Financial Statements adjustment
of its investment is necessary for Fiscal 2021. The carrying value of the Baoxin Investment was reported as $244,919 for Fiscal
2021 and $300,000 for Fiscal 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
reviewed information provided by Baoxin including its most recent audited financial statements and information regarding the completion
of its new facility in Shenzhen, China and the effects on Baoxin of the COVID 19 pandemic. The Company determined that adjustment
was necessary due to the fluctuation in the exchange rate of the RMB and the US dollar. The Company will continue to closely
monitor the situation and hopes to assists Baoxin with bringing their new facility online, as soon as is practical, considering
the current conditions in China. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Considering
the ongoing COVID 19 pandemic and its effects on Baoxin there is no assurance concerning the timing and processing volume or near
term utilization or future processing volumes of the Baoxin’s new facility. The timing of Baoxin’s opening of its
new facility in light of the pandemic, and its ability to continue to fund itself though investments until it can return to normal
operations is still uncertain. American CryoStem Management will continue to evaluate progress to determine if any further adjustment
needs to be made. The timing of any future adjustments, short or long term cannot be reasonably predicted at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The
Agreement with Baoxin is for Baoxin to develop, own and operate multiple laboratory/treatment/training facilities in China using
the American CryoStem’s intellectual property. Under the Agreement, American CryoStem received an upfront fee of $200,000
USD and a yearly minimum annual guarantee of $500,000 USD per year from Baoxin until the entire amount of the Contract ($6,000,000
USD) is paid. Additionally, as part of the transaction American CryoStem has invested $300,000 into Baoxin to obtain a 5% minority
equity in Baoxin (China) and an option to acquire up to a 20% equity ownership interest in its Regenerative Medicine Center in
Hong Kong (HK). The goals are to set up two additional GMP grade adipose tissue processing and storage facilities in Beijing and
Shanghai to cover the need of the whole China region, and a proper education facility in China to promote the use of ATGRAFT as
a more natural dermal filler over artificial fillers. Due to the uncertainty caused by the pandemic and our pending public offering,
the Company has decided to increase its allowance for doubtful accounts to include the amount owed by Baoxin at this time and
to suspend its recognition of revenue from Baoxin until such time as circumstances in China ease and Baoxin is able to return
to normal operations and make the contractual payments.</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-573" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_802_eus-gaap--ConcentrationRiskDisclosureTextBlock_zIx4g6GOsZJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
14. <span id="xdx_82A_zc1eUK9X5Py5">Concentration of Credit</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
received approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_c20201001__20210930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ClientMember_zqX38I2qCAU2"><span><ix:nonfraction name="us-gaap:ConcentrationRiskPercentage1" contextref="From2020-10-012021-09-30_us-gaap_SalesRevenueNetMember_custom_ClientMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-574" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78</ix:nonfraction></span>%</span> in Fiscal 2021; and approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_c20191001__20200930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ClientMember_zl5yhlmiPC97"><span><ix:nonfraction name="us-gaap:ConcentrationRiskPercentage1" contextref="From2019-10-012020-09-30_us-gaap_SalesRevenueNetMember_custom_ClientMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-575" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">92</ix:nonfraction></span>%</span> in Fiscal 2020 of its revenue from one client. The Company had
accounts receivable from Baoxin of $<span id="xdx_901_eus-gaap--AccountsReceivableNet_iI_c20210930__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--BaoxinLtdMember_zQwDmncd4fr6"><span><ix:nonfraction name="us-gaap:AccountsReceivableNet" contextref="AsOf2021-09-30_custom_BaoxinLtdMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-576" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,325,000</ix:nonfraction></span></span> at September 30, 2021 and $<span id="xdx_903_eus-gaap--AccountsReceivableNet_iI_c20200930__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--BaoxinLtdMember_z2u70PMbHal7"><span><ix:nonfraction name="us-gaap:AccountsReceivableNet" contextref="AsOf2020-09-30_custom_BaoxinLtdMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-577" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">825,000</ix:nonfraction></span></span> at September 30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company’s
accounts receivable from non-US countries was approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_c20201001__20210930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ForeignCountryMember_zgQkotl2HvW8"><span><ix:nonfraction name="us-gaap:ConcentrationRiskPercentage1" contextref="From2020-10-012021-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-578" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">92</ix:nonfraction></span>%</span> for Fiscal 2021 and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_c20191001__20200930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ForeignCountryMember_z4bLKwdugNE5"><span><ix:nonfraction name="us-gaap:ConcentrationRiskPercentage1" contextref="From2019-10-012020-09-30_us-gaap_SalesRevenueNetMember_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-579" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">98</ix:nonfraction></span>%</span> for Fiscal 2020. The Company received
approximately <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_c20201001__20210930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ForeignCountryMember_zI5QAXoRAqU7"><span><ix:nonfraction name="us-gaap:ConcentrationRiskPercentage1" contextref="From2020-10-012021-09-30_us-gaap_AccountsReceivableMember_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-580" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78</ix:nonfraction></span>%</span> of its revenues in Fiscal 2021 and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_c20191001__20200930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--ForeignCountryMember_zNcWpfAHS167"><span><ix:nonfraction name="us-gaap:ConcentrationRiskPercentage1" contextref="From2019-10-012020-09-30_us-gaap_AccountsReceivableMember_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-581" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">86</ix:nonfraction></span>%</span> of its revenues in Fiscal 2020 from non-US countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
regularly reviews all receivables and determines the amount of allowances if any on a quarterly basis</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The difficulties
and uncertainties caused by COVID, Chinese government policies and Baoxin’s going concern considerations have caused concern
as to the collectibility of the Baoxin receivable of $1,325,000. Communications and correspondence with Baoxin Management indicate
a continuing commitment to American CryoStem’s technology and the Agreement to a Territorial License of its patents and
other intellectual property. Baoxin recently completed its state of the art facilities in Shenzhen to roll out therapies to the
Chinese people. Although Baoxin has confirmed the validity of the receivable, the Technology Fees billed of $500,000 annually
and a total contractual obligation of $6,000,000, there is concern about to their ability to pay.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Baoxin
is still relying on investment (financing) to continue its operations, which is typical for biotechnology companies globally and
is currently in negotiations with the Chinese government which include funding requests. Management is optimistic that the effects
of the pandemic will eventually subside, Baoxin’s operations will return to normal and they will obtain the financing necessary
to pay American CryoStem, but determined it could not meet the probability threshold of collections under ASC 450-20-25-2 given
the collections history and uncertainties of future financing due to COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Due to
the uncertainty of future events management cannot reasonably estimate if a loss will be incurred, however, if Baoxin is unable
to pay its receivable to American CryoStem, the entire receivable would have to be written off.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">The Company
has made this determination following review of Baoxin’s most recent audited financial statements, receipt of their accounts
receivable confirmation, communications with Baoxin management and completion of their new facility.</span></p>

</ix:nonnumeric></span><p id="xdx_81E_zZXzDlEqthZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p id="xdx_236_zZEBx8FQSke4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>American
CryoStem Corporation</b></span></p>

<p id="xdx_231_zDXlKseWIo3f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to
the Consolidated Financial Statements</b></span></p>

<p id="xdx_23B_zeGEq3f5F68c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>September
30, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-582" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zAzhPuIPy7l8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
15. <span id="xdx_825_zHBL4e1xB1f">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">On
October 1, 2020 the Company executed a note with ACS Global, Inc. for a principal amount of $99,125 representing the
outstanding balance due to ACS Global. Inc. The Note matures on October 1, 2023 and carries an interest rate of 10% per annum
which may be paid in cash or stock. The note is due and payable in full upon maturity. On March 1, 2021, the note was
increased by $49,000. The note may be prepaid at any time by the Company. The principal balance of the Note is $<span id="xdx_900_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_c20210930_zHBF1S9JcoU"><span><ix:nonfraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-583" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">147,775</ix:nonfraction></span></span> at
Fiscal 2021 and $<span id="xdx_909_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_c20200930_zhaRuw9FeO5"><span><ix:nonfraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-584" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">99,125</ix:nonfraction></span></span> at Fiscal 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
was indebted to a company that is totally owned by the Company’s Chairman and Chief Executive Officer in the amount of $21,875
at September 30, 2021. The advances were unsecured, carried no interest rate and have subsequently been paid back.</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-585" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zEBi37Wkaftb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
16. <span id="xdx_82A_zjPzgxfX2oig">Income Taxes</span></b></span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-586" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zZ8mB4YYlqs3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><span id="xdx_8BB_zld2zUJlqJF3">Provision
for income taxes</span> is comprised of the following:</span></p>



<p style="margin: 0">&nbsp;</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="cryo:DisclosureIncomeTaxesDetailsAbstract" inside-table="false" id="fact-identifier-587" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--DisclosureIncomeTaxesDetailsAbstract_zmtRPtFi3I0e" summary="xdx: Disclosure - Income Taxes (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" id="xdx_49E_20201001__20210930_zOp32D9g93ug" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Sept
    30, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" id="xdx_496_20191001__20200930_z0oxcuQZ1zw9" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Sept
    30, 2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zNKolK2sLOl3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: justify; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font-size: 10pt">Net
    loss before provision for income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-588" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,819,586</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-589" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,179,285</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -8.65pt; padding-left: 8.65pt">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zqrugO4H6PEb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font-size: 10pt">Current
    tax expense:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40B_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCFSALzNkI_zDVFp4LFXaRe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font-size: 10pt">Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-590" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-591" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40D_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCFSALzNkI_z4YuBTmdsLD4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font-size: 10pt">State</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-592" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-593" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40E_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_i01T_mtCFSALzNkI_zIvYHaB8oeB2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-594" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-595" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -8.65pt; padding-left: 8.65pt; width: 74%">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&nbsp;</td><td id="xdx_49C_20210930_zXVjkNZLXE96" style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&nbsp;</td><td id="xdx_497_20200930_zWlEgfSbrctk" style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredIncomeTaxesAbstract_iB_z129ZoxNhmua" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font-size: 10pt">Less
    deferred tax benefit:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTANznBE_zqb0t780KOTk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font-size: 10pt">Tax
    loss carry forwards</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-596" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,100,506</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-597" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,290,920</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANznBE_zHtHUZLR6zLd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font-size: 10pt">Allowance
    for recoverability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-598" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,100,506</ix:nonfraction></span></p>


</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-599" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,290,920</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
<tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_i01TI_mtDTANznBE_zw427XZNMxNl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font-size: 10pt">Provision
    for income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsNet" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-600" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsNet" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-601" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
</tbody></table></ix:nonnumeric></span>

<p id="xdx_8AF_zSz5z2k36UX" style="margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-602" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zOlamiy0byra" style="margin: 0">A
    <span id="xdx_8B5_z8rfCWD3miq4">reconciliation of provision for income taxes at the statutory rate to provision for income taxes</span> at the Company’s effective
    tax rate is as follows:</p>

<p style="margin: 0">&nbsp;</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="cryo:DisclosureIncomeTaxesDetails2Abstract" inside-table="false" id="fact-identifier-603" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureIncomeTaxesDetails2Abstract_zLBDnNETqo7b" summary="xdx: Disclosure - Income Taxes (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -8.65pt; padding-left: 8.65pt; width: 74%">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&nbsp;</td><td id="xdx_491_20201001__20210930_zfuOQ8DMjf4l" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 8%">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&nbsp;</td><td id="xdx_49A_20191001__20200930_zyKGH3YTLy6e" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 8%">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_zZi1YPUNJFL6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font-size: 10pt">Statutory
    U.S. federal rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-604" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-605" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_zGxyM1VY81wd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font-size: 10pt">Statutory
    state and local income tax</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-606" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-607" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_z3uGs1YzRRef" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font-size: 10pt">Less
    allowance for tax recoverability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-608" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31.0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-609" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31.0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_zz9JieROCny1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -8.65pt; padding-left: 8.65pt; padding-bottom: 2.5pt"><span style="font-size: 10pt">Effective
    rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-610" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-611" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
</tbody></table></ix:nonnumeric></span>

<p id="xdx_8AD_znWmqJejFZ8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The effective
tax rate for the years ended September 30, 2021 and 2020 required the recording of any impact of the Tax Cuts and Jobs Act (the
“Tax Act”), enacted on December 22, 2017 by the U.S. government. The Tax Act made broad and complex changes to the
U.S. tax code that affect our fiscal years ended September 30, 2021 and 2020, including, but not limited to, (1)
reducing the U.S. federal corporate tax rate and (2) requiring a one-time transition tax on certain un-repatriated earnings of
foreign subsidiaries that is payable over eight years.</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-612" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80D_eus-gaap--CashFlowSupplementalDisclosuresTextBlock_zFH7tQb1eaX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE 17. <span id="xdx_823_z4CIdpOzLlz4">Non-Cash Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">As an
addendum to the consolidated statements of cash flows, the following non-cash transactions occurred in Fiscal Years 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The company
issued shares of common stock for the conversion of a note, including interest and fees in the amount of $180,217 in Fiscal 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The company
issued shares of common stock to pay a portion of its debt to its Parent in the amount of $<span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20191001__20200930_zthewWICqjm5"><span><ix:nonfraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-613" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span>, in Fiscal 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The company
issued shares of common stock to settle a contract valued at $166,667, in Fiscal 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The company
issued shares of common stock to pay interest of $<span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueIssuedForInterestDue_c20191001__20200930_zSePMO3nBJmd"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueIssuedForInterestDue" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-614" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">57,849</ix:nonfraction></span></span>, in Fiscal 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The company
issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvZEtz6DU3X6"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-615" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,400,000</ix:nonfraction></span></span> shares of common stock for options exercised at $0.20 per share, for a total amount of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20191001__20200930_zbfhgizGatYg"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-616" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">480,000</ix:nonfraction></span></span> in Fiscal 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The company
issued shares of common stock to prepay contract expenses valued at $<span id="xdx_906_ecustom--StockIssuedDuringPeriodValuePrepaidExpenses_c20201001__20210930_zqNknYzrBo1j"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValuePrepaidExpenses" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-617" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">75,000</ix:nonfraction></span></span>, in Fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The company
issued shares of common stock for services provided valued at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20201001__20210930_zvYufpyzF4c6"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-618" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">258,500</ix:nonfraction></span></span>, in Fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">The company
issued shares of common stock to pay interest of $<span id="xdx_904_ecustom--StockIssuedDuringPeriodValueIssuedForInterestDue_c20201001__20210930_zc7MqtEY5vEh"><span><ix:nonfraction name="cryo:StockIssuedDuringPeriodValueIssuedForInterestDue" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-619" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">48,546</ix:nonfraction></span></span>, in Fiscal 2021.</span></p>

</ix:nonnumeric></span><p id="xdx_818_zv74TWXGBVd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p id="xdx_236_zVtNd8ANB9yj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>American
CryoStem Corporation</b></span></p>

<p id="xdx_238_zYymA9yXXhuh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to
the Consolidated Financial Statements</b></span></p>

<p id="xdx_23E_zVxxd21qQ8oh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>September
30, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:SubsequentEventsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-620" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zeoZJIxwlGRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
18. <span id="xdx_829_z1xR5Kl7vkv6">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-size: 10pt">The Company
has made a review of material subsequent events from September 30, 2021 through the date of issuance of this report and has determined
to include the following subsequent event:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-size: 10pt">The Company
entered into an agreement with ACS Global, Inc wherein the Company exchanged 1,000,000 newly created Series A Voting Convertible
Preferred Shares for 20,000,000 common shares held by ACS Global, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Terms of the
Series A Voting Convertible Preferred Shares are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Each
                                         Series A Share is convertible into 20 shares of American CryoStem common stock $0.001
                                         par value, subject to any recapitalization event. </span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Stated
                                         annual dividend of $0.20 per share payable quarterly in cash or stock at the discretion
                                         of the Company’s Board of directors.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">3.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Each
                                         preferred share shall have 20 votes on all matters subject to a Company shareholder vote.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">4.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Convertible
                                         after one year at the discretion of the ACS Global board of directors. </span></td></tr></tbody></table>

</ix:nonnumeric></span><p id="xdx_81B_zz6M3vpPkcWl" style="margin-top: 0; margin-bottom: 0"></p>


    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></tbody></table></div>




<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->

</body>
</html>